

CITATION REPORT

List of articles citing

Toward defining the preclinical stages of Alzheimerts disease: recommendations from the National Institute on Aging-Alzheimerts Association workgroups on diagnostic guidelines for Alzheimerts disease

DOI: 10.1016/j.jalz.2011.03.003

Alzheimerts and Dementia, 2011, 7, 280-92.

Source: <https://exaly.com/paper-pdf/50444257/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2236	Diagnosis and biomarkers of predementia in Alzheimer's disease. 2010 , 8, 89		76
2235	Defining and describing the pre-dementia stages of familial Alzheimer's disease. 2011 , 3, 29		10
2234	Predicting Alzheimer's risk: why and how?. 2011 , 3, 33		12
2233	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. 2011 , 3, 34		36
2232	Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease. 2011 , 3, 35		33
2231	Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. 2011 , 15, 313-25		15
2230	Incidence and subtypes of MCI and dementia 1 year after first-ever stroke in patients without pre-existing cognitive impairment. 2011 , 32, 401-7		52
2229	Defining neurocognitive disorders. 2011 , 19, 909-14		0
2228	Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy. 2011 , 3, S460-7		332
2227	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. 2011 , 10, 698-712		1402
2226	Resolving controversies on the path to Alzheimer's therapeutics. 2011 , 17, 1060-5		383
2225	A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. 2011 , 3, 32		119
2224	Perspective: in search of biomarkers. 2011 , 475, S8		19
2223	Brain aging, Alzheimer's disease, and mitochondria. 2011 , 1812, 1630-9		206
2222	Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. 2011 , 32, 247-57		78
2221	Imagerie TEP-traceurs des plaques amyloïdes: le point de vue du clinicien. 2011 , 35, 608-612		1
2220	Lifespan brain activity, ßamyloid, and Alzheimer's disease. 2011 , 15, 520-6		151

2219	Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. 2011 , 34, 430-42		235
2218	Biomarkers for major depression and its delineation from neurodegenerative disorders. 2011 , 95, 703-17		30
2217	Prevention trials in Alzheimer's disease: an EU-US task force report. 2011 , 95, 594-600		52
2216	The future of Alzheimer's disease: the next 10 years. 2011 , 95, 718-28		156
2215	Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease. 2011 , 95, 517-9		21
2214	Potential of functional MRI as a biomarker in early Alzheimer's disease. 2011 , 32 Suppl 1, S37-43		105
2213	[The diagnostic approach to early Alzheimer's disease. What are we talking about? Conceptual considerations]. 2011 , 46 Suppl 1, 33-8		0
2212	Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. 2011 , 76, 1395-402		222
2211	Evidence for ordering of Alzheimer disease biomarkers. 2011 , 68, 1526-35		170
2210	Testing the right target and right drug at the right stage. 2011 , 3, 111cm33		366
2209	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 263-9	1.2	8211
2208	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." New criteria for a new era. <i>Alzheimer's and Dementia</i> , 2011 , 7, 328-9	1.2	7
2207	The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 270-9	1.2	5630
2206	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century. <i>Alzheimer's and Dementia</i> , 2011 , 7, 335-7	1.2	22
2205	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011 , 7, 474-485.e4	1.2	139
2204	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011 , 7, e60-e76	1.2	59
2203	Biomarkers to measure treatment effects in Alzheimer's disease: what should we look for?. 2011 , 2011, 598175		3
2202	Imaging the Alzheimer brain. 2011 , 26 Suppl 3, 1-27		30

2201	Diagnosis of Alzheimer's disease in Brazil: Supplementary exams. 2011 , 5, 167-177	14
2200	Criteria for the diagnosis of Alzheimer's disease: Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. 2011 , 5, 146-152	21
2199	Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders. 2011 , 5, 178-188	4
2198	Treatment of Alzheimer's disease in Brazil: II. Behavioral and psychological symptoms of dementia. 2011 , 5, 189-197	2
2197	Assessing the sociocultural impacts of emerging molecular technologies for the early diagnosis of Alzheimer's disease. 2011 , 2011, 184298	6
2196	Biomarkers in Alzheimer's disease. 2011 , 2, 46	14
2195	Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer's disease. 2011 , 2, 54	37
2194	Why age (and timing) really matters in developing drugs for neurodegenerative disease. 2011 , 8, 459-461	
2193	Evolution of the diagnostic criteria for degenerative and cognitive disorders. 2011 , 24, 532-41	32
2192	Age, Alzheimer's disease, and the big picture. 2011 , 23, 1531-4	11
2191	Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. 2011 , 23, 1191-6	26
2190	Ask the experts: PET amyloid imaging: can its diagnostic potential be effectively realized in the clinic?. 2011 , 1, 445-451	
2189	[Dementia: progress in diagnosis and treatment: Topics, II. Diagnosis; 2. Neuroimaging diagnosis of dementia (MRI SPECT and PET)]. 2011 , 100, 2116-24	
2188	Treatment of Alzheimer disease: the past, the present, and the future. 2011 , 56, 577-8	
2187	A comprehensive strategy for dementia from primary prevention to end-stage management. 2011 , 11, 131-4	1
2186	Specific subjective memory complaints in older persons may indicate poor cognitive function. 2011 , 59, 1612-7	141
2185	Obesity, leptin, and Alzheimer's disease. 2011 , 1243, 15-29	87
2184	Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. 2011 , 49, 2384-90	126

2183	Face-name associative memory performance is related to amyloid burden in normal elderly. 2011 , 49, 2776-83	145
2182	Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. 2011 , 10, 598-601	20
2181	Episodic memory on the path to Alzheimer's disease. 2011 , 21, 929-34	82
2180	Utility of imaging for nutritional intervention studies in Alzheimer's disease. 2011 , 668 Suppl 1, S59-69	12
2179	Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. 2012 , 10, 187-212	37
2178	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. 2011 , 122, 737-45	13
2177	[The future of biomarkers in dementia diagnostics]. 2011 , 82, 1385-6, 1388, 1390, passim	2
2176	Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. 2011 , 11, 455-63	7
2175	Predicting MCI outcome with clinically available MRI and CSF biomarkers. 2011 , 77, 1619-28	160
2174	New diagnostic criteria for Alzheimer's disease. 2011 , 5, 407-9	4
2173	A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. 2011 , 1, 431-440	2
2172	Perspective: prevention is better than cure. 2011 , 475, S15	29
2171	Genetics of dementia. 2011 , 31, 449-60	37
2170	Mapping the road forward in Alzheimer's disease. 2011 , 3, 114ps48	53
2169	Beta-secretase inhibitors for treating Alzheimer's disease: rationale and clinical data. 2011 , 1, 1175-1194	2
2168	The diagnostic value of controlled oral word association test-FAS and category fluency in single-domain amnesic mild cognitive impairment. 2011 , 32, 235-40	34
2167	Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. 2011 , 31, 17680-8	170
2166	Neuropsychological assessment: a valuable tool in the diagnosis and management of neurological, neurodevelopmental, medical, and psychiatric disorders. 2011 , 24, 107-14	43

2165	Protocol for a randomised controlled trial to improve cognitive functioning in older adults: the Iowa Healthy and Active Minds Study. 2011 , 1, e000218	10
2164	Neocortical and hippocampal amyloid- β and tau measures associate with dementia in the oldest-old. 2011 , 134, 3708-15	72
2163	Brain amyloid imaging. 2011 , 52, 1733-40	184
2162	Charting the path for early diagnosis and prevention of Alzheimer's disease. 2011 , 11, 1665-7	3
2161	Serotonin signaling is associated with lower amyloid- β levels and plaques in transgenic mice and humans. 2011 , 108, 14968-73	218
2160	Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. 2011 , 26 Suppl 3, 321-9	275
2159	Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. 2011 , 77, 1487-93	89
2158	A window into the heterogeneity of human cerebrospinal fluid A β peptides. 2011 , 2011, 697036	12
2157	Ethical issues in Alzheimer's disease: an overview. 2012 , 12, 557-67	16
2156	Sterol lipid metabolism in down syndrome revisited: down syndrome is associated with a selective reduction in serum brassicasterol levels. 2012 , 2012, 179318	9
2155	Overview and findings from the rush Memory and Aging Project. 2012 , 9, 646-63	529
2154	Dementia has a categorical, not dimensional, latent structure. 2012 , 27, 791-7; author reply 798-800	6
2153	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. 2012 , 34, 853-63	9
2152	The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. 2012 , 22, 2653-61	91
2151	Molecular brain imaging in the multimodality era. 2012 , 32, 1377-92	14
2150	Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?. 2012 , 446, 165-77	75
2149	Overview and findings from the religious orders study. 2012 , 9, 628-45	412
2148	Early-onset familial Alzheimer's disease (EOFAD). 2012 , 39, 436-45	126

2147	Region-specific hierarchy between atrophy, hypometabolism, and β amyloid (A β) load in Alzheimer's disease dementia. 2012 , 32, 16265-73	245
2146	Disruption of the sleep-wake cycle and diurnal fluctuation of β amyloid in mice with Alzheimer's disease pathology. 2012 , 4, 150ra122	339
2145	Subjective cognitive complaints of older adults at the population level: an item response theory analysis. 2012 , 26, 344-51	49
2144	The neurobiology of Alzheimer disease defined by neuroimaging. 2012 , 25, 410-20	28
2143	New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician. 2012 , 18, 356-63	29
2142	The neuropsychological profile of Alzheimer disease. 2012 , 2, a006171	309
2141	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. 2012 , 64, 27-81	66
2140	Amyloid- β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 2012 , 79, 1636-44	174
2139	β Amyloid burden in healthy aging: regional distribution and cognitive consequences. 2012 , 78, 387-95	282
2138	Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. 2012 , 78, 1769-76	37
2137	The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. 2012 , 2,	62
2136	Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease?. 2012 , 2, 483-491	95
2135	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. 2012 , 4, 343-357	10
2134	Validation of the Face Name Associative Memory Exam in cognitively normal older individuals. 2012 , 34, 580-7	43
2133	The use of informant-based questionnaires in differentiating mild cognitive impairment from normal aging. 2012 , 12, 637-9	2
2132	Alzheimer's disease in the retina: imaging retinal A β plaques for early diagnosis and therapy assessment. 2012 , 10, 285-93	148
2131	Identification of small molecule inhibitors of neurite loss induced by A β peptide using high content screening. 2012 , 287, 8714-23	16
2130	Immunotherapy for Alzheimer's disease: from anti- β amyloid to tau-based immunization strategies. 2012 , 4, 213-38	106

2129	Mini-Mental State Examination performance in frail, pre-frail, and non-frail community dwelling older adults in Ermelino Matarazzo, S Paulo, Brazil. 2012 , 24, 1725-31	60
2128	Indicators of amyloid burden in a population-based study of cognitively normal elderly. 2012 , 79, 1570-7	123
2127	Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. 2012 , 83, 923-6	80
2126	Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. 2012 , 53, 592-600	73
2125	P300 and neuropsychological assessment in mild cognitive impairment and Alzheimer dementia. 2012 , 3, 172	47
2124	Functional connectivity variations in mild cognitive impairment: associations with cognitive function. 2012 , 18, 39-48	40
2123	Regional dynamics of amyloid- deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. 2012 , 135, 2126-39	179
2122	A deposition in aging is associated with increases in brain activation during successful memory encoding. 2012 , 22, 1813-23	105
2121	Machine learning amplifies the effect of parental family history of Alzheimer's disease on list learning strategy. 2012 , 18, 428-39	6
2120	Alzheimer's disease, cerebrovascular disease, and the  amyloid cascade. 2012 , 39, 712-28	128
2119	Does ionizing radiation influence Alzheimer's disease risk?. 2012 , 53, 815-22	34
2118	Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions. 2012 , 25, 421-8	91
2117	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. 2012 , 69, 856-67	86
2116	Guidelines for the diagnosis and treatment of Alzheimer's disease. 2012 , 80-86	
2115	Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. 2012 , 71, 266-73	563
2114	Identifying earlier Alzheimer's disease: insights from the preclinical and prodromal phases. 2012 , 10, 158-60	12
2113	A random change point model for cognitive decline in Alzheimer's disease and mild cognitive impairment. 2012 , 39, 73-83	37
2112	The Lay Public's Understanding and Perception of Dementia in a Developed Asian Nation. 2012 , 2, 433-44	22

2111	Structural neuroimaging of concomitant depressive symptoms in amnesic mild cognitive impairment: a pilot study. 2012 , 2, 573-88	8
2110	Shifting our focus to blood-based biomarkers of Alzheimer's disease: the promise of ceramides and sphingomyelins. 2012 , 2, 91-94	
2109	Early indications of magnetic resonance spectroscopy changes associated with β amyloid load in the cognitively normal. 2012 , 7, 117-118	
2108	Increased expression of TrkB and Capzb2 accompanies preserved cognitive status in early Alzheimer disease pathology. 2012 , 71, 654-64	19
2107	So wichtig ist fr \ddot{u} he Demenzdiagnose. 2012 , 13, 50-57	1
2106	Biomarker reif f \ddot{u} die Routine?. 2012 , 13, 19-20	
2105	Selected findings from the Religious Orders Study and Rush Memory and Aging Project. 2013 , 33 Suppl 1, S397-403	40
2104	Assessment of Alzheimer's disease risk with functional magnetic resonance imaging: an arterial spin labeling study. 2012 , 31 Suppl 3, S59-74	61
2103	IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. 2012 ,	8
2102	Managing memory impairment in patients with Alzheimer's disease. 2012 , 2, 459-469	
2101	Will the Revised MCI Criteria Mean Fewer Alzheimer Disease Diagnoses?. 2012 , 12, 1	
2100	Passive immunisation with monoclonal anti-A β antibodies for the treatment of Alzheimer's disease. 2012 ,	
2099	Alzheimer's disease: a clinical practice-oriented review. 2012 , 3, 63	43
2098	Translational research in neurology: dementia. 2012 , 69, 969-77	10
2097	[Pharmacological treatment strategies targeting cognitive impairment associated with aging]. 2012 , 139, 157-9	1
2096	The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. 2012 , 71, 233-41	79
2095	Updated guidelines for the diagnosis of Alzheimer disease: a clinical review. 2012 , 25, 50-5	1
2094	Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia. 2012 , 24, 1076-84	22

2093	Amyloid and Alzheimer's disease: inside and out. 2012 , 39, 286-98	50
2092	4e Conférence canadienne consensuelle sur le diagnostic et le traitement de la démence. 2012 , 39, S1-S8	
2091	4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. 2012 , 39, S1-8	19
2090	Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer's disease patients. 2012 , 7, 395-401	1
2089	Mapping the long slow progression of neurodegeneration leading to Alzheimer's disease. 2012 , 8, 567-571	
2088	Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. 2012 , 11, 1048-56	347
2087	Predicting the development of mild cognitive impairment: a new use of pattern recognition. 2012 , 60, 894-901	22
2086	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. 2012 , 367, 795-804	2272
2085	Advances in the identification of β -secretase inhibitors for the treatment of Alzheimer's disease. 2012 , 7, 19-37	42
2084	Contribution of neuroimaging to the diagnosis of Alzheimer's disease and vascular dementia. 2012 , 43, 671-6	45
2083	Amyloid plaque formation precedes dendritic spine loss. 2012 , 124, 797-807	64
2082	Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. 2012 , 69, 1310-7	142
2081	Alzheimer's disease. 2012 , 65, 329-52	176
2080	The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?. 2012 , 12, 1339-50	57
2079	Primary or secondary prevention for AD: who cares?. 2012 , 11, 661-2	1
2078	Mild cognitive impairment in older adults. 2012 , 14, 320-7	50
2077	Relation of neuropathology to cognition in persons without cognitive impairment. 2012 , 72, 599-609	153
2076	Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. 2012 , 33, 3738-44	25

2075	Positive argument for debate in J Neural Transmission: Alzheimer's disease: are we intervening too late? Yes, by years if not decades. 2012 , 119, 1529-32		6
2074	Neuropsychology of Alzheimer's disease. 2012 , 43, 686-93		28
2073	Clinical diagnosis in preclinical stage of Alzheimer's disease. 2012 , 43, 667-70		4
2072	Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. 2012 , 43, 677-85		96
2071	The role of astrocytes in amyloid β protein toxicity and clearance. 2012 , 236, 1-5		97
2070	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012 , 8, 65-73	1.2	210
2069	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2012 , 8, S1-68	1.2	368
2068	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012 , 8, 1-13	1.2	1396
2067	Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012 , 8, 560-3	1.2	41
2066	2012 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2012 , 8, 131-68	1.2	700
2065	Worldwide Alzheimer's disease neuroimaging initiative. <i>Alzheimer's and Dementia</i> , 2012 , 8, 337-42	1.2	71
2064	Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. <i>Alzheimer's and Dementia</i> , 2012 , 8, 312-36	1.2	92
2063	Biomarker development: a population-level perspective. <i>Alzheimer's and Dementia</i> , 2012 , 8, 247-9	1.2	3
2062	Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. <i>Alzheimer's and Dementia</i> , 2012 , 8, 445-52	1.2	37
2061	Alzheimer's Association Update. 2012 , 8, 458-462		
2060	No se puede tapar el sol con las manos Nuevos criterios diagn3sticos en la enfermedad de Alzheimer. 2012 , 4, 3-5		
2059	Mild cognitive impairment: a subset of minor neurocognitive disorder?. 2012 , 20, 821-6		13
2058	[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia]. 2012 , 168, 471-82		19

2057	Encuesta sobre la enfermedad de Alzheimer en el contexto de los nuevos paradigmas diagnósticos. 2012 , 4, 118-125	4
2056	Evaluación y diagnóstico del deterioro cognitivo leve. 2012 , 32, 47-56	6
2055	[Markers of prodromal Alzheimer's disease]. 2012 , 168, 815-24	
2054	Explaining the encoding/retrieval flip: memory-related deactivations and activations in the posteromedial cortex. 2012 , 50, 3764-74	82
2053	Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. 2012 , 4, 24	24
2052	Apolipoprotein E, amyloid- β clearance and therapeutic opportunities in Alzheimer's disease. 2012 , 4, 32	40
2051	Alzheimer's disease diagnostic criteria: practical applications. 2012 , 4, 35	29
2050	The relevance voxel machine (RVoxM): a self-tuning Bayesian model for informative image-based prediction. 2012 , 31, 2290-306	37
2049	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. 2012 , 34, 345-58	92
2048	MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. 2012 , 78, 84-90	145
2047	Spezifische Marker zeigen die Erkrankung schon 15 Jahre vor der Demenz an. 2012 , 14, 10-11	
2046	Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. 2013 , 33 Suppl 1, S405-16	46
2045	Fluid biomarkers in Alzheimer disease. 2012 , 2, a006221	120
2044	Longitudinal imaging pattern analysis (SPARE-CD index) detects early structural and functional changes before cognitive decline in healthy older adults. 2012 , 33, 2733-45	26
2043	Structural and functional neural correlates of visuospatial information processing in normal aging and amnesic mild cognitive impairment. 2012 , 33, 2782-97	30
2042	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. 2012 , 97, 38-51	127
2041	Molecular imaging of dementia. 2012 , 12, 106-14	16
2040	Preventing Alzheimer's disease. 2012 , 337, 1488-92	280

2039	Selective changes in white matter integrity in MCI and older adults with cognitive complaints. 2012 , 1822, 423-30	79
2038	Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. 2012 , 1822, 631-8	172
2037	PET amyloid-beta imaging in preclinical Alzheimer's disease. 2012 , 1822, 370-9	102
2036	The use of PIB-PET as a dual pathological and functional biomarker in AD. 2012 , 1822, 380-5	41
2035	Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases?. 2012 , 1822, 1475-88	71
2034	Mouse models of Alzheimer's disease. 2012 , 88, 3-12	191
2033	Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. 2012 , 16, 1434-55	133
2032	Alzheimer's disease markers from structural MRI and FDG-PET brain images. 2012 , 127, 1	13
2031	Neurodegenerative dementias: From MR Physics lab to assessment room. 2012 , 127, 1	3
2030	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. 2012 , 12, 72	20
2029	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. 2012 , 10, 127	37
2028	Association of the interleukin 1 beta gene and brain spontaneous activity in amnesic mild cognitive impairment. 2012 , 9, 263	18
2027	Prevention strategies for Alzheimer's disease. 2012 , 1, 13	17
2026	Screening and treatment for Alzheimer's disease: predicting population-level outcomes. <i>Alzheimer's and Dementia</i> , 2012 , 8, 31-8	1.2 2
2025	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. 2012 , 6, 419-30	230
2024	Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. 2012 , 69, 1621-7	170
2023	Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. 2012 , 9, 176-86	32
2022	Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. 2012 , 8, 135-49	65

2021	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. 2012 , 6, 391-400	45
2020	Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. 2012 , 64, 327-71	60
2019	Development of positron emission tomography amyloid plaque imaging agents. 2012 , 42, 423-32	132
2018	Traumatic brain injury and neuropsychiatric outcomes. 2012 , 11, 1020-1	
2017	Altered spontaneous activity in Alzheimer's disease and mild cognitive impairment revealed by Regional Homogeneity. 2012 , 59, 1429-40	190
2016	Diagnostic neuroimaging across diseases. 2012 , 61, 457-63	199
2015	Brain imaging in the study of Alzheimer's disease. 2012 , 61, 505-16	83
2014	Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease. 2012 , 60, 221-9	101
2013	Correlations between FDG PET glucose uptake-MRI gray matter volume scores and apolipoprotein E ϵ 4 gene dose in cognitively normal adults: a cross-validation study using voxel-based multi-modal partial least squares. 2012 , 60, 2316-22	31
2012	Imaging brain amyloid deposition using grating-based differential phase contrast tomography. 2012 , 61, 1336-46	62
2011	Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. 2012 , 62, 1-8	70
2010	A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort. 2012 , 63, 1478-86	148
2009	Neurocognitive disorders in DSM 5 project - personal comments. 2012 , 322, 17-9	6
2008	Hippocampal atrophy in Alzheimer's disease. 2012 , 2, 197-209	2
2007	Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. 2012 , 64, 83-126	49
2006	Clinical and research diagnostic criteria for Alzheimer's disease. 2012 , 22, 23-32,viii	39
2005	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. 2012 , 262 Suppl 2, S71-7	19
2004	Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. 2012 , 6, 610-20	46

2003	Cortical signatures of cognition and their relationship to Alzheimer's disease. 2012 , 6, 584-98	19
2002	Assessing dementia in resource-poor regions. 2012 , 12, 511-9	36
2001	Évaluation des procédures diagnostiques de la maladie d'Alzheimer : une revue systématique des méta-analyses. 2012 , 4, 330-344	1
2000	Alzheimer's disease pathologic cascades: who comes first, what drives what. 2012 , 22, 182-94	51
1999	Clinical research risk assessment among individuals with mild cognitive impairment. 2012 , 20, 878-86	8
1998	The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. 2012 , 16, 135-41	20
1997	Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. 2012 , 69, 700-8	110
1996	OPTIMIZING DIAGNOSIS AND MANAGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. 2012 , 2, 291-304	9
1995	Recent Alzheimer's disease research highlights. 2012 , 4, 14	
1994	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. 2012 , 7, e38639	56
1993	Poor decision making is a consequence of cognitive decline among older persons without Alzheimer's disease or mild cognitive impairment. 2012 , 7, e43647	104
1992	Disrupted small-world brain networks in moderate Alzheimer's disease: a resting-state FMRI study. 2012 , 7, e33540	154
1991	Small-animal PET imaging of amyloid-beta plaques with [¹¹ C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. 2012 , 7, e31310	94
1990	Using support vector machines with multiple indices of diffusion for automated classification of mild cognitive impairment. 2012 , 7, e32441	74
1989	CSF and brain structural imaging markers of the Alzheimer's pathological cascade. 2012 , 7, e47406	32
1988	Enrichment and stratification for predementia Alzheimer disease clinical trials. 2012 , 7, e47739	56
1987	Executive Dysfunction in MCI: Subtype or Early Symptom. 2012 , 2012, 936272	32
1986	Historical perspectives on the discovery and development of drugs to treat neurological disorders. 129-148	3

1985	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). 2012 , 15, 120-6	98
1984	Structural brain alterations before mild cognitive impairment in ADNI: validation of volume loss in a predefined antero-temporal region. 2012 , 31 Suppl 3, S49-58	20
1983	Plasma microRNA biomarkers for detection of mild cognitive impairment. 2012 , 4, 590-605	138
1982	Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. 2012 , 263, 344-61	166
1981	Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. 2012 , 78, 1576-82	202
1980	Amyloid- β associated clinical decline occurs only in the presence of elevated P-tau. 2012 , 69, 709-13	103
1979	Diagnosis. 2012 , 139-191	
1978	The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. 2012 , 112, 5147-92	636
1977	Trajectory of white matter hyperintensity burden preceding mild cognitive impairment. 2012 , 79, 741-7	75
1976	Oxidative damage to RNA in aging and neurodegenerative disorders. 2012 , 22, 231-48	131
1975	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. 2012 , 73, 504-17	207
1974	An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. 2012 , 71, 765-75	435
1973	The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia. 2012 , 2, 211-219	1
1972	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. 2012 , 2, 183-195	16
1971	Neuroscience-based Tests for Assessing Cognitive Changes in Normal Aging and in the Prodromal Phase of Alzheimer's Disease. 2012 , 1, 1-10	
1970	[Advances in the diagnostics of Alzheimer's disease]. 2012 , 83, 661-73	6
1969	Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. 2012 , 6, 244-54	328
1968	Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. 2012 , 16, 339-45	31

1967	The prognostic value of amyloid imaging. 2012 , 39, 1207-19	26
1966	Dementia: new criteria but no new treatments. 2012 , 11, 4-5	19
1965	Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. 2012 , 22, 472-84	20
1964	Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil. 2012 , 18, 524-9	17
1963	Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. 2012 , 134, 8-25	153
1962	Subjective cognitive complaints: not to be dismissed. 2012 , 19, 665	1
1961	Neuroimaging results impose new views on Alzheimer's disease--the role of amyloid revised. 2012 , 45, 153-72	38
1960	A brief update on dementia prevention. 2012 , 45, 7-10	2
1959	Mild cognitive impairment: pathology and mechanisms. 2012 , 123, 13-30	150
1958	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. 2012 , 123, 1-11	1425
1957	Progress in Alzheimer's disease. 2012 , 259, 201-11	71
1956	The development of effective biomarkers for Alzheimer's disease: a review. 2013 , 28, 331-40	36
1955	Does posterior cortical atrophy on MRI discriminate between Alzheimer's disease, dementia with Lewy bodies, and normal aging?. 2013 , 25, 111-9	21
1954	Fluid biomarkers in Alzheimer's disease - current concepts. 2013 , 8, 20	147
1953	The UP-TECH project, an intervention to support caregivers of Alzheimer's disease patients in Italy: study protocol for a randomized controlled trial. 2013 , 14, 155	25
1952	A 12-week multidomain intervention versus active control to reduce risk of Alzheimer's disease: study protocol for a randomized controlled trial. 2013 , 14, 60	17
1951	(18)F-florbetaben Aβimaging in mild cognitive impairment. 2013 , 5, 4	40
1950	Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. 2013 , 4, 6	36

1949	Organic delirious states and other psychiatric disorders: lessons for the hepatologists. 2013 , 28, 235-8	9
1948	Apraxia and Alzheimer's disease: review and perspectives. 2013 , 23, 234-56	48
1947	STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcellation. 2013 , 17, 671-84	188
1946	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. 2013 , 101-102, 1-17	88
1945	Physical activity and brain function in older adults at increased risk for Alzheimer's disease. 2013 , 3, 54-83	38
1944	Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. 2013 , 14, 626-36	495
1943	Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. 2013 , 6, 423-42	7
1942	Ushering in the study and treatment of preclinical Alzheimer disease. 2013 , 9, 371-81	103
1941	Genetic susceptibility for Alzheimer disease neuritic plaque pathology. 2013 , 70, 1150-7	113
1940	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. 2013 , 17, 54-63	24
1939	Early detection of memory impairment in people over 65 years old consulting at Health Examination Centers for the French health insurance: the EVATEM protocol. 2013 , 13, 55	16
1938	Medial temporal lobe function during emotional memory in early Alzheimer's disease, mild cognitive impairment and healthy ageing: an fMRI study. 2013 , 13, 76	28
1937	Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. 2013 , 76, 167-77	58
1936	Is the WMS-IV verbal paired associates as effective as other memory tasks in discriminating amnesic mild cognitive impairment from normal aging?. 2013 , 27, 908-23	9
1935	APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. 2013 , 37, 1322-35	82
1934	Amyloid β peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. 2013 , 19, 823-35	347
1933	Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease. 2013 , 263, 553-60	38
1932	Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. 2013 , 14, 744-8	536

1931	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. 2013 , 74, 655-68	129
1930	A hypnic hypothesis of Alzheimer's disease. 2013 , 12, 165-76	11
1929	The therapeutics of Alzheimer's disease: where we stand and where we are heading. 2013 , 74, 328-36	91
1928	Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. 2013 , 40, 125-32	91
1927	CSF β -synuclein improves diagnostic and prognostic performance of CSF tau and A β in Alzheimer's disease. 2013 , 126, 683-97	75
1926	Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease. 2013 , 1, 39-51	11
1925	Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. 2013 , 27, 505-14	329
1924	Interaction between two cholesterol metabolism genes influences memory: findings from the Wisconsin Registry for Alzheimer's Prevention. 2013 , 36, 749-57	29
1923	FDG PET and cognitive symptoms of dementia. 2013 , 1, 247-260	14
1922	Magnetic resonance spectroscopy in common dementias. 2013 , 23, 393-406	36
1921	A new paradigm for testing AD drugs [neuroimaging biomarkers as surrogate outcomes homologous in animals and humans. 2013 , 10, e63-e71	
1920	Executive functions in clinical and preclinical Alzheimer's disease. 2013 , 169, 695-708	18
1919	Les biomarqueurs du LCR et du plasma : utilisation diagnostique et pronostique dans la maladie d'Alzheimer et les syndromes apparentés. 2013 , 4, 65-72	
1918	APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. 2013 , 22, 1361-9	73
1917	Decreased functional connectivity of the amygdala in Alzheimer's disease revealed by resting-state fMRI. 2013 , 82, 1531-8	58
1916	Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review. 2013 , 34, 1275-82	22
1915	The diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease. 2013 , 3, 352-60	62
1914	Improving Alzheimer's disease phase II clinical trials. <i>Alzheimer's and Dementia</i> , 2013 , 9, 39-49	1.2 24

1913	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. <i>Alzheimer's and Dementia</i> , 2013 , 9, e96-e105	1.2	57
1912	The sensitivity and specificity of subjective memory complaints and the subjective memory rating scale, deterioration cognitive observee, mini-mental state examination, six-item screener and clock drawing test in dementia screening. 2013 , 36, 119-35		28
1911	Normal cognitive aging. 2013 , 29, 737-52		867
1910	Emerging biomarkers in cognition. 2013 , 29, 809-28		11
1909	How close are we to a readily available, clinically reliable blood test for Alzheimer's disease?. 2013 , 3, 397-400		
1908	Pathology of clinical and preclinical Alzheimer's disease. 2013 , 263 Suppl 2, S137-45		39
1907	Brain amyloid- β oligomers in ageing and Alzheimer's disease. 2013 , 136, 1383-98		325
1906	Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. 2013 , 13, 415		75
1905	Current and emerging therapies for Alzheimer's disease. 2013 , 35, 1480-9		24
1904	2013 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2013 , 9, 208-45	1.2	947
1903	Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study. 2013 , 28, 477-487		1
1902	An overview of PET neuroimaging. 2013 , 43, 449-61		34
1901	Cerebral amyloid PET imaging in Alzheimer's disease. 2013 , 126, 643-57		79
1900	Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?. 2013 , 126, 625-9		2
1899	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. 2013 , 5, 58		114
1898	Amyloid PET Imaging: MCI and AD. 2013 , 8, 431-45		2
1897	Biomarker modeling of Alzheimer's disease. 2013 , 80, 1347-58		586
1896	Pharmacologic inhibition of ROCK2 suppresses amyloid- β production in an Alzheimer's disease mouse model. 2013 , 33, 19086-98		98

1895	Meta-analysis of functional network alterations in Alzheimer's disease: toward a network biomarker. 2013 , 37, 753-65	81
1894	CSF biomarkers of Alzheimer disease: "noncognitive" outcomes. 2013 , 81, 2028-31	21
1893	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. 2013 , 126, 479-97	287
1892	Drug development in dementia. 2013 , 76, 260-6	2
1891	Biomarker utility in Alzheimer's disease clinical trials. 2013 , 10, e55-e62	1
1890	After the Diagnosis. 2013 , 97-110	
1889	Molecular neuroimaging in degenerative dementias. 2013 , 32, 301-309	2
1888	MRI and MRS predictors of mild cognitive impairment in a population-based sample. 2013 , 81, 126-33	71
1887	Pharmacotherapeutic management of dementia across settings of care. 2013 , 61, 723-33	31
1886	Modeling Alzheimer's disease in transgenic rats. 2013 , 8, 37	103
1885	Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. 2013 , 5, 43	26
1884	Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer's disease. 2013 , 1, 279-288	2
1883	Cognitive frailty: rationale and definition from an (I.A.N.A./I.A.G.G.) international consensus group. 2013 , 17, 726-34	442
1882	Do preclinical Alzheimer's disease criteria work?. 2013 , 12, 933-5	6
1881	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. 2013 , 12, 957-65	389
1880	Loss of fornix white matter volume as a predictor of cognitive impairment in cognitively normal elderly individuals. 2013 , 70, 1389-95	79
1879	Alzheimer disease: from biomarkers to diagnosis. 2013 , 169, 744-51	15
1878	Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers. 2013 , 169, 729-36	22

1877	APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. 2013 , 34, 1007-17	51
1876	Alzheimer Disease: Genetic and Environmental Influences. 2013 ,	
1875	Predicting Alzheimer disease with β amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. 2013 , 74, 905-13	158
1874	Multiplex biomarkers in blood. 2013 , 5, 31	23
1873	Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. 2013 , 5, S2	81
1872	Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product?. 2013 , 18, 134-41	49
1871	Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer's disease. 2013 , 4, 143-51	25
1870	The epigenome and nature/nurture reunification: a challenge for anthropology. 2013 , 32, 291-308	109
1869	Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. 2013 , 34, 62-72	40
1868	Apolipoprotein E β and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. 2013 , 34, 1-12	167
1867	Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 2013 , 34, 822-31	106
1866	Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. 2013 , 120, 157-67	24
1865	Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice. 2013 , 25, 286-91	6
1864	Resting state functional connectivity in preclinical Alzheimer's disease. 2013 , 74, 340-7	302
1863	Alzheimer disease: A β independent processes-rethinking preclinical AD. 2013 , 9, 123-4	137
1862	Improving dementia care: the role of screening and detection of cognitive impairment. <i>Alzheimer's and Dementia</i> , 2013 , 9, 151-9	1.2 153
1861	Introduction to Cognitive Screening Instruments: Rationale, Desiderata, and Assessment of Utility. 2013 , 1-14	5
1860	Fast in vivo imaging of amyloid plaques using β MRI Gd-staining combined with ultrasound-induced blood-brain barrier opening. 2013 , 79, 288-94	24

1859	Top 20 articles cited from Alzheimer's & Dementia since 2008. <i>Alzheimer's and Dementia</i> , 2013 , 9, 619-211.2		
1858	Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ϵ carriers. 2013 , 2, 512-20		36
1857	Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. 2013 , 34, 2827-34		52
1856	Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2013 , 9, 594-601	1.2	35
1855	Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. 2013 , 2, 356-65		227
1854	Alzheimer's Association Update for January 2013. 2013 , 9, 98-98		
1853	Cognitive aging in persons with minimal amyloid- β and white matter hyperintensities. 2013 , 51, 2202-9		26
1852	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2013 , 9, e111-94	1.2	296
1851	[Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study]. 2013 , 28, 477-87		3
1850	Leveraging global resources to end the Alzheimer's pandemic. <i>Alzheimer's and Dementia</i> , 2013 , 9, 363-5	1.2	6
1849	Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013 , 9, 602-8	1.2	215
1848	Structural and Functional Magnetic Resonance Imaging: Mild Cognitive Impairment and Alzheimer Disease. 2013 , 8, 407-30		1
1847	Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. 2013 , 71, 207-15		68
1846	Molecular neuroimaging in degenerative dementias. 2013 , 32, 301-9		3
1845	β Amyloid, cognition, and APOE genotype in healthy older adults. <i>Alzheimer's and Dementia</i> , 2013 , 9, 538-45	1.2	45
1844	Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. 2013 , 34, 1133-44		95
1843	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. 2013 , 2, 249-57		35
1842	Current and future treatments for Alzheimer's disease. 2013 , 6, 19-33		346

1841	Imaging markers for Alzheimer disease: which vs how. 2013 , 81, 487-500		173
1840	Classification of diffusion tensor images for the early detection of Alzheimer's disease. 2013 , 43, 1313-20		29
1839	Translational proteomics in Alzheimer's disease and related disorders. 2013 , 46, 480-6		17
1838	Decreased gray matter diffusivity: a potential early Alzheimer's disease biomarker?. <i>Alzheimer's and Dementia</i> , 2013 , 9, 93-7	1.2	27
1837	Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease. 2013 , 12, 823-31		68
1836	Getting lost in Alzheimer's disease: a break in the mental frame syncing. 2013 , 80, 416-21		44
1835	The retooling of old cognitive tests as an interim step on the path to validating a next generation of neuropsychological paradigms and assays. <i>Alzheimer's and Dementia</i> , 2013 , 9, S1-3	1.2	5
1834	Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD. 2013 , 51, 1094-102		45
1833	Research and standardization in Alzheimer's trials: reaching international consensus. <i>Alzheimer's and Dementia</i> , 2013 , 9, 160-8	1.2	16
1832	The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. 2013 , 76, 332-44		140
1831	The economics of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2013 , 9, 58-62	1.2	40
1830	L'imagerie c�rbrale des plaques amyloides: le point de vue du clinicien. 2013 , 4, 59-63		
1829	Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. 2013 , 88, 87-101		53
1828	Cerebrospinal fluid A�2 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013 , 9, 481-7	1.2	139
1827	Perceptual and response interference in Alzheimer's disease and mild cognitive impairment. 2013 , 124, 2389-96		35
1826	Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013 , 9, 519-28	1.2	75
1825	Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. 2013 , 78, 474-80		38
1824	Frailty syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Aging. <i>Alzheimer's and Dementia</i> , 2013 , 9, 113-22	1.2	86

1823	Risk and resilience: A new perspective on Alzheimer's disease. 2013 , 1, 47-55		2
1822	Alzheimer's disease genes and cognition in the nondemented general population. 2013 , 73, 429-34		67
1821	Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture. 2013 , 79, 1035-7		11
1820	Nutritional approaches in the risk reduction and management of Alzheimer's disease. 2013 , 29, 1080-9		56
1819	Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. <i>Alzheimer's and Dementia</i> , 2013 , 9, 438-44	1.2	111
1818	Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment. <i>Alzheimer's and Dementia</i> , 2013 , 9, 356-359.e1	1.2	25
1817	The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. <i>Alzheimer's and Dementia</i> , 2013 , 9, 687-698.e1	1.2	55
1816	Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. <i>Alzheimer's and Dementia</i> , 2013 , 9, S39-44	1.2	67
1815	Alzheimer's Association Update. 2013 , 9, 360-361		
1814	Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. 2013 , 12, 324		48
1813	Slaying dementia dragons with blood, lungs, and guts. 2013 , 61, 155-7		3
1812	Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. 2013 , 80, 1307-14		78
1811	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. 2013 , 12, 357-67		1336
1810	Positron Emission Tomography in Alzheimer Disease. 2013 , 131-174		2
1809	Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. 2013 , 124, 837-50		60
1808	Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013 , 9, 123-131.e1	1.2	82
1807	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. <i>Alzheimer's and Dementia</i> , 2013 , 9, 677-86	1.2	43
1806	Are subjective cognitive complaints relevant in preclinical Alzheimer's disease? A review and guidelines for healthcare professionals. 2013 , 23, 61-74		21

1805	The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. 2013 , 173, 797-804	240
1804	Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. 2013 , 139, 41-50	77
1803	Diagnosis and management of Alzheimer's disease: past, present and future ethical issues. 2013 , 110, 102-13	73
1802	Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β amyloid in cognitively normal older individuals. 2013 , 33, 5553-63	113
1801	Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. 2013 , 70, 462-8	139
1800	Metabolomics in Alzheimer's disease research. 2013 , 34, n/a-n/a	3
1799	White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies. 2013 , 13, 483-93	51
1798	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of tau in cerebrospinal fluid. 2013 , 126, 631-41	103
1797	Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. 2013 , 51, 3-12	110
1796	Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?. 2013 , 13, 1075-84	83
1795	Sleep quality and preclinical Alzheimer disease. 2013 , 70, 587-93	414
1794	Clinical trials in prodementia stages of Alzheimer disease. 2013 , 97, 439-57	37
1793	Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. 2013 , 97, 399-424	108
1792	Applying the IWG research criteria in clinical practice: feasibility and ethical issues. 2013 , 97, 477-84	9
1791	Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?. 2013 , 74, 329-32	23
1790	Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?. 2013 , 9, 279-90	20
1789	Brain changes in older adults at very low risk for Alzheimer's disease. 2013 , 33, 8237-42	152
1788	The olfactory system in Alzheimer's disease: Pathology, pathophysiology and pathway for therapy. 2013 , 4,	13

1787	Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. 2013 , 9, 621-48	84
1786	Resting-state functional connectivity in normal brain aging. 2013 , 37, 384-400	345
1785	An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival, and risk factors. 2013 , 27, 822-9	53
1784	BDNF Val66Met, A β amyloid, and cognitive decline in preclinical Alzheimer's disease. 2013 , 34, 2457-64	93
1783	CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. 2013 , 16, 848-50	370
1782	Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. 2013 , 138, 3991-7	61
1781	Tau Pathology: A Selected View on the Current Status. 2013 , 69-92	
1780	FDG-PET in early AD diagnosis. 2013 , 97, 485-94	9
1779	Brain injury biomarkers are not dependent on A β amyloid in normal elderly. 2013 , 73, 472-80	133
1778	Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. 2013 , 65, 167-75	286
1777	Amyloid β protein oligomers and Alzheimer's disease. 2013 , 5, 60	150
1776	Qualitative neuropsychological measures: normative data on executive functioning tests from the Framingham offspring study. 2013 , 39, 515-35	12
1775	A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. 2013 , 110, 114-23	19
1774	Dementia and personal identity: implications for decision-making. 2013 , 118, 409-18	7
1773	MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. 2013 , 3,	56
1772	Cerebrospinal fluid A β 2, phosphorylated Tau181, and resting-state functional connectivity. 2013 , 70, 1242-8	68
1771	Detecting amyloid biomarkers: Embodied risk and Alzheimer prevention. 2013 , 8, 107-123	7
1770	Correlation of specific amyloid- β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. 2013 , 70, 594-9	46

1769	New diagnostic concepts in Alzheimer's disease. 2013 , 19, 242-249	3
1768	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. 2013 , 136, 2217-27	94
1767	In vivo characterization of the early states of the amyloid-beta network. 2013 , 136, 2239-52	84
1766	Neuroimaging and the search for a cure for Alzheimer disease. 2013 , 269, 671-91	37
1765	Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review. 2013 , 3,	91
1764	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. 2013 , 80, 2121-9	37
1763	Risk factors for β amyloid deposition in healthy aging: vascular and genetic effects. 2013 , 70, 600-6	173
1762	Should we disclose amyloid imaging results to cognitively normal individuals?. 2013 , 3, 43-51	24
1761	Apolipoprotein E epsilon4 does not modulate amyloid- β associated neurodegeneration in preclinical Alzheimer disease. 2013 , 34, 505-10	15
1760	An expanded role for neuroimaging in the evaluation of memory impairment. 2013 , 34, 2075-82	20
1759	Effect and mechanism of acupuncture on Alzheimer's disease. 2013 , 111, 181-95	28
1758	Ethical issues in the neurology of aging and cognitive decline. 2013 , 118, 233-42	4
1757	Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. 2013 , 8, e64318	52
1756	The role of β amyloid in alzheimer's disease-related neurodegeneration. 2013 , 33, 12910-1	19
1755	Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. 2013 , 10, e1001500	88
1754	Preclinical Alzheimer disease and risk of falls. 2013 , 81, 437-43	53
1753	Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. 2013 , 70, 320-5	98
1752	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. 2013 , 81, 736-44	115

1751	Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS). 2013 , 28, 320-30	70
1750	Semantic memory functional MRI and cognitive function after exercise intervention in mild cognitive impairment. 2013 , 37, 197-215	91
1749	Physical activity and memory complaints in middle-age Americans: results from the MIDUS study. 2013 , 28, 600-5	6
1748	Meta-analysis of amyloid-cognition relations in cognitively normal older adults. 2013 , 80, 1341-8	235
1747	Biomarkers in Alzheimer's disease with a special emphasis on event-related oscillatory responses. 2013 , 62, 237-73	52
1746	Residential distance to high-voltage power lines and risk of neurodegenerative diseases: a Danish population-based case-control study. 2013 , 177, 970-8	19
1745	Neither Body nor Brain: Comparing Preventive Attitudes to Prostate Cancer and Alzheimer's Disease. 2013 , 19, 61-91	7
1744	Neuroimaging biomarkers of neurodegenerative diseases and dementia. 2013 , 33, 386-416	87
1743	Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. 2013 , 70, 1512-9	119
1742	Pathology and pathogenesis of vascular cognitive impairment-a critical update. 2013 , 5, 17	208
1741	Association of brain pathology with the progression of frailty in older adults. 2013 , 80, 2055-61	116
1740	Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. 2013 , 80, 1194-201	99
1739	What links gait speed and MCI with dementia? A fresh look at the association between motor and cognitive function. 2013 , 68, 409-11	58
1738	Impaired visual recognition memory predicts Alzheimer's disease in amnesic mild cognitive impairment. 2013 , 35, 291-9	50
1737	Current guidelines for dementia screening: shortcomings and recommended changes. 2013 , 3, 565-573	10
1736	Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. 2013 , 25, 699-710	10
1735	Renovating Alzheimer's: "constructive" reflections on the new clinical and research diagnostic guidelines. 2013 , 53, 378-87	14
1734	The association of Amyloid and composite cognitive measures in healthy older adults and MCI. 2013 , 25, 1667-77	21

1733	Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging. 2013 , 27, 1247-64	99
1732	Cholinergic Depletion in Alzheimer's Disease Shown by [(18) F]FEOBV Autoradiography. 2013 , 2013, 205045	28
1731	Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs. 2013 , 4, 167	50
1730	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. 2013 , 81, 1732-40	142
1729	Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. 2013 , 8, e79378	59
1728	VETSA: the Vietnam Era Twin Study of Aging. 2013 , 16, 399-402	83
1727	Young-onset dementia. 2013 , 33, 365-85	44
1726	Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies. 2013 , 162B, 789-99	58
1725	Proton MRS in mild cognitive impairment. 2013 , 37, 770-7	46
1724	Alteration of affective Theory of Mind in amnesic mild cognitive impairment. 2013 , 7, 121-31	16
1723	The clinical spectrum of sport-related traumatic brain injury. 2013 , 9, 222-30	249
1722	CSF biomarker changes precede symptom onset of mild cognitive impairment. 2013 , 81, 1753-8	74
1721	Disrupting Alzheimer's Disease Research. 2013 , 1, 157-160	
1720	Disease-modifying therapy for Alzheimer's disease: Challenges and hopes. 2013 , 1, 49-54	9
1719	Genetics of brain structure: contributions from the Vietnam Era Twin Study of Aging. 2013 , 162B, 751-61	36
1718	Cerebrovascular contributions to Alzheimer's disease pathophysiology and potential therapeutic interventions in mouse models. 2013 , 37, 1994-2004	8
1717	Context dependence of protein misfolding and structural strains in neurodegenerative diseases. 2013 , 100, 722-30	12
1716	Everyday technologies across the continuum of dementia care. 2013 , 2013, 7040-3	1

1715	The Framingham Heart Study clock drawing performance: normative data from the offspring cohort. 2013 , 39, 80-108	18
1714	Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations. 2014 , 95, 67-77	17
1713	Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. 2013 , 84, 556-61	38
1712	Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. 2013 , 3, e233	167
1711	Dementia: Disclosure of results to participants in dementia research. 2013 , 9, 608-9	2
1710	Preclinical Alzheimer disease-the challenges ahead. 2013 , 9, 54-8	177
1709	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. 2013 , 80, 1784-91	175
1708	The Challenges of Cognitive Aging: Integrating Approaches from Neuroscience to Intergenerational Relationships. 2013 , 11, 105-117	8
1707	Life course health care and preemptive approach to non-communicable diseases. 2013 , 89, 462-73	29
1706	Which neuropsychological tests predict progression to Alzheimer's disease in Hispanics?. 2013 , 27, 343-355	14
1705	The impact of age and Alzheimer's disease risk factors on memory performance over time. 2013 , 9, 115-124	1
1704	Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. 2013 , 3, 219-229	39
1703	The accuracy of ¹⁸ F-FDG-PET in the early diagnosis of Alzheimer's disease dementia and other dementias in people with MCI. 2013 ,	5
1702	Cognitive activities and cognitive performance in middle-aged adults at risk for Alzheimer's disease. 2013 , 28, 1004-14	36
1701	Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial. 2013 , 36, 433-43	7
1700	Daytime sleepiness is associated with decreased default mode network connectivity in both young and cognitively intact elderly subjects. 2013 , 36, 1609-15	40
1699	Cognitive assessment in Parkinson's disease. 53-64	
1698	Diagnosis and biomarkers: CSF. 97-108	

1697	Context memory in Alzheimer's disease. 2013 , 3, 342-50	35
1696	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. 2013 , 5, 48	100
1695	Comparing regional brain atrophy in mild cognitive impairment and Alzheimer's disease. 2013 , 3, 417-426	
1694	CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2013 ,	6
1693	The Brazilian version of the Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity in dementia. 2013 , 25, 1503-11	18
1692	Commentary. 2013 , 25, 181-4	1
1691	Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β amyloidosis. 2013 , 70, 1030-8	58
1690	^{11}C -PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2013 ,	1
1689	Neuroinflammation and brain functional disconnection in Alzheimer's disease. 2013 , 5, 81	20
1688	The pivotal role of semantic memory in remembering the past and imagining the future. 2013 , 7, 27	181
1687	Healthy lifestyles reduce the incidence of chronic diseases and dementia: evidence from the Caerphilly cohort study. 2013 , 8, e81877	102
1686	IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a general practice (primary care) setting. 2013 ,	3
1685	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. 2013 , 5, 59	63
1684	Ratio of $\text{A}\beta_{2}/\text{P-tau}_{181\text{p}}$ in CSF is associated with aberrant default mode network in AD. 2013 , 3, 1339	32
1683	Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease. 2013 , 35, 284-94	14
1682	Assessment of neuropsychiatric symptoms in dementia: toward improving accuracy. 2013 , 7, 244-251	9
1681	Neurodegenerative disorders. 23-71	
1680	The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. 2013 , 2013, 939786	22

1679	Mild cognitive impairment. Part 1: clinical characteristics and predictors of dementia. 2013 , 35, 178-85	34
1678	Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool. 2013 , 8, e55246	28
1677	Regional amyloid deposition in amnesic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. 2013 , 8, e58974	37
1676	Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. 2013 , 8, e68860	72
1675	Epistatic genetic effects among Alzheimer's candidate genes. 2013 , 8, e80839	22
1674	IQCODE for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. 2013 ,	2
1673	Refining the diagnosis of Huntington disease: the PREDICT-HD study. 2013 , 5, 12	58
1672	Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons. 2013 , 5, 21	6
1671	βAmyloid oligomers in aging and Alzheimer's disease. 2013 , 5, 28	47
1670	The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. 2013 , 5, 47	28
1669	Relation of neuropathology with cognitive decline among older persons without dementia. 2013 , 5, 50	74
1668	A combined electrophysiological and morphological examination of episodic memory decline in amnesic mild cognitive impairment. 2013 , 5, 51	11
1667	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. 2013 , 5, 58	95
1666	EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment. 2013 , 5, 63	31
1665	Spatial navigation in young versus older adults. 2013 , 5, 94	75
1664	The attenuation of retinal nerve fiber layer thickness and cognitive deterioration. 2013 , 7, 142	32
1663	Traumatic brain injury, neuroimaging, and neurodegeneration. 2013 , 7, 395	128
1662	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. 2013 , 5, 6	69

1661	Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. 2013 , 2013, 589308	7
1660	Magnetic resonance spectroscopy in Alzheimer's disease. 2013 , 9, 687-96	46
1659	Drug therapies for Alzheimer's disease. 2013 , 2, 78-83	
1658	General anesthetic and the risk of dementia in elderly patients: current insights. 2014 , 9, 1619-28	47
1657	Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer's disease. 2014 , 9, e99897	59
1656	A clinical index to predict progression from mild cognitive impairment to dementia due to Alzheimer's disease. 2014 , 9, e113535	26
1655	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. 2014 , 2014, 1-15	2
1654	Role of EEG as biomarker in the early detection and classification of dementia. 2014 , 2014, 906038	81
1653	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. 2014 , 2014, 1-14	11
1652	Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of disease. 2014 , 2014, 520152	10
1651	The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition. 2014 , 40, 331-41	20
1650	MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. 2014 , 6, 23	13
1649	What is the role of spatial processing in the decline of episodic memory in Alzheimer's disease? The "mental frame syncing" hypothesis. 2014 , 6, 33	14
1648	Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. 2014 , 6, 42	80
1647	The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice. 2014 , 6, 45	4
1646	Early Brain Loss in Circuits Affected by Alzheimer's Disease is Predicted by Fornix Microstructure but may be Independent of Gray Matter. 2014 , 6, 106	27
1645	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. 2014 , 6, 145	23
1644	Regional Fluid-Attenuated Inversion Recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects. 2014 , 6, 240	12

1643	Relationship between herpes simplex virus-1-specific antibody titers and cortical brain damage in Alzheimer's disease and amnesic mild cognitive impairment. 2014 , 6, 285	35
1642	Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. 2014 , 8, 321	45
1641	Why looking at the whole hippocampus is not enough-a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer's disease diagnosis. 2014 , 8, 95	73
1640	Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. 2014 , 8, 203	47
1639	Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction. 2014 , 8, 921	19
1638	Enhancing cognition before clinical symptoms of dementia. 2014 , 8, 240	1
1637	Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease. 2014 , 11, 367-88	22
1636	Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. 2014 , 10, 1677-91	80
1635	Biological markers of Alzheimer's disease. 2014 , 72, 227-31	14
1634	Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease. 2014 , 10, 439-51	22
1633	The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies. 2014 , 36, 344-57	7
1632	Prevalence of dementia in Colombian populations. 2014 , 8, 323-329	2
1631	Obesity, Cognitive Functioning, and Dementia. 2014 , 385-402	
1630	(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2014 , CD010386	66
1629	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. 2014 , CD010771	31
1628	The potentially protective effect of donepezil in Alzheimer's disease. 2014 , 38, 170-7	8
1627	Development of a psychometrically equivalent short form of the Face-Name Associative Memory Exam for use along the early Alzheimer's disease trajectory. 2014 , 28, 771-85	40
1626	Single neuropsychological test scores associated with rate of cognitive decline in early Alzheimer disease. 2014 , 28, 926-40	10

1625	Amyloid imaging in Alzheimer's disease: a literature review. 2014 , 18, 723-40	8
1624	Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?. 2014 , 15, 38-49	1
1623	Analysis of neural dynamics in mild cognitive impairment and Alzheimer's disease using wavelet turbulence. 2014 , 11, 026010	22
1622	Astrocytosis measured by [¹¹ C]-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. 2014 , 41, 2120-6	46
1621	Optimizing the use of expert panel reference diagnoses in diagnostic studies of multidimensional syndromes. 2014 , 14, 190	8
1620	The diagnosis and management of mild cognitive impairment: a clinical review. 2014 , 312, 2551-61	527
1619	PPAR α recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. 2014 , 34, 4054-63	51
1618	D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease. 2014 , 8, 119-24	32
1617	[Clinically validated molecular biomarkers of neurodegenerative dementia]. 2014 , 85, 1372-81	4
1616	Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. 2014 , 20, 836-47	134
1615	Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. 2014 , 14, 973-86	33
1614	Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. 2014 , 8, 1151-69	33
1613	Retinal manifestations of Alzheimer's disease. 2014 , 4, 241-52	22
1612	Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease. 2014 , 289, 35296-313	28
1611	Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 2014 , 19, 1044-51	143
1610	Alzheimer's disease progression model based on integrated biomarkers and clinical measures. 2014 , 35, 1111-20	15
1609	The sleep-wake cycle and Alzheimer's disease: what do we know?. 2014 , 4, 351-62	84
1608	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. 2014 , 83, 434-40	51

1607	The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries. 2014 , 5, 102	15
1606	Aging, Overview. 2014 , 76-80	0
1605	The need for better AD animal models. 2014 , 5, 227	9
1604	Physical activity attenuates age-related biomarker alterations in preclinical AD. 2014 , 83, 1753-60	135
1603	Exaggerated reaction to novelty as a subclinical consequence of mild traumatic brain injury. 2014 , 28, 972-9	7
1602	Role of neuroimaging in HIV-associated neurocognitive disorders. 2014 , 34, 89-102	57
1601	Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. 2014 , 71, 55-61	162
1600	Metabolomics in the Study of Alzheimer's Disease. 2014 , 64, 249-278	1
1599	Is verbal episodic memory in elderly with amyloid deposits preserved through altered neuronal function?. 2014 , 24, 2210-8	30
1598	Apathy correlates with prefrontal amyloid deposition in Alzheimer's disease. 2014 , 85, 449-55	66
1597	Preclinical biomarkers in Alzheimer disease: a sum greater than the parts. 2014 , 71, 1357-8	3
1596	Invited commentary: how exposure to air pollution may shape dementia risk, and what epidemiology can say about it. 2014 , 180, 367-71	19
1595	A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. 2014 , 2014, 785039	37
1594	Protein phosphatase 2A dysfunction in Alzheimer's disease. 2014 , 7, 16	173
1593	Alzheimer's disease in African Americans: risk factors and challenges for the future. 2014 , 33, 580-6	154
1592	Comparison of the repeatable battery for the assessment of neuropsychological status effort scale and effort index in a dementia sample. 2014 , 29, 633-41	12
1591	The A4 study: stopping AD before symptoms begin?. 2014 , 6, 228fs13	455
1590	Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. 2014 , 83, 364-73	146

1589	Amyloid and APOE ϵ interact to influence short-term decline in preclinical Alzheimer disease. 2014 , 82, 1760-7	209
1588	The Default Network of the Brain. 2014 , 169-181	
1587	Cognitive function in midlife and beyond: physical and cognitive activity related to episodic memory and executive functions. 2014 , 79, 263-78	14
1586	Serum metabolomic biomarkers of dementia. 2014 , 4, 252-62	37
1585	Subjective cognitive impairment subjects in our clinical practice. 2014 , 4, 419-30	25
1584	Newly Identified Blood Biomarkers Predict Conversion to Alzheimer's. 2014 , 14, 6	
1583	Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. 2014 , 171, 201-8	76
1582	Molecular imaging of Alzheimer disease pathology. 2014 , 35, S12-7	13
1581	A data-driven model of biomarker changes in sporadic Alzheimer's disease. 2014 , 137, 2564-77	149
1580	Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. 2014 , 137, 2578-87	101
1579	New tools for the evaluation of patients with neurodegenerative diseases. 2014 , 4, 403-5	
1578	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. 2014 , 6, 445-54	133
1577	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. 2014 , 9, 597-613	2
1576	Longitudinal alteration of amygdalar functional connectivity in mild cognitive impairment subjects revealed by resting-state fMRI. 2014 , 4, 361-70	21
1575	Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease. 2014 , 14, 716-23	32
1574	Topological graph kernel on multiple thresholded functional connectivity networks for mild cognitive impairment classification. 2014 , 35, 2876-97	77
1573	Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease. 2014 , 264 Suppl 1, S3-7	86
1572	Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. 2014 , 34, 9096-106	57

1571	Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. 2014 , 39, 25-37	46
1570	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. 2014 , 275, 251-83	437
1569	Comparison of cortical thickness in patients with early-stage versus late-stage amnesic mild cognitive impairment. 2014 , 21, 86-92	31
1568	Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. 2014 , 211, 2487-96	138
1567	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. 2014 , 1, 534-43	78
1566	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. 2014 , 35, 2665-2670	23
1565	Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease. 2014 , 43, 131-9	1
1564	Pathogenesis and treatment of vascular cognitive impairment. 2014 , 4, 471-90	23
1563	Tau PET imaging in Alzheimer's disease. 2014 , 14, 500	119
1562	Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy?. 2014 , 61, 1739-42	4
1561	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. 2014 , 2, 26	65
1560	White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. 2014 , 71, 1547-54	45
1559	Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. 2014 , 83, 718-26	233
1558	A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. 2014 , 12, 575-93	177
1557	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. 2014 , 6, 226ra30	244
1556	Intracellular A β pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. 2014 , 2, 61	62
1555	Imaging endpoints for clinical trials in Alzheimer's disease. 2014 , 6, 87	40
1554	Preclinical Alzheimer's disease. 2014 , 24, 117-121	

1553	Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications. 2014 , 4, 73-81	4
1552	Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. 2014 , 55, 2003-11	42
1551	Neuropsychiatric symptoms in the prodromal stages of dementia. 2014 , 27, 230-5	36
1550	Midlife cardiovascular risk impacts executive function: Framingham offspring study. 2014 , 28, 16-22	32
1549	FDG-PET and amyloid-PET imaging: the diverging paths. 2014 , 27, 405-13	48
1548	Imaging biomarkers for amyloid: a new generation of probes and what lies ahead. 2014 , 26, 703-7	1
1547	Theoretical impact of Flortbetapir (18F) amyloid imaging on diagnosis of Alzheimer dementia and detection of preclinical cortical amyloid. 2014 , 73, 948-53	25
1546	How to Diagnose and Define Alzheimer's. 2014 , 14, 1	
1545	Help-seeking for dementia: a systematic review of the literature. 2014 , 28, 299-310	56
1544	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). 2014 , 26, 543-54	30
1543	Neutral polymers as coatings for high resolution electrophoretic separation of A β peptides on glass microchips. 2014 , 139, 6547-55	13
1542	Facilitating Alzheimer disease research recruitment. 2014 , 28, 1-8	63
1541	Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. 2014 , 28, 234-8	5
1540	Functional disorganization of small-world brain networks in mild Alzheimer's Disease and amnesic Mild Cognitive Impairment: an EEG study using Relative Wavelet Entropy (RWE). 2014 , 6, 224	68
1539	Synergistic effect of β amyloid and neurodegeneration on cognitive decline in clinically normal individuals. 2014 , 71, 1379-85	227
1538	The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. 2014 , 71, 961-70	372
1537	Assessment of Relation Between Subjective Memory Complaints and Objective Cognitive Performance of Elderly Over 55 Years Old Age. 2014 , 51, 57-62	5
1536	Mild cognitive impairment: a concept and diagnostic entity in need of input from neuropsychology. 2014 , 20, 129-34	57

1535	Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. 2014 , 20, 422-33	21
1534	Retrospective lifetime dietary patterns predict cognitive performance in community-dwelling older Australians. 2014 , 112, 228-37	16
1533	Emerging β amyloid pathology and accelerated cortical atrophy. 2014 , 71, 725-34	43
1532	How are we going to live with Alzheimer's disease?. 2014 , 33, 541-6	4
1531	Incidence of cerebral microbleeds in preclinical Alzheimer disease. 2014 , 82, 1266-73	110
1530	Neuroinflammation in Alzheimer's Disease. 2014 , 161-177	1
1529	Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies. 2014 , 5, 132	43
1528	Alzheimer's disease: The role for neurosurgery. 2014 , 5, S385-90	8
1527	Reverse Fox test for detecting visuospatial dysfunction corresponding to parietal hypoperfusion in mild Alzheimer's disease. 2014 , 29, 177-82	5
1526	Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. 2014 , 42 Suppl 4, S411-9	123
1525	Double compression: a vision for compressing morbidity and caregiving in dementia. 2014 , 54, 901-8	4
1524	A distinct subfraction of A β s responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. 2014 , 131, 356-68	22
1523	The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. 2014 , 1842, 1219-31	411
1522	Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment. 2014 , 35, 130-42	47
1521	Very mild Alzheimer's disease is characterized by increased sensitivity to mnemonic interference. 2014 , 59, 47-56	6
1520	Event-related potential index of age-related differences in memory processes in adults with Down syndrome. 2014 , 35, 247-53	10
1519	A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 646-55	1.2 34
1518	Dihydrotestosterone treatment delays the conversion from mild cognitive impairment to Alzheimer's disease in SAMP8 mice. 2014 , 65, 505-15	36

1517	APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. 2014 , 35, 2479-2485		29
1516	Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease. 2014 , 35, 1973-81		38
1515	Microdosing of scopolamine as a "cognitive stress test": rationale and test of a very low dose in an at-risk cohort of older adults. <i>Alzheimer's and Dementia</i> , 2014 , 10, 262-7	1.2	24
1514	Functional connectivity and graph theory in preclinical Alzheimer's disease. 2014 , 35, 757-68		230
1513	Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. 2014 , 4, 45-52		78
1512	Amyloid- β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. 2014 , 35 Suppl 2, S29-34		96
1511	n-3 LCPUFA improves cognition: the young, the old and the sick. 2014 , 91, 1-20		78
1510	Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease. 2014 , 5, 178-87		68
1509	Preventing cognitive decline in preclinical Alzheimer's disease. 2014 , 14, 18-22		14
1508	The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective. 2014 , 88, 677-81		23
1507	The neuropsychology of normal aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 84-92	1.2	48
1506	Imaging and cognitive reserve studies predict dementia in presymptomatic Alzheimer's disease subjects. 2014 , 13, 157-9		18
1505	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. 2014 , 261, 144-51		45
1504	Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography. 2014 , 133, 85-93		25
1503	Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. 2014 , 8, 262-73		125
1502	Biomarker modelling of early molecular changes in Alzheimer's disease. 2014 , 18, 213-27		4
1501	Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. 2014 , 88, 617-30		32
1500	Plasma phospholipids identify antecedent memory impairment in older adults. 2014 , 20, 415-8		706

1499	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. 2014 , 137, 1762-71		197
1498	Magnetic resonance imaging predictors of treatment response in late-life depression. 2014 , 27, 24-32		32
1497	The clinical utility of the auditory P300 latency subcomponent event-related potential in preclinical diagnosis of patients with mild cognitive impairment and Alzheimer's disease. 2014 , 86, 64-74		55
1496	Diagnosis disclosure and advance care planning in Alzheimer disease: opinions of a sample of Italian citizens. 2014 , 26, 427-34		11
1495	Souvenaid [®] : a new approach to management of early Alzheimer's disease. 2014 , 18, 291-9		16
1494	Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment. 2014 , 41, 739-48		21
1493	Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. 2014 , 75, 678-85		80
1492	Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. 2014 , 34, 5200-10		56
1491	2014 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2014 , 10, e47-92	1.2	674
1490	Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. 2014 , 35, 3132-42		102
1489	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 844-52	1.2	1219
1488	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. 2014 , 117, 20-40		412
1487	Early detection of Alzheimer's disease using PiB and FDG PET. 2014 , 72 Pt A, 117-22		131
1486	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. 2014 , 13, 614-29		1985
1485	Analysis of sampling techniques for imbalanced data: An n = 648 ADNI study. 2014 , 87, 220-41		114
1484	Sex modifies the APOE-related risk of developing Alzheimer disease. 2014 , 75, 563-73		424
1483	Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. 2014 , 22, 1642-51		133
1482	Global brain hypoperfusion and oxygenation in amnesic mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2014 , 10, 162-70	1.2	51

1481	Cerebrospinal fluid amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. 2014 , 76, 223-30		88
1480	Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. 2014 , 30, 199-205		29
1479	Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. 2014 , 17, 304-11		336
1478	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. 2014 , 137, 221-31		145
1477	Magnetization transfer contrast imaging reveals amyloid pathology in Alzheimer's disease transgenic mice. 2014 , 87, 111-9		18
1476	Sleep and Alzheimer disease pathology--a bidirectional relationship. 2014 , 10, 115-9		457
1475	Early identification and heritability of mild cognitive impairment. 2014 , 43, 600-10		43
1474	Impaired long distance functional connectivity and weighted network architecture in Alzheimer's disease. 2014 , 24, 1422-35		142
1473	CSF A β -42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 381-92	1.2	53
1472	Advances in the prevention of Alzheimer's disease and dementia. 2014 , 275, 229-50		182
1471	Diagnostic classification of arterial spin labeling and structural MRI in presenile early stage dementia. 2014 , 35, 4916-31		65
1470	Alzheimer disease: the landscape of ageing--insights from AD imaging markers. 2014 , 10, 678-9		9
1469	Body mass index in dementia. 2014 , 68, 1204-9		49
1468	Early neuropsychological detection of Alzheimer's disease. 2014 , 68, 1192-9		46
1467	Unbiased approaches to biomarker discovery in neurodegenerative diseases. 2014 , 84, 594-607		40
1466	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014 , 10, 779-89	1.2	19
1465	The evolution of preclinical Alzheimer's disease: implications for prevention trials. 2014 , 84, 608-22		429
1464	Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 690-703	1.2	24

1463	Editorial. <i>Alzheimer's and Dementia</i> , 2014 , 10, 590-1	1.2
1462	Short and long telomeres increase risk of amnesic mild cognitive impairment. 2014 , 141-142, 64-9	25
1461	The emerging link between O-GlcNAc and Alzheimer disease. 2014 , 289, 34472-81	151
1460	Regional analysis of striatal and cortical amyloid deposition in patients with Alzheimer's disease. 2014 , 40, 2701-6	20
1459	Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases. 2014 , 10, 743	101
1458	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. 2014 , 4, 31-40	59
1457	Hohe Prävalenz und rasches Fortschreiten. 2014 , 16, 21-22	
1456	Aging trajectories of fluid intelligence in late life: The influence of age, practice and childhood IQ on Raven's Progressive Matrices. 2014 , 47, 194-201	20
1455	Memory for the 2008 presidential election in healthy ageing and mild cognitive impairment. 2014 , 28, 1407-21	5
1454	Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. 2014 , 111, E4359-66	123
1453	A comparison of early diagnostic utility of Alzheimer disease biomarkers in magnetic resonance and cerebrospinal fluid. 2014 , 29, 397-401	
1452	Intrinsic functional component analysis via sparse representation on Alzheimer's disease neuroimaging initiative database. 2014 , 4, 575-86	14
1451	Harmonized diagnostic criteria for Alzheimer's disease: recommendations. 2014 , 275, 204-13	82
1450	Electrochemical immunosensors for effective evaluation of amyloid-beta modulators on oligomeric and fibrillar aggregation processes. 2014 , 86, 4901-9	59
1449	Insulin resistance in Alzheimer's disease. 2014 , 72 Pt A, 92-103	78
1448	Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. 2014 , 1175, 323-556	50
1447	Extracting salient brain patterns for imaging-based classification of neurodegenerative diseases. 2014 , 33, 1262-74	21
1446	Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis. 2014 , 224, 81-8	36

1445	The relationship between amyloid deposition, neurodegeneration, and cognitive decline in dementia. 2014 , 14, 498		10
1444	Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. 2014 , 16, 490		82
1443	Recommendations of the Alzheimer's disease-related dementias conference. 2014 , 83, 851-60		80
1442	Standardization of MRI and Amyloid Imaging. 2014 , 131-156		0
1441	Clinical workout for the early detection of cognitive decline and dementia. 2014 , 68, 1186-91		11
1440	Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening. 2014 , 4, 253-9		5
1439	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, 808-17	1.2	132
1438	Plasma A β but not tau is related to brain PiB retention in early Alzheimer's disease. 2014 , 5, 830-6		81
1437	Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. 2014 , 29, 339-345		2
1436	Structural imaging measures of brain aging. 2014 , 24, 271-89		144
1435	Age-specific population frequencies of cerebral β amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. 2014 , 13, 997-1005		246
1434	Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. 2014 , 24, 290-9		54
1433	The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations. 2014 , 24, 300-12		26
1432	Neuroimaging of the aging brain: introduction to the special issue of neuropsychology review. 2014 , 24, 267-70		4
1431	How does it STAC up? Revisiting the scaffolding theory of aging and cognition. 2014 , 24, 355-70		409
1430	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. 2014 , 11, 120		66
1429	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. 2014 , 6, 1		110
1428	Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity. 2014 , 6, 58		9

1427	Imago Mundi, Imago AD, Imago ADNI. 2014 , 6, 62	4
1426	Connectome-scale assessments of structural and functional connectivity in MCI. 2014 , 35, 2911-23	52
1425	Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. 2014 , 137, 3327-38	89
1424	Fluorodeoxyglucose PET in Neurology and Psychiatry. 2014 , 9, 371-90, v	44
1423	Targeting brain α 7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status. 2014 , 28, 975-87	38
1422	The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease. 2014 , 275, 418-27	35
1421	Neural compensation in older people with brain amyloid- β deposition. 2014 , 17, 1316-8	123
1420	Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. 2014 , 83, 1613-9	40
1419	Biomarkers in dementia: clinical utility and new directions. 2014 , 85, 1426-34	98
1418	Influence of central nervous system-acting drugs on results of cognitive testing in geriatric inpatients. 2014 , 47, 279-84	7
1417	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. 2014 , 35, 2383-93	84
1416	Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. 2014 , 17, 1156-63	579
1415	[Neurocognitive disorders in DSM-5: pervasive changes in the diagnostics of dementia]. 2014 , 85, 564-70	19
1414	Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. 2014 , 219, 2029-49	26
1413	The earlier the better: Alzheimer's prevention, early detection, and the quest for pharmacological interventions. 2014 , 38, 217-36	18
1412	Diagnostic effectiveness of quantitative [18 F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. 2014 , 2, 46	16
1411	Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ϵ 4 status and cerebrospinal fluid amyloid- β levels. 2014 , 6, 20	39
1410	Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?. 2014 , 5,	1

1409	Biochemical stages of amyloid- β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. 2014 , 137, 887-903	109
1408	Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process. 2014 , 40, 1-17	24
1407	A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. 2014 , 29, 551-61	51
1406	Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. 2014 , 35, 819-26	58
1405	Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. 2014 , 275, 304-16	43
1404	Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?. 2014 , 14, 1465-76	50
1403	Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases. 2014 , 55, 475-555	46
1402	Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer's disease. 2014 , 30, 217-32	95
1401	Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study. 2014 , 30, 477-89	27
1400	Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models. 2014 , 3, 110-129	6
1399	Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing. 2014 , 14, 101	132
1398	Fibrillar amyloid correlates of preclinical cognitive decline. <i>Alzheimer's and Dementia</i> , 2014 , 10, e1-8	1.2 12
1397	Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis. 2014 , 4, 299-311	100
1396	Personalized Medicine of Alzheimer's Disease. 2014 , 563-615	1
1395	At the crossroads of preclinical AD and normal brain ageing. 2014 , 13, 965-6	2
1394	Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. 2014 , 21, 143-8	23
1393	Vision function abnormalities in Alzheimer disease. 2014 , 59, 414-33	70
1392	Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. 2014 , 35, 1873-82	82

1391	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimer's and Dementia</i> , 2014 , 10, 456-467	1.2	12
1390	Detecting gene mutations in Japanese Alzheimer's patients by semiconductor sequencing. 2014 , 35, 1780.e1-5		17
1389	An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 666-74	1.2	89
1388	White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults. 2014 , 35, 2263-71		45
1387	Alzheimer's Association Update for January 2014. 2014 , 10, 132-133		1
1386	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S12-25	1.2	87
1385	Abundant cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 743-751.e1	1.2	62
1384	Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. 2014 , 35, 1318-24		83
1383	Amyloid burden and neural function in people at risk for Alzheimer's Disease. 2014 , 35, 576-84		117
1382	Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. 2014 , 29, 339-45		13
1381	Parahippocampal white matter volume predicts Alzheimer's disease risk in cognitively normal old adults. 2014 , 35, 1855-61		15
1380	Gray matter atrophy pattern in elderly with subjective memory impairment. <i>Alzheimer's and Dementia</i> , 2014 , 10, 99-108	1.2	100
1379	The role of human cognitive neuroscience in drug discovery for the dementias. 2014 , 14, 62-73		8
1378	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. 2014 , 88, 426-49		84
1377	Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. 2014 , 42, 275-89		324
1376	Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study. 2014 , 35, 3903-18		47
1375	The critical need for defining preclinical biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S196-212	1.2	89
1374	Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. <i>Alzheimer's and Dementia</i> , 2014 , 10, S122-45	1.2	194

1373	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. 2014 , 273, 65-71		46
1372	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid β protein 42 levels. 2014 , 35, 2671-2680		56
1371	Sex and gender differences in the causes of dementia: a narrative review. 2014 , 79, 196-201		103
1370	The role of egocentric and allocentric abilities in Alzheimer's disease: a systematic review. 2014 , 16, 32-44		71
1369	Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. 2014 , 30, 421-42		354
1368	Progress update: fluid and imaging biomarkers in Alzheimer's disease. 2014 , 75, 520-6		18
1367	A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid. 2014 , 29, 397-401		5
1366	tDCS-enhanced motor and cognitive function in neurological diseases. 2014 , 85 Pt 3, 934-47		255
1365	Diagnosing Alzheimer's disease: a systematic review of economic evaluations. <i>Alzheimer's and Dementia</i> , 2014 , 10, 225-37	1.2	29
1364	APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. 2014 , 19, 351-7		145
1363	A blood-based predictor for neocortical A β burden in Alzheimer's disease: results from the AIBL study. 2014 , 19, 519-26		85
1362	Qualification of a surrogate matrix-based absolute quantification method for amyloid- β in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. 2014 , 41, 441-51		77
1361	Molecular imaging in sporadic Alzheimer's disease populations and those genetically at risk. 2014 , 13, 160-2		5
1360	A review of β amyloid neuroimaging in Alzheimer's disease. 2014 , 8, 327		61
1359	Cortical Amyloid Beta in Cognitively Normal Elderly Adults is Associated with Decreased Network Efficiency within the Cerebro-Cerebellar System. 2014 , 6, 52		17
1358	Recent updates on subcortical ischemic vascular dementia. 2014 , 16, 18-26		63
1357	Electroencephalographic upper/low alpha frequency power ratio relates to cortex thinning in mild cognitive impairment. 2014 , 14, 18-30		14
1356	Early Intervention in Older Adults [A Focus on Alzheimer's Dementia]. 2014 , 103-115		

1355	Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms. 2014 , 13, 163-5	9
1354	Diagnosing motoric cognitive risk syndrome to predict progression to dementia. 2014 , 4, 339-42	14
1353	Rates of Amyloid accumulation are independent of hippocampal neurodegeneration. 2014 , 82, 1605-12	100
1352	How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?. 2014 , 13, 197-9	3
1351	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's dementia and other dementias in asymptomatic and previously clinically unevaluated people aged over 65 years in community and primary care populations. 2014 ,	12
1350	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. 2015 , 21, 841-50	37
1349	The role of nutrition on cognition and brain health in ageing: a targeted approach. 2015 , 28, 167-180	17
1348	Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. 2015 , 21, 573-83	23
1347	Back to the future: Alzheimer's disease heterogeneity revisited. 2015 , 1, 368-370	26
1346	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. 2015 , 74, 1086-92	19
1345	CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?. 2015 , 2, 131-9	25
1344	A practical algorithm for managing Alzheimer's disease: what, when, and why?. 2015 , 2, 307-23	52
1343	Low neural exosomal levels of cellular survival factors in Alzheimer's disease. 2015 , 2, 769-73	121
1342	Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease. 2015 , 63, 1749-56	50
1341	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. 2015 , 2, 534-47	25
1340	Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment. 2015 , 47, 253-70	9
1339	A connectivity-based test-retest dataset of multi-modal magnetic resonance imaging in young healthy adults. 2015 , 2, 150056	30
1338	Episodic Memory in Neurodegenerative Disorders. 2015 , 415-433	2

1337	Alzheimer's disease. 2015 , 1, 15056	755
1336	The latent dementia phenotype in the uniform data set: Cross-validation and extension. 2015 , 29, 344-52	33
1335	Residual decline in cognition after adjustment for common neuropathologic conditions. 2015 , 29, 335-43	38
1334	Absence of practice effects in preclinical Alzheimer's disease. 2015 , 29, 940-8	73
1333	Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer's Disease. 2015 , 46, 491-5	15
1332	Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. 2015 , 46, 817-36	37
1331	Identification of Conversion from Normal Elderly Cognition to Alzheimer's Disease using Multimodal Support Vector Machine. 2015 , 47, 1057-67	9
1330	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. 2015 , 46, 63-73	65
1329	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. 2015 , 48 Suppl 1, S63-86	253
1328	Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. 2015 , 47, 669-79	40
1327	Magnetic Resonance Spectroscopy in Alzheimer's Disease: Systematic Review and Meta-Analysis. 2015 , 46, 1049-70	63
1326	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. 2015 , 48, 433-41	28
1325	Projecting Burden of Dementia in Spain, 2010-2050: Impact of Modifying Risk Factors. 2015 , 48, 721-30	19
1324	A review of ethical issues in dementia. 2015 , 27, 1635-47	28
1323	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. 2015 , 47, 793-813	80
1322	Investigation of neurodegenerative diseases from body fluid samples using Fourier transform infrared spectroscopy. 2015 , 4, 341-357	9
1321	Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials. 2015 , 48, 581-9	8
1320	Reduced Benefit of Memory Elaboration in Older Adults with Subjective Memory Decline. 2015 , 47, 705-13	7

1319	Subjective Memory Complaints in APOEε4 Carriers are Associated with High Amyloid-β Burden. 2016 , 49, 1115-22	40
1318	Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family). 2015 , 48, 613-25	16
1317	Mapping the Relationship of Contributing Factors for Preclinical Alzheimer's Disease. 2015 , 5, 11259	4
1316	Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. 2015 , 125, 350-64	97
1315	Hippocampal Subfield Volumetry and 3D Surface Mapping in Subjective Cognitive Decline. 2015 , 48 Suppl 1, S141-50	80
1314	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. 2015 , 48 Suppl 1, S171-91	29
1313	New Perspectives on Alzheimer's Disease and Nutrition. 2015 , 46, 1111-27	47
1312	Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. 2015 , 48, 411-24	53
1311	Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. 2015 , 47, 231-42	101
1310	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. 2015 , 46, 889-99	11
1309	Feature Binding Deficits in Subjective Cognitive Decline and in Mild Cognitive Impairment. 2015 , 48 Suppl 1, S161-70	32
1308	Nonlinear parameters of surface electromyogram for diagnostics of neuromuscular disorders and normal conditions of the human motor system. 2015 , 41, 672-679	3
1307	Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?. 2015 , 1, 521-32	22
1306	The New Conceptualization of Alzheimer's Disease under the Microscope of Influential Definitions of Disease. 2015 , 48, 359-67	5
1305	Welche Rolle spielt das Amyloid-PET für die Diagnose?. 2015 , 17, 32-33	
1304	Antemortem Prediction of Braak Stage. 2015 , 74, 1061-70	10
1303	Self-perceived memory loss is associated with an increased risk of hip fracture in the elderly: a population-based NREPOS cohort study. 2015 , 15, 134	5
1302	Amyloid-α Peptide in olfactory mucosa and mesenchymal stromal cells of mild cognitive impairment and Alzheimer's disease patients. 2015 , 25, 136-45	12

1301	A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. 2015 , 7, 50	8
1300	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- β concentrations collected by lumbar puncture and indwelling lumbar catheter. 2015 , 7, 53	20
1299	Diagnostic value of cerebrospinal fluid A β ratios in preclinical Alzheimer's disease. 2015 , 7, 75	38
1298	Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. 2015 , 77, 338-42	106
1297	Etiology-based classification--the way forward for psychiatry. 2015 , 132, 81	1
1296	Volumetric and shape analysis of the thalamus and striatum in amnesic mild cognitive impairment. 2016 , 49, 237-49	12
1295	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. 2015 , 47, 205-14	39
1294	Successful Scene Encoding in Presymptomatic Early-Onset Alzheimer's Disease. 2015 , 47, 955-64	5
1293	Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis. 2015 , 69, 674-81	22
1292	A Meta-Analysis of fMRI Activation Differences during Episodic Memory in Alzheimer's Disease and Mild Cognitive Impairment. 2015 , 25, 849-60	23
1291	Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. 2015 , 36, 2826-41	68
1290	Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer's disease patients. 2015 , 30, 1230-7	22
1289	Clinical features of repetitive traumatic brain injury and chronic traumatic encephalopathy. 2015 , 25, 304-17	48
1288	The effect of beta-amyloid on face processing in young and old adults: A multivariate analysis of the BOLD signal. 2015 , 36, 2514-26	20
1287	Mild Neurocognitive Disorder: An Old Wine in a New Bottle. 2015 , 23, 368-76	40
1286	Obesity and Aging: Consequences for Cognition, Brain Structure, and Brain Function. 2015 , 77, 697-709	84
1285	Diagnostic Pathways to Alzheimer Disease: Costs Incurred in a Medicare Population. 2015 , 29, 330-7	12
1284	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. 2015 , 47, 421-32	50

1283	Amyloid- β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. 2015 , 48 Suppl 1, S151-9	65
1282	Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer's disease. 2015 , 11, 461-70	9
1281	Association of EEG, MRI, and regional blood flow biomarkers is predictive of prodromal Alzheimer's disease. 2015 , 11, 2779-91	9
1280	Assessment of subjective cognitive impairment among older adults. 2015 , 41, 28-35; quiz 36-7	16
1279	Dissociating Statistically-Determined Alzheimer's Disease/Vascular Dementia Neuropsychological Syndromes Using White and Gray Neuroradiological Parameters. 2015 , 48, 833-47	9
1278	Inflammatory Cyclooxygenase Activity and PGE Signaling in Models of Alzheimer's Disease. 2015 , 11, 125-131	12
1277	Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. 2015 , 45, 27-33	33
1276	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. 2015 , 6, 282-99	75
1275	Alzheimer's disease and language impairments: social intervention and medical treatment. 2015 , 10, 1401-7	67
1274	Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. 2015 , 10, 4981-5003	150
1273	Intravenous immunoglobulin for Alzheimer's disease. 2015 ,	
1272	Network Neurodegeneration in Alzheimer's Disease via MRI Based Shape Diffeomorphometry and High-Field Atlasing. 2015 , 3, 54	30
1271	Comparison of Regional Brain Perfusion Levels in Chronically Smoking and Non-Smoking Adults. 2015 , 12, 8198-213	34
1270	Fornix White Matter is Correlated with Resting-State Functional Connectivity of the Thalamus and Hippocampus in Healthy Aging but Not in Mild Cognitive Impairment - A Preliminary Study. 2015 , 7, 10	11
1269	Reliability of a novel serious game using dual-task gait profiles to early characterize aMCI. 2015 , 7, 50	28
1268	Interaction between therapeutic interventions for Alzheimer's disease and physiological A β clearance mechanisms. 2015 , 7, 64	19
1267	Cognitive reserve and lifestyle: moving towards preclinical Alzheimer's disease. 2015 , 7, 134	88
1266	Overestimating the Effects of Healthy Aging. 2015 , 7, 164	4

1265	The Vallecas Project: A Cohort to Identify Early Markers and Mechanisms of Alzheimer's Disease. 2015 , 7, 181	17
1264	Mental Rotation as an Indicator of Motor Representation in Patients with Mild Cognitive Impairment. 2015 , 7, 238	7
1263	Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. 2015 , 6, 142	18
1262	Mild Cognitive Impairment: Structural, Metabolical, and Neurophysiological Evidence of a Novel EEG Biomarker. 2015 , 6, 152	9
1261	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. 2015 , 6, 186	19
1260	Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease. 2015 , 6, 237	75
1259	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. 2015 , 6, 256	10
1258	Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer's disease: a machine learning approach. 2015 , 9, 307	110
1257	Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment. 2015 , 47, 901-13	54
1256	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. 2015 , 12, 712-22	104
1255	Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. 2016 , 49, 493-502	11
1254	Cerebrospinal fluid β amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis. 2015 , 10, e0116802	36
1253	Vascular factors and multiple measures of early brain health: CARDIA brain MRI study. 2015 , 10, e0122138	71
1252	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease. 2015 , 10, e0126423	147
1251	Cannabinoid CB2 Receptors in a Mouse Model of AD Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. 2015 , 10, e0129618	67
1250	Diagnostic Value of Subjective Memory Complaints Assessed with a Single Item in Dominantly Inherited Alzheimer's Disease: Results of the DIAN Study. 2015 , 2015, 828120	6
1249	Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. 2015 , 2015, 287843	53
1248	Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort. 2015 , 2015, 647389	17

1247	A hybrid intelligent diagnosis approach for quick screening of Alzheimer's disease based on multiple neuropsychological rating scales. 2015 , 2015, 258761	5
1246	Exploring Visual Selective Attention towards Novel Stimuli in Alzheimer's Disease Patients. 2015 , 5, 492-502	20
1245	Neuroplastic effects of combined computerized physical and cognitive training in elderly individuals at risk for dementia: an eLORETA controlled study on resting states. 2015 , 2015, 172192	48
1244	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. 2015 , 6, 26663-74	67
1243	Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. 2015 , 7, 1198-211	251
1242	Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases. 2015 , 82, 266-73	17
1241	Hyperglycemia modulates extracellular amyloid- β concentrations and neuronal activity in vivo. 2015 , 125, 2463-7	122
1240	What does it mean to be 'amyloid-positive'?. 2015 , 138, 514-6	8
1239	Guidelines on Cerebrospinal Fluid Analysis. 2015 , 407-428	
1238	Brain amyloid- β burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. 2015 , 35, 3240-7	41
1237	A kernel machine method for detecting effects of interaction between multidimensional variable sets: an imaging genetics application. 2015 , 109, 505-514	18
1236	The Role of Inflammation in Alzheimer's Disease. 2015 , 313-336	1
1235	Systems biology of neurodegenerative diseases. 2015 , 7, 758-75	32
1234	Subjective memory complaints, cortical thinning, and cognitive dysfunction in middle-aged adults at risk for AD. 2015 , 1, 33-40	68
1233	Changes in A β biomarkers and associations with APOE genotype in 2 longitudinal cohorts. 2015 , 36, 2333-9	49
1232	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). 2015 , CD010783	256
1231	The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. 2015 , 32, 537-47	75
1230	The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. 2015 , 38, 309-22	9

1229	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1191-201	1.2	59
1228	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. 2015 , 73, 169-75		48
1227	The case for rejecting the amyloid cascade hypothesis. 2015 , 18, 794-9		463
1226	Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. 2015 , 85, 40-7		265
1225	Souvenaid for Alzheimer's disease. 2015 ,		2
1224	Understanding early dementia: EEG, MRI, SPECT and memory evaluation. 2015 , 6, 32-46		7
1223	What has electron microscopy contributed to Alzheimer's research?. 2015 , 10, 515-527		2
1222	Voices from the field: Expert reflections on mild cognitive impairment. 2015 , 14, 285-97		8
1221	Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. 2015 , 72, 1484-90		30
1220	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. 2015 , 1, 412-9		66
1219	Massachusetts Alzheimer's Disease Research Center: progress and challenges. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1241-5	1.2	3
1218	Ambient Technology to Support Elderly People in Outdoor Risk Situations. 2015 , 35-56		1
1217	[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid- β pathology. <i>Alzheimer's and Dementia</i> , 2015 , 11, 975-85	1.2	93
1216	Toward Context-Aware Smart Oven to Prevent Cooking Risks in Kitchen of Elderly People. 2015 , 57-77		3
1215	SVM-Based Classification of Diffusion Tensor Imaging Data for Diagnosing Alzheimer's Disease and Mild Cognitive Impairment. 2015 , 489-499		2
1214	Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus. 2015 , 74, 470-9		40
1213	Quantitative EEG Applying the Statistical Recognition Pattern Method: A Useful Tool in Dementia Diagnostic Workup. 2015 , 40, 1-12		46
1212	Independent information from cerebrospinal fluid amyloid- β and florbetapir imaging in Alzheimer's disease. 2015 , 138, 772-83		169

1211	Rapid biodiagnostic ex vivo imaging at 1 μ m pixel resolution with thermal source FTIR FPA. 2015 , 140, 2493-503		42
1210	Amyloid-beta and depression in healthy older adults: a systematic review. 2015 , 49, 36-46		45
1209	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. 2015 , 7, 34-42		69
1208	A newly designed molecule J2326 for Alzheimer's disease disaggregates amyloid fibrils and induces neurite outgrowth. 2015 , 92, 146-57		9
1207	Nicotinic ACh receptors as therapeutic targets in CNS disorders. 2015 , 36, 96-108		299
1206	Cognitive Impairment and Dementia. 2015 , 3-11		
1205	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. 2015 , 58, 4365-82		77
1204	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 511-22	1.2	45
1203	Relationship Between Nutritional and Psycho-Functional Status in Alzheimer's Disease. 2015 , 435-446		
1202	Evolving brain structural changes in PSEN1 mutation carriers. 2015 , 36, 1261-70		27
1201	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. 2015 , 69, 1-8		16
1200	A novel cortical thickness estimation method based on volumetric Laplace-Beltrami operator and heat kernel. 2015 , 22, 1-20		20
1199	The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease. 2015 , 36, 2093-117		42
1198	Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers. 2015 , 56, 229-33		27
1197	Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's disease. 2015 , 290, 80-9		38
1196	Age-related hearing impairment-a risk factor and frailty marker for dementia and AD. 2015 , 11, 166-75		132
1195	Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology. 2015 , 122, 531-9		26
1194	Identifying and Mapping Connectivity Patterns of Brain Network Hubs in Alzheimer's Disease. 2015 , 25, 3723-42		184

1193	Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. 2015 , 131, 139-47		18
1192	18 -FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2015 , 1, CD010632		76
1191	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. 2015 , 21, 738-47		
1190	Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. 2015 , 7, 187-94		72
1189	Do NIA-AA criteria distinguish Alzheimer's disease from frontotemporal dementia?. <i>Alzheimer's and Dementia</i> , 2015 , 11, 207-15	1.2	18
1188	Is there an MCI reversion to cognitively normal? Analysis of Alzheimer's disease biomarkers profiles. 2015 , 27, 429-37		15
1187	The Link Between Physical Activity and Cognitive Dysfunction in Alzheimer Disease. 2015 , 95, 1046-60		42
1186	Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. 2015 , 60, 76-82		47
1185	Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. 2015 , 36, 1765.e7-1765.e16		63
1184	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. 2015 , 138, 1036-45		54
1183	Diagnostic Values of Cerebrospinal Fluid T-Tau and A β Using Meso Scale Discovery Assays for Alzheimer's Disease. 2015 , 45, 709-19		23
1182	Pulmonary function as a risk factor for dementia death: an individual participant meta-analysis of six UK general population cohort studies. 2015 , 69, 550-6		21
1181	Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. 2015 , 122, 1007-18		41
1180	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. 2015 , 115, 547-55		7
1179	Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. 2015 , 72, 446-54		103
1178	Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB). 2015 , 265, 407-17		28
1177	PART is part of Alzheimer disease. 2015 , 129, 749-56		198
1176	Amyloid- β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. 2015 , 138, 1023-35		143

1175	Enfermedad de Alzheimer. 2015 , 11, 4306-4315		2
1174	Principal Dynamic Mode Analysis of EEG Data for Assisting the Diagnosis of Alzheimer's Disease. 2015 , 3, 1800110		14
1173	Clinical and imaging features of mixed Alzheimer and vascular pathologies. 2015 , 7, 21		69
1172	Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. <i>Alzheimer's and Dementia</i> , 2015 , 11, 494-503.e3	1.2	49
1171	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015 , 11, e1-120	1.2	206
1170	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. 2015 , 138, 1370-81		224
1169	The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations. <i>Alzheimer's and Dementia</i> , 2015 , 11, 533-540.e2	1.2	8
1168	Usefulness of data from magnetic resonance imaging to improve prediction of dementia: population based cohort study. 2015 , 350, h2863		28
1167	Specific multi-nutrient enriched diet enhances hippocampal cholinergic transmission in aged rats. 2015 , 36, 344-51		31
1166	Le diagnostic prẽcoce de la maladie d'Alzheimer : panacẽ ou catastrophe ?. 2015 , 1, 151-154		1
1165	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015 , 11, 772-91	1.2	53
1164	The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1510-1519	1.2	62
1163	A comparison of 2 screening questionnaires for clinical assessment of canine cognitive dysfunction. 2015 , 10, 452-458		9
1162	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. 2015 , 1, 103-11		140
1161	Mediterranean diet and preserved brain structural connectivity in 'older' subjects. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1023-31	1.2	74
1160	Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. 2015 , 36, 2568-76		129
1159	Reduced uptake of 18F-FDG and 15O-H2O in Alzheimer's disease-related regions after glucose loading. 2015 , 35, 1380-5		26
1158	Alzheimer's Disease Neuroimaging Initiative: A decade of progress in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 727-9	1.2	7

1157	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. 2015 , 36, 1619-1628		27
1156	Relationship of contextual cueing and hippocampal volume in amnesic mild cognitive impairment patients and cognitively normal older adults. 2015 , 21, 285-96		11
1155	Altered whole-brain white matter networks in preclinical Alzheimer's disease. 2015 , 8, 660-6		61
1154	Progression of mild cognitive impairment to dementia due to AD in clinical settings. 2015 , 85, 331-8		50
1153	Amyloid- β as a biomarker for Alzheimer's disease: quantification methods in body fluids. 2015 , 12, 343-54		18
1152	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. 2015 , 72, 1029-42		190
1151	CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. 2015 , 138, 2383-98		105
1150	DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease. 2014 , 4, 7130		89
1149	Vitamin D deficiency and Alzheimer disease: Common links. 2015 , 84, 84-98		39
1148	Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome. 2015 , 30, 192-200		25
1147	CSF proteins and resting-state functional connectivity in Parkinson disease. 2015 , 84, 2413-21		40
1146	Should we screen for cognitive decline and dementia?. 2015 , 82, 28-35		15
1145	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1470-1479	1.2	12
1144	Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics. 2015 , 29, 519-28		5
1143	[(18)F]Florbetaben: a review in β amyloid PET imaging in cognitive impairment. 2015 , 29, 605-13		19
1142	Alzheimer's Disease?. 2015 ,		
1141	Dual ligand immunoliposomes for drug delivery to the brain. 2015 , 134, 213-9		41
1140	Tract-specific white matter degeneration in aging: the Rotterdam Study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 321-30	1.2	127

1139	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). <i>Alzheimer's and Dementia</i> , 2015 , 11, 840-9	1.2	8
1138	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. <i>Alzheimer's and Dementia</i> , 2015 , 11, 823-31	1.2	41
1137	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. 2015 , 43-44, 16-24		11
1136	Clearance systems in the brain-implications for Alzheimer disease. 2015 , 11, 457-70		759
1135	Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. 2015 , 35, 10402-11		90
1134	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015 , 11, 740-56	1.2	101
1133	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. 2015 , 14, 926-944		187
1132	Subjective cognitive concerns, amyloid- β and neurodegeneration in clinically normal elderly. 2015 , 85, 56-62		105
1131	The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2015 , 11, 860-4	1.2	12
1130	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. 2015 , 85, 626-33		107
1129	Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings. 2015 , 85, 144-53		28
1128	Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages. 2015 , 58, 101-9		61
1127	Imaging Alzheimer's Disease: The Evolution of Biomarkers. 2015 , 619-623		1
1126	Amyloid Tracers. 2015 , 633-639		
1125	Recent advances and applications of metabolomics to investigate neurodegenerative diseases. 2015 , 122, 95-132		12
1124	Treatment and Management of Dementia Due to Alzheimer's Disease. 2015 , 17, 363		4
1123	Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study. 2015 , 72, 912-9		65
1122	Neuronal hyperactivity--A key defect in Alzheimer's disease?. 2015 , 37, 624-32		109

1121	Role of 5-hydroxymethylcytosine in neurodegeneration. 2015 , 570, 17-24		51
1120	Alzheimer's Disease and the Search for Environmental Risk Factors. 2015 , 315-327		
1119	How amyloid, sleep and memory connect. 2015 , 18, 933-4		37
1118	Alzheimer's disease clinical trials: past failures and future opportunities. 2015 , 5, 297-309		11
1117	Diffusion-MRI in neurodegenerative disorders. 2015 , 33, 853-76		60
1116	Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. 2015 , 84, 1488-94		37
1115	Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project. <i>Alzheimer's and Dementia</i> , 2015 , 11, 151-60.e5	1.2	32
1114	Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. 2015 , 592, 54-8		58
1113	Cerebrovascular disease, amyloid plaques, and dementia. 2015 , 46, 1402-7		26
1112	Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. 2015 , 23, 985-93		91
1111	Hippocampal atrophy varies by neuropsychologically defined MCI among men in their 50s. 2015 , 23, 456-65		14
1110	Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. 2015 , 36, 434-45		77
1109	Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. <i>Alzheimer's and Dementia</i> , 2015 , 11, 126-38	1.2	96
1108	Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease. 2015 , 1, 67-74		4
1107	[Novel methods for dementia diagnostics]. 2015 , 86, 452-60		4
1106	Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid- β in Mild Cognitive Impairment. 2015 , 46, 901-12		17
1105	The use of amyloid imaging in clinical praxis: a critical review. 2015 , 3, 7-11		4
1104	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. 2015 , 3, 65-74		6

1103	MR-based attenuation correction using ultrashort-echo-time pulse sequences in dementia patients. 2015 , 56, 423-9	49
1102	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. 2015 , 36, 2018-23	64
1101	Advances in Alzheimer's disease drug development. 2015 , 13, 62	62
1100	Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. 2015 , 7, 2	17
1099	Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. 2015 , 7, 31	60
1098	Early neurone loss in Alzheimer's disease: cortical or subcortical?. 2015 , 3, 10	101
1097	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. 2015 , 72, 656-65	66
1096	Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. 2015 , 21, 768-75	36
1095	A call for new thoughts about what might influence human brain aging: aging, apolipoprotein E, and amyloid. 2015 , 72, 500-2	2
1094	Age, Sex, and APOE ϵ Effects on Memory, Brain Structure, and ϵ Amyloid Across the Adult Life Span. 2015 , 72, 511-9	229
1093	Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. 2015 , 72, 316-24	112
1092	APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1417-1429	1.2 116
1091	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. 2015 , 313, 1924-38	842
1090	Magnetization transfer MRI in dementia disorders, Huntington's disease and parkinsonism. 2015 , 353, 1-8	17
1089	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. 2015 , 7, 26	80
1088	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 ϵ Amyloid Measures Across the Spectrum of Alzheimer Disease. 2015 , 72, 571-81	73
1087	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. 2015 , 84, 508-15	96
1086	Body mass index and cognitive function: the potential for reverse causation. 2015 , 39, 1383-9	64

1085	The role and therapeutic targeting of β and β secretase in Alzheimer's disease. 2015 , 1, FSO11		53
1084	Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. 2015 , CD010772		54
1083	Commonalities and challenges in the development of clinical trial measures in neurology. 2015 , 12, 151-69		5
1082	Verbal memory and brain aging: an exploratory analysis of the role of error responses in the Framingham Study. 2015 , 30, 622-8		4
1081	Plasma amyloid- β and risk of Alzheimer's disease in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 249-57.e1	1.2	66
1080	2015 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2015 , 11, 332-84	1.2	1212
1079	Statins, cognition, and dementia: Systematic review and methodological commentary. 2015 , 11, 220-9		73
1078	Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition. 2015 , 18, 389-412		83
1077	Opportunities in pharmacogenomics for the treatment of Alzheimer's disease. 2015 , 10, 229-252		18
1076	Spatially distinct atrophy is linked to β amyloid and tau in preclinical Alzheimer disease. 2015 , 84, 1254-60		51
1075	Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. 2015 , 175, 401-7		612
1074	Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. 2015 , 212, 601-5		28
1073	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. 2015 , 84, 2153-60		78
1072	Effect of common neuropathologies on progression of late life cognitive impairment. 2015 , 36, 2225-2231		18
1071	Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease. 2015 , 93, 1413-22		11
1070	APOE ϵ Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons. 2015 , 27, 322-5		9
1069	Increased cerebral vascular reactivity in the tau expressing rTg4510 mouse: evidence against the role of tau pathology to impair vascular health in Alzheimer's disease. 2015 , 35, 359-62		21
1068	Differentiated clinical presentation of early and late-onset Alzheimer's disease: is 65 years of age providing a reliable threshold?. 2015 , 262, 1238-46		27

1067	The Impact of Age on Cognition. 2015 , 36, 111-21		361
1066	Gold Nanoparticles: Synthesis and Biological Applications. 2015 , 05, 1542007		16
1065	PKR Inhibition Rescues Memory Deficit and ATF4 Overexpression in ApoE ϵ Human Replacement Mice. 2015 , 35, 12986-93		40
1064	Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. 2015 , 78, 63-72		28
1063	Benefits and risks of add-on therapies for Alzheimer's disease. 2015 , 5, 445-62		3
1062	Aging, Practice Effects, and Genetic Risk in the Wisconsin Registry for Alzheimer's Prevention. 2015 , 29, 426-41		12
1061	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. 2015 , 138, 3747-59		128
1060	From Cognitive Science to Dementia Assessment. 2015 , 2, 81-91		25
1059	Memory complaints and risk of cognitive impairment after nearly 2 decades among older women. 2015 , 85, 1852-8		73
1058	[Late onset dementia: Specific clinical and pathophysiological features]. 2015 , 50, 261-3		1
1057	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. 2015 , 85, 790-8		23
1056	Development of a straightforward and sensitive scale for MCI and early AD clinical trials. <i>Alzheimer's and Dementia</i> , 2015 , 11, 404-14	1.2	14
1055	A novel method for early diagnosis of Alzheimer's disease based on pseudo Zernike moment from structural MRI. 2015 , 305, 361-71		39
1054	Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. 2015 , 1, 160-169		26
1053	The Use of Smartwatches for Health Monitoring in Home-Based Dementia Care. 2015 , 15-26		29
1052	Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease. 2015 , 4, e256		54
1051	Intraneuronal amyloid- β accumulation in basal forebrain cholinergic neurons: a marker of vulnerability, yet inversely related to neurodegeneration. 2015 , 138, 1444-5		3
1050	Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. 2015 , 85, 1712-21		52

1049 [Stress and optimal ageing]. **2015**, 48, 524-8

1048	14th Annual Meeting of the Society for Clinical Pharmacology and Therapeutics: Threading through peripheral and central nervous system presentations. 2015 , 75, 143-57	2
1047	Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. 2015 , 309, 29-50	174
1046	The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment. 2015 , 143, 117-27	44
1045	Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability. 2015 , 130, 501-10	31
1044	Alzheimer's disease: Potential preventive, non-invasive, intervention strategies in lowering the risk of cognitive decline - A review study. 2015 , 13, 257-261	32
1043	βAmyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [¹¹ C]AZD2184. 2015 , 42, 1507-11	4
1042	Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. 2015 , 22, 761-76	109
1041	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. 2015 , 85, 1240-9	192
1040	Integrated multimodal imaging in neurodegenerative disease. 2015 , 14, 973-5	1
1039	Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. 2015 , 37, 1632-42	29
1038	FDG-PET Contributions to the Pathophysiology of Memory Impairment. 2015 , 25, 326-55	17
1037	Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. 2015 , 256, 168-83	42
1036	The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin. 2015 , 81, 49-65	82
1035	Locus Coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease. 2015 , 2, 73-84	41
1034	Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele. <i>Alzheimer's and Dementia</i> , 2015 , 11, 648-57.e1	1.2 65
1033	Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 917-32	1.2 51
1032	Suspected non-AD pathology in mild cognitive impairment. 2015 , 36, 3152-3162	49

1031	Brain health: a primary health care viewpoint. 2015 , 16, 720-1		10
1030	Isobaric Quantification of Cerebrospinal Fluid Amyloid- β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. 2015 , 14, 4834-43		6
1029	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. 2015 , 15, 83-105		53
1028	Imaging biomarkers associated with cognitive decline: a review. 2015 , 77, 685-92		39
1027	Neuropathology and biochemistry of A β and its aggregates in Alzheimer's disease. 2015 , 129, 167-82		141
1026	Plaque array method and proteomics-based identification of biomarkers from Alzheimer's disease serum. 2015 , 441, 79-85		6
1025	Alzheimer Disease. 2015 , 321-338		3
1024	Dementia and "obesity paradox": is this for real or are we missing something? An epidemiologist's perspective. 2015 , 16, 78-9		6
1023	Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial A β 2 phagocytosis. 2015 , 185, 230-9		29
1022	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 561-78	1.2	146
1021	The detection of β amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO. 2015 , 70, 74-80		25
1020	Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease. 2015 , 36, 60-7		69
1019	Posterior cingulate β aminobutyric acid and glutamate/glutamine are reduced in amnesic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype. 2015 , 36, 53-9		46
1018	Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. 2015 , 36, 149-56		12
1017	Neuroimaging studies of depression, dementia, and mobility in older adults. 2015 , 23, 1-3		1
1016	Raman spectroscopy of blood serum for Alzheimer's disease diagnostics: specificity relative to other types of dementia. 2015 , 8, 584-96		86
1015	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 455-61	1.2	7
1014	Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. <i>Alzheimer's and Dementia</i> , 2015 , 11, 184-94	1.2	40

1013	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 58-69	1.2	271
1012	Epigenomics of Alzheimer's disease. 2015 , 165, 200-20		79
1011	Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. <i>Alzheimer's and Dementia</i> , 2015 , 11, 415-24	1.2	147
1010	Physical activity, body mass index, and brain atrophy in Alzheimer's disease. 2015 , 36 Suppl 1, S194-S202		45
1009	Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. 2015 , 29, 589-96		218
1008	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences Part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. 2015 , 215, 97-101		19
1007	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 600-7.e1	1.2	479
1006	Challenges of multimorbidity of the aging brain: a critical update. 2015 , 122, 505-21		91
1005	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 70-98	1.2	271
1004	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , 2015 , 11, 195-206.e1	1.2	45
1003	Toward an integrated pipeline for protein biomarker development. 2015 , 1854, 677-86		41
1002	Bioactive Nutrients for Brain Health. 2015 , 49-56		
1001	Subjective cognitive impairment: Towards early identification of Alzheimer disease. 2016 , 31, 562-71		34
1000	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. 2016 , 26, 1388-400		114
999	Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease. 231-241		
998	Lessons learned: neuroprotective trials in Parkinson's disease. 265-279		
997	Postoperative Cognitive Dysfunction. 2016 , 411-427		2
996	Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE e4 Genotype. 2016 , 52, 849-61		43

995	Validation of Immunoassay-Based Tools for the Comprehensive Quantification of A β 0 and A β 2 Peptides in Plasma. 2016 , 54, 751-62	19
994	[Not Available]. 2016 , 19, 74-82	2
993	Cognitive Impairment and Social Security's Representative Payee Program. 2016 ,	2
992	qPR: An adaptive partial-report procedure based on Bayesian inference. 2016 , 16, 25	8
991	Electroencephalography-driven approach to prodromal Alzheimer's disease diagnosis: from biomarker integration to network-level comprehension. 2016 , 11, 897-912	8
990	Imaging Alzheimer's disease pathophysiology with PET. 2016 , 10, 79-90	21
989	Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders. 2016 , 20, S2-7	139
988	The New Criteria for Alzheimer's Disease - Implications for Geriatricians. 2016 , 19, 66-73	10
987	Toward precision medicine in Alzheimer's disease. 2016 , 4, 107	55
986	Role of MTCC1325 in membrane-bound transport ATPases system in Alzheimer's disease-induced rat brain. 2016 , 6, 203-209	14
985	The Aging Mind in Transition. 2016 , 87-103	1
984	Cognitive and Physical Aging. 2016 , 125-146	2
983	FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging. 2016 , 53, 1609-16	25
982	Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?. 2016 , 10, 170-177	53
981	Targeting neuroinflammation in Alzheimer's disease. 2016 , 9, 199-208	144
980	Mouse Genetic Models of Human Brain Disorders. 2016 , 7, 40	34
979	Expression of Alzheimer-Type Neurofibrillary Epitopes in Primary Rat Cortical Neurons Following Infection with Enterococcus faecalis. 2015 , 7, 259	4
978	The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging. 2016 , 8, 92	7

977	Review of Sparse Representation-Based Classification Methods on EEG Signal Processing for Epilepsy Detection, Brain-Computer Interface and Cognitive Impairment. 2016 , 8, 172	22
976	Association of Cerebral Amyloidosis, Blood Pressure, and Neuronal Injury with Late-Life Onset Depression. 2016 , 8, 236	3
975	Cognitive Intervention As an Early Non-pharmacological Strategy in Alzheimer's Disease: A Translational Perspective. 2016 , 8, 280	5
974	Beta-Band Functional Connectivity is Reorganized in Mild Cognitive Impairment after Combined Computerized Physical and Cognitive Training. 2016 , 10, 55	32
973	Ammonia as a Potential Neurotoxic Factor in Alzheimer's Disease. 2016 , 9, 57	34
972	Early Dementia Screening. 2016 , 6,	41
971	Influence of APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study. 2016 , 11, e0152901	40
970	Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment. 2016 , 11, e0146449	22
969	Effects of Neurotrophic Support and Amyloid-Targeted Combined Therapy on Adult Hippocampal Neurogenesis in a Transgenic Model of Alzheimer's Disease. 2016 , 11, e0165393	7
968	Association of Functional Impairments and Co-Morbid Conditions with Driving Performance among Cognitively Normal Older Adults. 2016 , 11, e0167751	7
967	Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnesic Mild Cognitive Impairment. 2016 , 11, e0168816	15
966	What can imaging tell us about cognitive impairment and dementia?. 2016 , 8, 240-54	26
965	Chocolate, Air Pollution and Children's Neuroprotection: What Cognition Tools should be at Hand to Evaluate Interventions?. 2016 , 7, 232	7
964	Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease. 2016 , 7, 134	27
963	The amyloid cascade hypothesis: are we poised for success or failure?. 2016 , 139 Suppl 2, 237-252	235
962	Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid- β levels in brain. 2016 , 138, 525-31	59
961	Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction. 2016 , 124, 353-61	73
960	Peripheral Inflammation and Alzheimer's Disease: Periodontal Disease. 2016 , 93-106	

959	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. 2016 , 43, 503-12	22
958	Default Mode Network Functional Connectivity in Early and Late Mild Cognitive Impairment: Results From the Alzheimer's Disease Neuroimaging Initiative. 2016 , 30, 289-296	52
957	Proton magnetic resonance spectroscopy as a diagnostic biomarker in mild cognitive impairment following stroke in acute phase. 2016 , 27, 559-63	4
956	Bioenergetics and metabolism: a bench to bedside perspective. 2016 , 139 Suppl 2, 126-135	26
955	Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting: A Visual and Semiquantitative Analysis. 2016 , 41, e18-23	14
954	Short-term white matter alterations in Alzheimer's disease characterized by diffusion tensor imaging. 2016 , 43, 627-34	7
953	The use of MALDI-MSI in the investigation of psychiatric and neurodegenerative disorders: A review. 2016 , 16, 1747-58	27
952	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. 2016 , 87, 539-47	710
951	Effects of change in FreeSurfer version on classification accuracy of patients with Alzheimer's disease and mild cognitive impairment. 2016 , 37, 1831-41	18
950	Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. 2016 , 37, 621-31	15
949	Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading. 2016 , 37, 2823-32	13
948	DNA methylation in the NCAPH2/LMF2 promoter region is associated with hippocampal atrophy in Alzheimer's disease and amnesic mild cognitive impairment patients. 2016 , 629, 33-37	13
947	Alzheimer's disease: A review of its visual system neuropathology. Optical coherence tomography-a potential role as a study tool in vivo. 2016 , 254, 2079-2092	17
946	Reversion From Mild Cognitive Impairment to Normal Cognition: A Meta-Analysis. 2016 , 30, 324-330	92
945	Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study. 2016 , 31, 361-6	9
944	Nutritional interventions for Alzheimer's prevention: a clinical precision medicine approach. 2016 , 1367, 50-6	29
943	Spatial Navigation in Preclinical Alzheimer's Disease. 2016 , 52, 77-90	101
942	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. 2016 , 8, 1184-1196	152

941	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. 2016 , 6, 313-329	9
940	Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study. 2016 , 52, 133-43	37
939	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. 2016 , 51, 97-106	17
938	Glutamine and Glutamate Complex, as Measured by Functional Magnetic Resonance Spectroscopy, Alters During Face-Name Association Task in Patients with Mild Cognitive Impairment and Alzheimer's Disease. 2016 , 52, 145-59	13
937	Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives. 2016 , 50, 927-45	19
936	Identifying biomarkers of dementia prevalent among amnesic mild cognitively impaired ethnic female patients. 2016 , 8, 43	9
935	Examining if being overweight really confers protection against dementia: Sixty-four year follow-up of participants in the Glasgow University alumni cohort study. 2016 , 15, 19	5
934	Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. 2016 , 52, 1055-64	6
933	18F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2016 ,	5
932	Altered DNA base excision repair profile in brain tissue and blood in Alzheimer's disease. 2016 , 9, 61	25
931	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. 2016 , 8, 466-76	256
930	Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. 2016 , 54, 1135-1146	53
929	Neural correlates of older adults' self-overestimation of stepping-over ability. 2016 , 38, 351-361	4
928	PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease. 2016 , 53, 1563-76	18
927	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. 2016 , 87, 993-9	82
926	Topographical Information-Based High-Order Functional Connectivity and Its Application in Abnormality Detection for Mild Cognitive Impairment. 2016 , 54, 1095-1112	70
925	Memory Binding Test Predicts Incident Amnesic Mild Cognitive Impairment. 2016 , 53, 1585-1595	18
924	Elevated Epstein-Barr Virus Antibody Level is Associated with Cognitive Decline in the Korean Elderly. 2017 , 55, 293-301	14

923	Retirement and memory in Europe. 2016 , 36, 1434-1458	9
922	Change Point Estimation of the Hippocampal Volumes in Alzheimer's Disease. 2016 ,	
921	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. 2016 , 16, 217	9
920	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. 2016 , 52, 875-85	7
919	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. 2016 , 8, 41	78
918	Longitudinal Study of Impaired Intra- and Inter-Network Brain Connectivity in Subjects at High Risk for Alzheimer's Disease. 2016 , 52, 913-27	35
917	Ab immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. 2016 , 18, e13	26
916	Diffusion Tensor Imaging Predictors of Episodic Memory Decline in Healthy Elders at Genetic Risk for Alzheimer's Disease. 2016 , 22, 1005-1015	16
915	A Metal-Free Method for Producing MRI Contrast at Amyloid- β 2017 , 55, 1667-1681	6
914	Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. 2017 , 72, 431-437	10
913	Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer's disease: metabolic basis for dementia. 2016 , 6, 27524	46
912	Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects. 2017 , 55, 343-358	8
911	Redox Based-Peripheral Biomarkers in Alzheimer's Disease: Challenges, Limits and Prospects. 2016 , 377-397	1
910	Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease. 2016 , 22, 991-1004	9
909	The Memory Binding Test: Development of Two Alternate Forms into Spanish and Catalan. 2016 , 52, 283-93	16
908	Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid- β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort. 2016 , 54, 691-705	11
907	Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. 2016 , 22, 978-990	13
906	Relative Alterations in Blood-Based Levels of Sestrin in Alzheimer's Disease and Mild Cognitive Impairment Patients. 2016 , 54, 1147-1155	17

905	Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. 2016 , 6, 35514	98
904	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. 2016 , 53, 1097-105	28
903	Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?. 2016 , 28, 1111-24	13
902	Redefining Amnestic Mild Cognitive Impairment as an Early Form of Alzheimer's Disease Based on Assessment of Memory Systems. 2016 , 53, 705-12	3
901	Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimer's Disease: Opening the Conversation to Prepare Ethical Responses. 2016 , 51, 1-9	5
900	What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?. 2016 , 51, 793-800	7
899	Developing Cognitive Markers of Alzheimer's Disease for Primary Care: Implications for Behavioral and Global Prevention. 2016 , 54, 1259-1272	7
898	Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. 2016 , 61, 5768-80	18
897	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. 2016 , 29, 749-755	7
896	Altered Executive Function in Pre-Mild Cognitive Impairment. 2016 , 54, 933-940	25
895	Quantitative T2 mapping of white matter: applications for ageing and cognitive decline. 2016 , 61, 5587-605	23
894	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease. 2016 , 51, 1085-97	10
893	Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field. 2016 , 5, 1-2	
892	Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and Amyloid imaging. 2016 , 5, 23-34	30
891	Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. 2016 , 22, 968-977	11
890	Estandarizaci3n de aspectos preanal3ticos para el estudio de biomarcadores de la enfermedad de Alzheimer en el l3quido cefalorraqu3deo. 2016 , 9, 184-188	
889	Distinctive Pattern of Serum Elements During the Progression of Alzheimer's Disease. 2016 , 6, 22769	50
888	Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. 2016 , 50, 873-86	75

887	Clinical trials in Alzheimer's disease. 2016 , 153-172	
886	A TgCRND8 Mouse Model of Alzheimer's Disease Exhibits Sexual Dimorphisms in Behavioral Indices of Cognitive Reserve. 2016 , 51, 757-73	21
885	Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. 2016 , 52, 271-81	63
884	Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype. 2016 , 40, 155-163	32
883	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. 2016 , 43, 23-33	35
882	Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. 2016 , CD011145	214
881	White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. 2016 , 4, 18-27	48
880	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. 2016 , 39, 99-107	18
879	Patterns of 11 C-PIB cerebral retention in mild cognitive impairment patients. 2016 , 35, 171-174	
878	The Role of Amyloid- β Oligomers in Toxicity, Propagation, and Immunotherapy. 2016 , 6, 42-49	365
877	Regional brain stiffness changes across the Alzheimer's disease spectrum. 2016 , 10, 283-90	104
876	Function and clinical meaningfulness of treatments for mild Alzheimer's disease. 2016 , 2, 105-12	10
875	Patterns of 11C-PIB cerebral retention in mild cognitive impairment patients. 2016 , 35, 171-4	3
874	Group-based exercise and cognitive-physical training in older adults with self-reported cognitive complaints: The Multiple-Modality, Mind-Motor (M4) study protocol. 2016 , 16, 17	15
873	Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. 2016 , 16, 104	39
872	Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. 2016 , 31, 675-688	31
871	A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid Load. 2016 , 24, 804-13	57
870	Cerebrospinal fluid analysis detects cerebral amyloid- β accumulation earlier than positron emission tomography. 2016 , 139, 1226-36	229

869 Nuclear Imaging of Dementia. **2016**, 233-240

868 Alzheimer's disease imaging biomarkers using small-angle x-ray scattering. **2016**, 1

867 Arterial spin labeling imaging reveals widespread and Aβ-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers. **2016**, 36, 581-95 31

866 Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. **2016**, 86, 1887-96 37

865 NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. **2016**, 44, 1-8 65

864 Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. **2016**, 73, 698-705 80

863 Neuroimaging in dementia and Alzheimer's disease: Current protocols and practice in the Republic of Ireland. **2016**, 22, 177-184 1

862 Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. **2016**, 8, 2 31

861 Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. **2016**, 24, 1095-1104 58

860 The effect of aging on brain barriers and the consequences for Alzheimer's disease development. **2016**, 27, 407-20 33

859 The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline. **2016**, 36, 281-8 109

858 Life-course blood pressure in relation to brain volumes. *Alzheimer's and Dementia*, **2016**, 12, 890-9 1.2 45

857 2016 Alzheimer's disease facts and figures. *Alzheimer's and Dementia*, **2016**, 12, 459-509 1.2 1615

856 Individual estimates of age at detectable amyloid onset for risk factor assessment. *Alzheimer's and Dementia*, **2016**, 12, 373-9 1.2 49

855 Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. **2016**, 44, 114-126 44

854 One-Year Reference Norms of Cognitive Change in Spanish Old Adults: Data from the NEURONORMA Sample. **2016**, 31, 378-88 17

853 [Non-invasive brain stimulation in neurology : Transcranial direct current stimulation to enhance cognitive functioning]. **2016**, 87, 838-45 4

852 Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. **2016**, 22, 937-943 68

851	Strategy-Based Cognitive Training for Improving Executive Functions in Older Adults: a Systematic Review. 2016 , 26, 252-270	34
850	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. 2016 , 48, 122-134	36
849	Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease. 2016 , 30, 4141-4148	196
848	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. 2016 , 139, 2540-53	93
847	Modeling practice effects in healthy middle-aged participants of the Alzheimer and Families parent cohort. 2016 , 4, 149-158	3
846	Cognitive and functional changes associated with A β pathology and the progression to mild cognitive impairment. 2016 , 48, 172-181	22
845	Magnetic Resonance Spectroscopy in Dementia. 2016 , 55-70	
844	Subjective cognitive impairment: Towards early identification of Alzheimer disease. 2016 , 31, 562-571	9
843	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. 2016 , 2, 233-240	4
842	Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APP ^{si} transgenic model of Alzheimer's disease. 2016 , 96, 171-185	10
841	fMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications. 2016 , 699-739	4
840	Emerging drugs to reduce abnormal β amyloid protein in Alzheimer's disease patients. 2016 , 21, 377-391	43
839	Effects of dihydrotestosterone on synaptic plasticity of the hippocampus in mild cognitive impairment male SAMP8 mice. 2016 , 12, 1455-1463	31
838	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. 2016 , 80, 846-857	25
837	Cortical amyloid burden and age moderate hippocampal activity in cognitively-normal adults. 2016 , 12, 78-84	16
836	Cortical thickness in relation to clinical symptom onset in preclinical AD. 2016 , 12, 116-22	40
835	Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. 2016 , 16, 3042-3053	39
834	The future of dementia risk reduction research: barriers and solutions. 2017 , 39, e275-e281	11

833	Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. 2016 , 113, E6535-E6544	95
832	Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective. 2016 , 26, 664-71	4
831	Alzheimer disease: Preclinical Alzheimer disease - the new frontier. 2016 , 12, 620-621	7
830	Preoperative Cognitive Performance Dominates Risk for Delirium Among Older Adults. 2016 , 29, 320-327	22
829	Incident parkinsonism in older adults without Parkinson disease. 2016 , 87, 1036-44	45
828	Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. 2016 , 75, 955-962	18
827	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1132-1148 ^{1,2}	62
826	Genetically modified pig models for neurodegenerative disorders. 2016 , 238, 267-87	68
825	Frontal-posterior coherence and cognitive function in older adults. 2016 , 110, 217-230	22
824	Alzheimer's disease prevention: A way forward. 2016 , 216, 495-503	2
823	Analysis of lipophilic fluorescent products in blood of Alzheimer's disease patients. 2016 , 20, 1367-72	11
822	Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks. 2016 , 37, 35-53	83
821	Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. 2016 , 23, 110-9	13
820	Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. 2016 , 30, 1111-1120	84
819	Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. 2016 , 241, 1676-83	27
818	Age-dependent effects of APOE ϵ 4 in preclinical Alzheimer's disease. 2016 , 3, 668-77	31
817	The effect of β amyloid positivity on cerebral metabolism in cognitively normal seniors. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1250-1258	1.2 8
816	A Smart Near-Infrared Fluorescence Probe for Selective Detection of Tau Fibrils in Alzheimer's Disease. 2016 , 7, 1474-1481	28

815	Network-Based Statistic Show Aberrant Functional Connectivity in Alzheimer's Disease. 2016 , 10, 1182-1188	15
814	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. 2016 , 73, 1185-1191	40
813	Longitudinal β Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. 2016 , 73, 1192-1200	63
812	Introduction to Alzheimer's Disease Biomarkers. 2016 , 3-23	3
811	Clinical Diagnosis of Alzheimer's Disease. 2016 , 27-48	2
810	Neuroimaging Biomarkers in Alzheimer's Disease. 2016 , 51-100	4
809	Alzheimer's Disease Cerebrospinal Fluid (CSF) Biomarkers. 2016 , 139-180	3
808	Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. 2016 , 87, 1235-41	31
807	Alzheimer's disease patient groups derived from a multivariate analysis of cognitive test outcomes in the Coalition Against Major Diseases dataset. 2016 , 2, FSO140	3
806	Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease. 2016 , 30, 3853-3859	178
805	The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease. 2016 , 142, 498-511	25
804	Genome research in pre-dementia stages of Alzheimer's disease. 2016 , 18, e11	12
803	democracy with dementia: problematising democratic theoretical and practical implications. 2016 , 15, 343-358	2
802	Clinical decision support for Alzheimer's disease based on deep learning and brain network. 2016 ,	22
801	Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. 2016 , 87, 1093-101	23
800	FTIR and Raman Spectroscopy Applied to Dementia Diagnosis Through Analysis of Biological Fluids. 2016 , 52, 801-12	23
799	Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. 2016 , 8, 46	39
798	Alzheimer's Disease and Medicinal Plants: An Overview. 2016 , 12, 95-105	4

797	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. 2016 , 15, 1044-53		135
796	Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?. 2016 , 213, 1375-85		113
795	Genetic and degenerative disorders primarily causing dementia. 2016 , 135, 525-564		3
794	Alzheimer's disease risk: amyloid versus neurodegeneration. 2016 , 15, 1000-1		1
793	Population Normative Data for the CERAD Word List and Victoria Stroop Test in Younger- and Middle-Aged Adults: Cross-Sectional Analyses from the Framingham Heart Study. 2016 , 42, 315-28		14
792	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β Amyloid and Tauopathy. 2016 , 73, 1070-7		179
791	Deficits in object-in-place but not relative recency performance in the APP ^{swe} /PS1 ^{dE9} mouse model of Alzheimer's disease: Implications for object recognition. 2016 , 313, 71-81		4
790	Forty years of structural imaging in psychosis: promises and truth. 2016 , 134, 207-24		33
789	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1259-1272	1.2	67
788	Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. 2016 , 87, 2050-2057		43
787	The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid- β in Young and Old APP/PS1 Mice. 2016 , 36, 11704-11715		31
786	Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach. 2016 , 29, 210-219		39
785	Tau and A β imaging, CSF measures, and cognition in Alzheimer's disease. 2016 , 8, 338ra66		418
784	COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer's disease. 2016 , 6, 34567		12
783	Exploring spatiotemporal dynamics of the human brain by multimodal imaging. 2016 , 2016, 57-60		
782	Impaired episodic memory network in subjects at high risk for Alzheimer's disease. 2016 , 2016, 4017-4020		3
781	Alzheimer's Disease: An Overview. 2016 , 58-63		0
780	Financial exploitation, financial capacity, and Alzheimer's disease. 2016 , 71, 312-20		35

779	An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). 2016 , 28, 1576-1585	8
778	Transient Microneedle Insertion into Hippocampus Triggers Neurogenesis and Decreases Amyloid Burden in a Mouse Model of Alzheimer's Disease. 2016 , 25, 1853-1861	1
777	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. 2016 , 73, 1230-1237	96
776	Treating Hypertension to Prevent Cognitive Decline and Dementia: Re-Opening the Debate. 2017 , 956, 447-473	19
775	Combining multiple approaches for the early diagnosis of Alzheimer's Disease. 2016 , 84, 259-266	22
774	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. 2016 , 39, 1253-60	35
773	Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and A β 2 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants. 2017 , 55, 1471-1480	30
772	Alzheimer's disease: the role of mitochondrial dysfunction and potential new therapies. 2016 , 9,	9
771	Promising Role of Neuromodulation in Predicting the Progression of Mild Cognitive Impairment to Dementia. 2016 , 53, 1375-88	22
770	Early Postmenopausal Transdermal 17 β Estradiol Therapy and Amyloid- β Deposition. 2016 , 53, 547-56	70
769	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. 2016 , 8, 27	12
768	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. 2016 , 11, 65	13
767	Mark W. Bondi, PhD, Recipient of 2016 Alzheimer Award. 2016 , 54, 1-2	1
766	Vitamin B1 (thiamine) and dementia. 2016 , 1367, 21-30	99
765	A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. 2016 , 11, 2	34
764	Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer's disease: dementia. 2016 , 28, 1409-24	55
763	Anti-Amyloid- β Immunotherapy for Alzheimer's Disease. 2016 , 193-226	6
762	Clinical Issues in Alzheimer Drug Development. 2016 , 503-521	1

761	Molecular Imaging in Alzheimer Clinical Trials. 2016 , 523-563	
760	Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. 2016 , 8, 8	39
759	Exposure to air pollution as a potential contributor to cognitive function, cognitive decline, brain imaging, and dementia: A systematic review of epidemiologic research. 2016 , 56, 235-253	200
758	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. 2016 , 139, 2261-74	27
757	Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. 2016 , 68, 547-562	88
756	Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease. 2016 , 46, 68-75	18
755	Alzheimer's disease prevention: A way forward. 2016 , 216, 495-503	3
754	Detecting Anatomical Landmarks for Fast Alzheimer's Disease Diagnosis. 2016 , 35, 2524-2533	105
753	A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure. 2016 , 2, 23-29	18
752	Immunotherapy Against Amyloid- β in Alzheimer's Disease: An Overview. 2016 , 3-17	1
751	Cerebrospinal fluid ratios with A β 2 predict preclinical brain β amyloid accumulation. 2016 , 2, 27-38	35
750	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. 2016 , 42, 124-31	23
749	Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease. 2016 , 31, 156-62	1
748	CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease. 2016 , 4, 14	23
747	(1)H-MRS asymmetry changes in the anterior and posterior cingulate gyrus in patients with mild cognitive impairment and mild Alzheimer's disease. 2016 , 69, 179-85	7
746	Two-stage screening for early dementia in primary care. 2016 , 38, 1038-49	8
745	Subjective Cognitive Impairment and Affective Symptoms: A Systematic Review. 2016 , 56, e109-e127	100
744	Integrative Frequency Power of EEG Correlates with Progression of Mild Cognitive Impairment to Dementia in Parkinson's Disease. 2016 , 47, 113-7	17

743	Rapid eye movement sleep behavior disorder in patients with probable Alzheimer’s disease. 2016 , 28, 951-7	20
742	Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment. 2016 , 20, 161-9	48
741	Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer’s disease. 2016 , 10, 9-17	46
740	Suspected non-Alzheimer disease pathophysiology--concept and controversy. 2016 , 12, 117-24	174
739	Alzheimer’s disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. 2016 , 361, 256-71	89
738	Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid- β . 2016 , 139, 193-203	19
737	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. 2016 , 16, 69-76	34
736	Detection of Alzheimer’s Disease. 2018 , 91, 291-300	17
735	A Review on the Trajectory of Attentional Mechanisms in Aging and the Alzheimer’s Disease Continuum through the Attention Network Test. 2019 , 92, 37-51	13
734	Assessing and preventing cognitive impairment in the elderly. 2017 , 12, 14-18	1
733	The Role of Cyclooxygenase 2 in the Cognitive Impairment Induced by Alcohol or Stress in Rats.. 2021 , 10, 44	
732	Mild Cognitive Impairment: Current Aspects of Diagnosis and Treatment. 2021 , 51, 1033-1039	
731	Spontaneous Language Analysis in Alzheimer’s Disease: Evaluation of Natural Language Processing Technique for Analyzing Lexical Performance. 1	1
730	ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods. <i>Alzheimer’s and Dementia</i> , 2021 ,	1.2 0
729	Lack of Convincing Evidence that <i>Borrelia burgdorferi</i> Infection Causes Either Alzheimer’s Disease or Lewy Body Dementia. 2021 ,	1
728	Alzheimer’s Disease and Type 2 Diabetes Mellitus: The Use of MCT Oil and a Ketogenic Diet. 2021 , 22,	1
727	Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis. 2021 , 7, 105	2
726	Longitudinal Study of the Association between General Anesthesia and Increased Risk of Developing Dementia. 2021 , 11,	0

725	Decreased Resting-State Functional Complexity in Elderly with Subjective Cognitive Decline.. 2021 , 23,		
724	Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's disease. 2021 , 18, 273		0
723	Diet May Moderate the Relationship Between Arterial Stiffness and Cognitive Performance in Older Adults. 2021 ,		0
722	Long-term prognosis and educational determinants of brain network decline in older adult individuals.. 2021 , 1, 1053-1067		4
721	Regional Brain Volume, Brain Reserve and MMSE Performance in Healthy Aging From the NEUROAGE Cohort: Contributions of Sex, Education, and Depression Symptoms. 2021 , 13, 711301		0
720	Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. 2021 ,		1
719	Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: mediation by amyloid pathology. 2021 , 11, 577		4
718	Aging in the Digital Age: Using Technology to Increase the Reach of the Clinician Expert and Close the Gap Between Health Span and Life Span. 2021 , 3, 755008		2
717	Survival Analysis in Cognitively Normal Subjects and in Patients with Mild Cognitive Impairment Using a Proportional Hazards Model with Extreme Gradient Boosting Regression. 2021 ,		
716	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	2
715	Alzheimer's Disease. 2021 , 415-422		
714	The Vulnerability Index: A weighted measure of dementia and cognitive impairment risk.. 2021 , 13, e12249		
713	Cerebrovascular stiffness and flow dynamics in the presence of amyloid and tau biomarkers.. 2021 , 13, e12253		
712	The Future of Artificial Intelligence for Alzheimer's Disease Diagnostics. 2021 , 10, 53-59		1
711	Encyclopedia of Gerontology and Population Aging. 2021 , 706-707		
710	Prediction and Modeling of Neuropsychological Scores in Alzheimer's Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks.. 2021 , 15, 769982		0
709	Serum neurofilament light chain level as a predictor of cognitive stage transition.. 2022 , 14, 6		2
708	The Therapeutic and Diagnostic Potential of Amyloid Oligomers Selective Antibodies to Treat Alzheimer's Disease.. 2021 , 15, 768646		0

707	Trials and Treatments for Vascular Brain Health: Risk Factor Modification and Cognitive Outcomes.. 2022 , STROKEAHA121032614	1
706	Protection against Amyloid- β Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimer's Disease Dementia.. 2022 , 11,	0
705	The influence of different types of auditory change on processes associated with the switching of attention in older adults and people with mild cognitive impairment. 2022 , 2, 100074	
704	Neuropsychological prediction of dementia using the neuropsychological test battery Vienna β A retrospective study. 2022 , 5, 100028	
703	Nanozyme sensor array based on manganese dioxide for the distinction between multiple amyloid β peptides and their dynamic aggregation process.. 2021 , 199, 113881	4
702	Discriminating speech traits of Alzheimer's disease assessed through a corpus of reading task for Spanish language. 2022 , 73, 101341	3
701	Bibliographie. 2014 , 233-256	
700	THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER'S DISEASE. 2015 , 2, 1-12	11
699	A Network-Guided Reaction-Diffusion Model of AT[N] Biomarkers in Alzheimer's Disease. 2020 ,	
698	Correction of Mitochondrial Dysfunction by 4-Hydroxy-3,5-Ditretbutyl Cinnamic Acid in Experimental Alzheimer's Disease Induced by A β Injection in Rats. 2020 , 27, 313-325	1
697	Early Detection of Mild Cognitive Impairment using Neuropsychological Data and Machine Learning Techniques. 2020 ,	1
696	Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses.. 2021 , 1339, 415-422	0
695	Subtle mistakes in self-report surveys predict future transition to dementia.. 2021 , 13, e12252	0
694	Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms. 2021 , 1	1
693	Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease. 2021 , 12, 1964-1976	8
692	Predicting Working Memory in Healthy Older Adults Using Real-Life Language and Social Context Information: A Machine Learning Approach.. 2022 , 5, e28333	1
691	Electrophysiological Resting State Brain Network and Episodic Memory in Healthy Aging Adults.. 2022 , 118926	0
690	Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults.. 2022 , 9, 297-305	

689	Age-related differences in white matter microstructure measured by advanced diffusion MRI in healthy older adults at risk for Alzheimer's disease. 2022 , 100030	0
688	A snapshot of brain and cognition in healthy mid-life and older adults.	0
687	Prolonged Diet-Induced Obesity Modifies DNA Methylation and Gene Expression in the Hippocampus.	
686	Trait mindfulness is associated with less amyloid, tau, and cognitive decline in individuals at risk for Alzheimer's disease. 2022 ,	0
685	Late-Life Obesity Associated with Tau Pathology in Cognitively Normal Individuals: The CABLE Study.. 2021 ,	0
684	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report.. 2021 , 13, 761932	0
683	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.. 2022 ,	1
682	Patterns of Symptom Tracking by Caregivers and Patients With Dementia and Mild Cognitive Impairment: Cross-sectional Study.. 2022 , 24, e29219	1
681	Late-Life Physical Activities Moderate the Relationship of Amyloid- β Pathology with Neurodegeneration in Individuals Without Dementia.. 2022 ,	
680	Abnormal characterization of dynamic functional connectivity in Alzheimer's disease.. 2022 , 17, 2014-2021	4
679	Connectomic analysis of Alzheimer's disease using percolation theory. 1-21	0
678	Diagnosis of early mild cognitive impairment using a multiobjective optimization algorithm based on T1-MRI data.. 2022 , 12, 1020	1
677	Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline.. 2021 , 33, 102923	3
676	Episodic Memory Impairment Mediates the Loss of Awareness in Mild Cognitive Impairment.. 2021 , 13, 802501	0
675	APOE $\epsilon 4$ resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2 2
674	Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation.. 2022 , 2022, 1278092	
673	The Multiple Sclerosis Prodrome: Evidence to Action.. 2021 , 12, 761408	1
672	Development of a Sex-Specific Risk Scoring System for the Prediction of Cognitively Normal People to Patients With Mild Cognitive Impairment (SRSS-CNMCI).. 2021 , 13, 774804	

671	Genetically identical twins show comparable tau PET load and spatial distribution.. 2022,	1
670	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach.. 2022,	2
669	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease.. 2021, 13, 800126	2
668	Simple Quantification of Surface Uptake in F-18 Florapronol PET/CT Imaging for the Validation of Alzheimer's Disease.. 2022, 12,	0
667	Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimer's Disease.. 2021,	0
666	Prospects for the use of graphene-based biological sensors in the early diagnosis of Alzheimer's disease (review of literature).. 2022, 67, 5-12	
665	Application of QPLEX biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition.. 2022,	
664	Resistance-exercise training attenuates LPS-induced astrocyte remodeling and neuroinflammatory cytokine expression in female Wistar rats.. 2021,	0
663	The prevalence and associated factors of motoric cognitive risk syndrome in multiple ethnic middle-aged to older adults in west China: a cross-sectional study.. 2022,	1
662	Deep proteome analysis of plasma reveals novel biomarkers of mild cognitive impairment and Alzheimer's disease: A longitudinal study.	0
661	Hippocampal-Subregion Mechanisms of Repetitive Transcranial Magnetic Stimulation Causally Associated with Amelioration of Episodic Memory in Amnesic Mild Cognitive Impairment.. 2021,	0
660	Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.. 2021,	0
659	Forecasting the prevalence of dementia.. 2022,	2
658	Association of Lipidomics Signatures in Blood with Clinical Progression in Preclinical and Prodromal Alzheimer's Disease.. 2021,	2
657	Studying APOE e4 Allele Dose Effects with a Univariate Morphometry Biomarker.. 2021,	0
656	Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial.. <i>Alzheimer's and Dementia,</i> 2022,	1.2 2
655	Development of a Novel Nutrition-Related Multivariate Biomarker for Mild Cognitive Impairment Based on the Plasma Free Amino Acid Profile.. 2022, 14,	1
654	Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers.. 2022,	0

653	Wireless USB-like electrochemical platform for individual electrochemical sensing in microdroplets.. 2022 , 1197, 339526	1
652	Designing a clinical decision support system for Alzheimer's diagnosis on OASIS-3 data set. 2022 , 74, 103527	1
651	Impact of sex and β on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults.. 2022 , 14, e12271	0
650	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and Genotype: Importance of Striatal Amyloid.. 2022 , 14, 829202	1
649	EEG/ERP evidence of possible hyperexcitability in older adults with elevated beta-amyloid.. 2022 , 11, 8	2
648	Association of Performance on the Financial Capacity Instrument's Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults. 10.1212/CPJ.0000000000001157	
647	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics.. 2022 , 13, 826423	0
646	Correlation Between Urine Formaldehyde and Cognitive Abilities in the Clinical Spectrum of Alzheimer's Disease.. 2022 , 14, 820385	1
645	Alzheimer's disease - standard of diagnosis, treatment, care, and prevention.. 2022 ,	0
644	Sulcal morphology as cognitive decline predictor in older adults with memory complaints.. 2022 , 113, 84-94	
643	Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease. 2021 , 13, 132-138	3
642	Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer's disease. 2022 , 223-242	
641	Anodal transcranial direct current stimulation alleviates cognitive impairment in an APP/PS1 model of Alzheimer's disease in the preclinical stage.. 2022 , 17, 2278-2285	0
640	Risk of conversion from mild cognitive impairment to dementia in low- and middle-income countries: A systematic review and meta-analysis.. 2022 , 8, e12267	4
639	Alzheimer's disease detection using artificial intelligence. 2022 , 53-74	0
638	Molecular Imaging Precision Medicine. 2022 , 79-92	
637	Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials.. 2022 , 8, e12280	
636	A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease.. 2022 , 8, e12270	

635	Nanomedical drug delivery for neurodegenerative disease. 2022 , 67-79	
634	Development of early biomarkers of Alzheimer's disease: A precision medicine perspective. 2022 ,	
633	Early Alzheimer's disease-like reductions in gray matter and cognitive function with aging in nonhuman primates.. 2022 , 8, e12284	
632	Neurological signs of ageing. 2022 , 561-569	
631	Cognitive Test Scores and Progressive Cognitive Decline in the Aberdeen 1921 and 1936 Birth Cohorts.. 2022 , 12,	
630	On diagnostic accuracy measure with cut-points criterion for ordinal disease classification based on concordance and discordance. 1-18	
629	Amyloid- β -stimulated hippocampal lactate release is coupled to glutamate uptake.. 2022 , 12, 2775	0
628	A Systematic Review of Neuroimaging Studies Comparing Individuals with Subjective Cognitive Decline to Healthy Controls.. 2022 ,	0
627	The China Alzheimer Report 2022.. 2022 , 35, e100751	3
626	Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration.. 2022 , 23,	2
625	Predicting Brain Amyloid- β PET Grades with Graph Convolutional Networks Based on Functional MRI and Multi-Level Functional Connectivity.. 2022 ,	
624	The Association between Bodily Pain and Cognitive Impairment in Community-Dwelling Older Adults.. 2022 , 12,	1
623	Alzheimer's disease amyloid- β pathology in the lens of the eye.. 2022 , 108974	1
622	Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort.. 2022 , 22, 59	0
621	Model of glymphatic clearance of aggregating proteins from the brain interstitium.. 2022 , 105, 024405	0
620	The Humanistic and Economic Burden of Alzheimer's Disease.. 2022 , 1	5
619	Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients.. 2021 , 13, 762649	1
618	Potential Roles of Extracellular Vesicles as Diagnosis Biomarkers and Therapeutic Approaches for Cognitive Impairment in Alzheimer's Disease.. 2022 ,	1

617	Alzheimer's Disease: Epidemiology and Clinical Progression.. 2022 , 1		4
616	Cognitive differences across ethnoracial category, socioeconomic status across the Alzheimer's disease spectrum: Can an ability discrepancy score level the playing field?. 2022 , 1		1
615	Measuring age-related changes in everyday function in vivo: A neuropsychological framework for emerging digital tools (Preprint).		
614	Technological Solutions for Diagnosis, Management and Treatment of Alzheimer's Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature.. 2022 , 19,		1
613	Dynamics of the Brain Functional Network Associated With Subjective Cognitive Decline and Its Relationship to Apolipoprotein E ϵ Alleles.. 2022 , 14, 806032		0
612	A Digital Screening System for Alzheimer Disease Based on a Neuropsychological Test and a Convolutional Neural Network: System Development and Validation.. 2022 , 10, e31106		1
611	Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer's Disease.. 2022 , 11,		0
610	Plasma A β s a biomarker for predicting A β PET status in Alzheimer's disease:a systematic review with meta-analysis.. 2022 ,		0
609	Lay Health Workers in Community-Based Care and Management of Dementia: A Qualitative 'Pre' and 'Post' Intervention Study in Southwestern Uganda.. 2022 , 2022, 9443229		
608	Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.. 2022 , 56, 501-516		1
607	2022 Alzheimer's disease facts and figures.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	95
606	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.. 2022 , 12,		0
605	Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development. 2022 , 486-495		
604	Association of Indication for Hospitalization with Subsequent Amyloid PET and MRI Biomarkers.. 2022 ,		
603	Identification of cognitively impaired patients at risk for development of Alzheimer's disease dementia: an analysis of US Medicare claims data.. 2022 ,		1
602	Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice.. 2022 , 12,		0
601	Examination of Neurofilament Light Chain Serum Concentrations, Physical Activity, and Cognitive Decline in Older Adults.. 2022 , 5, e223596		0
600	Peripheral Immune Cells and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.. 2022 ,		

599	Alzheimer's disease: history, ethics and medical humanities in the context of assisted suicide.. 2022 , 17, 4	
598	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.. 2022 ,	1
597	Rates of β Amyloid deposition indicate widespread simultaneous accumulation throughout the brain.. 2022 , 115, 1-11	
596	La « dñentification subjective » comme effet de l'ñbologie Alzheimer. 2022 ,	0
595	Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.. 2022 , 14, 831807	1
594	Projective LDDMM: Spatially Reconstructing a Story of Rostrally-Dominant Tau in Alzheimer's Disease.	
593	Sharpening Working Memory With Real-Time Electrophysiological Brain Signals: Which Neurofeedback Paradigms Work?. 2022 , 14, 780817	0
592	Amyloid and Tau Protein Concentrations in Children with Meningitis and Encephalitis.. 2022 , 14,	
591	Searching for optimal machine learning model to classify mild cognitive impairment (MCI) subtypes using multimodal MRI data.. 2022 , 12, 4284	2
590	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age.. 2022 , 14, 811146	1
589	Accelerated decline in white matter microstructure in subsequently impaired older adults and its relationship with cognitive decline.. 2022 , 4, fca051	1
588	Targeted Lipidomics To Measure Phospholipids and Sphingomyelins in Plasma: A Pilot Study To Understand the Impact of Race/Ethnicity in Alzheimer's Disease.. 2022 ,	1
587	Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer's model.. 2022 , 11,	1
586	The Role of Online Registries in Accelerating Alzheimer's Disease Drug Development. 2022 , 257-265	
585	Icarisid II rescues cognitive dysfunction via activation of Wnt/ β catenin signaling pathway promoting hippocampal neurogenesis in APP/PS1 transgenic mice.. 2022 ,	1
584	Frequency of preclinical Alzheimer's disease in Japanese clinical study settings: a meta-analysis.	
583	Association of Emerging β Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.. 2022 ,	1
582	Subjective Cognitive Decline Is More Accurate When Metamemory Is Better.. 2022 , 14, 787552	1

581	Dementia classification using MR imaging and clinical data with voting based machine learning models. 1	1
580	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.. 2022,	0
579	Impact of clinical symptoms and diagnosis: the electronic Person-Specific Outcome Measure (ePSOM) development programme.. 2022, 6, 33	0
578	Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.. 2022,	0
577	Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers.. 2022, 10,	1
576	Retaining Participants in Longitudinal Studies of Alzheimer's Disease.. 2022,	0
575	Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease.. 2022, 14, 357-367	0
574	Primary care costs due to prodromal Alzheimer disease: a real-world study in patients with 10-year or longer medical history.. 2022, 1-9	
573	Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework.. 2022,	
572	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease.. 2022, 8, eabm5667	0
571	Are subjective cognitive complaints associated with executive functions and mental health of older adults?. 2022, 1	0
570	Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.. 2022, 6, 177-193	1
569	Cerebrovascular disease in Suspected Non-Alzheimer's Pathophysiology and cognitive decline over time.. 2022,	1
568	[18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer's disease pathology in APP/PS1 mice..	
567	Sporadic Alzheimer's Disease- and Neurotoxicity-Related microRNAs Affecting Key Events of Tau-Driven Adverse Outcome Pathway Toward Memory Loss.. 2022,	3
566	Automatic Classification of Subjects of the PSEN1-E280A Family at Risk of Developing Alzheimer's Disease Using Machine Learning and Resting State Electroencephalography.. 2022,	
565	Amyloid- β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease.. 2022, 119, e2113641119	2
564	Structure-constrained combination-based nonlinear association analysis between incomplete multimodal imaging and genetic data for biomarker detection of neurodegenerative diseases.. 2022, 78, 102419	0

563	Trajectories of cognitive functioning in later life: Disparities by race/ethnicity, educational attainment, sex, and multimorbidity combinations.. 2022 , 18, 101084	1
562	Hemoglobin concentration is associated with the hippocampal volume in community-dwelling adults.. 2022 , 101, 104668	0
561	Enhancing Cortical Network-level Participation Coefficient as a Potential Mechanism for Transfer in Cognitive Training in aMCI.. 2022 , 119124	0
560	Vascular risk burden is a key player in the early progression of Alzheimer’s disease.	
559	Effects of Specific Inhibitors for CaMK1D on a Primary Neuron Model for Alzheimer’s Disease.. 2021 , 26,	1
558	Apathy as a Risky Neuropsychiatric Syndrome of Progression From Normal Aging to Mild Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis.. 2021 , 12, 792168	2
557	Saturation Transfer MRI for Detection of Metabolic and Microstructural Impairments Underlying Neurodegeneration in Alzheimer’s Disease.. 2021 , 12,	0
556	Adverse Childhood Experiences and Subjective Cognitive Decline in the US.. 2021 , 7334648211058718	1
555	Monitoring Older Adult Blood Pressure Trends at Home as a Proxy for Brain Health.. 2021 , 13, e16	1
554	Information and communication technologies for the improvement of cognitive function in healthy older adults: a systematic review protocol.. 2021 , 11, e046544	
553	Rest-Activity Pattern and Circadian Phase Alterations Across the Alzheimer’s Disease Clinical Spectrum. 2021 , 3, 137-141	1
552	Association between dementia parental family history and mid-life modifiable risk factors for dementia: a cross-sectional study using propensity score matching within the Lifelines cohort.. 2021 , 11, e049918	1
551	Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.	0
550	An explainable Artificial Intelligence approach to study MCI to AD conversion via HD-EEG processing. 2021 , 15500594211063662	4
549	Validation of Plasma Amyloid- β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.. 2021 ,	7
548	Blood-based biomarkers for Alzheimer’s disease. 2021 , e14408	7
547	Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease.. 2021 , 36,	1
546	Closing the Gap between Observational Research and Randomized Controlled Trials for Prevention of Alzheimer’s Disease and Dementia.. 2022 ,	

- 545 The Impact of Genes and Environment on Brain Ageing in Males Aged 51 to 72 Years.. **2022**, 14, 831002 ○
- 544 What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis.. **2022**, ○
- 543 Alzheimer's Disease-Related Psychosis: An Overview of Clinical Manifestations, Pathogenesis, and Current Treatment.. **2022**,
- 542 New potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation.. **2022**, 14, 35-42 1
- 541 Young Adults with a Parent with Dementia Show Early Abnormalities in Brain Activity and Brain Volume in the Hippocampus: A Matched Case-Control Study.. **2022**, 12, 1
- 540 Phytochemical compounds loaded to nanocarriers as potential therapeutic substances for Alzheimer's Disease-Could they be effective?. **2022**,
- 539 High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimer's Disease.. **2022**, 12, 1
- 538 Cross-tissue meta-analysis of blood and brain epigenome-wide association studies in Alzheimer's disease. ○
- 537 A Transfer Learning Method for Detecting Alzheimer's Disease Based on Speech and Natural Language Processing.. **2022**, 10, 772592 ○
- 536 Diagnostic Performance of Generative Adversarial Network-Based Deep Learning Methods for Alzheimer's Disease: A Systematic Review and Meta-Analysis.. **2022**, 14, 841696 ○
- 535 Oculomotor abnormalities during reading in offspring of late-onset Alzheimer's disease.. **2022**,
- 534 Possibility of Enlargement in Left Medial Temporal Areas Against Cerebral Amyloid Deposition Observed During Preclinical Stage.. **2022**, 14, 847094
- 533 Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design.. **2022**, ○
- 532 Impact of Early Intervention for Idiopathic Normal Pressure Hydrocephalus on Long-Term Prognosis in Prodromal Phase.. **2022**, 13, 866352 ○
- 531 Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease.. **2022**, ○
- 530 Quality of survey responses at older ages predicts cognitive decline and mortality risk. ○
- 529 Current trends in blood biomarker detection and imaging for Alzheimer's disease.. **2022**, 210, 114278 1
- 528 Data_Sheet_1.docx. **2020**,

527 Image_1.TIF. **2020**,

526 Image_2.TIF. **2020**,

525 Image_3.TIF. **2020**,

524 Image_4.TIF. **2020**,

523 Data_Sheet_1.pdf. **2018**,

522 Table_1.pdf. **2019**,

521 Table_1.docx. **2018**,

520 Data_Sheet_1.PDF. **2018**,

519 Table_1.docx. **2020**,

518 Data_Sheet_1.ZIP. **2019**,

517 Image_1.tif. **2019**,

516 Image_2.tif. **2019**,

515 Image_3.tif. **2019**,

514 Image_4.jpg. **2019**,

513 Data_Sheet_1.docx. **2020**,

512 Table_1.docx. **2019**,

511 Image_1.TIF. **2019**,

510 Image_2.TIF. **2019**,

509 Image_3.TIF. 2019,

508 Image_4.TIF. 2019,

507 Image_5.TIF. 2019,

506 Data_Sheet_1.doc. 2020,

505 Data_Sheet_1.pdf. 2020,

504 Data_Sheet_1.XLS. 2020,

503 Image_1.TIF. 2020,

502 Data_Sheet_1.pdf. 2018,

501 Data_Sheet_1.docx. 2019,

500 Data_Sheet_2.xlsx. 2019,

499 Table_1.docx. 2020,

498 Table_2.docx. 2020,

497 Table_1.DOCX. 2020,

496 Data_Sheet_1.pdf. 2020,

495 Data_Sheet_1.PDF. 2020,

494 Table_1.DOCX. 2018,

493 Image_1.pdf. 2019,

492 Image_2.pdf. 2019,

491 Table_1.pdf. **2019**,

490 Table_2.pdf. **2019**,

489 Table_3.pdf. **2019**,

488 Image_1.TIF. **2020**,

487 Table_1.DOCX. **2020**,

486 Table_2.docx. **2020**,

485 Table_3.docx. **2020**,

484 Table_1.xlsx. **2019**,

483 Data_Sheet_1.pdf. **2018**,

482 Data_Sheet_1.docx. **2019**,

481 DataSheet_1.docx. **2020**,

480 Image_1.jpg. **2020**,

479 Prolonged diet-induced obesity modifies DNA methylation and gene expression in the hippocampus.. **2022**, 136656 ○

478 Exploring the Relationship Between Engagement in Enriching Early-Life Activities During Adolescence and Cognition in Later-Life: Results From the Health and Retirement Study.. **2022**, 1640275221085660

477 The lateral entorhinal cortex is a hub for local and global dysfunction in early Alzheimer's disease states.. **2022**, 271678X221082016 ○

476 Validation of Picture Free and Cued Selective Reminding Test for Illiteracy in Lima, Peru.. **2022**, 37, 15333175221094395

475 Prefrontal hyperactivation during dual-task walking related to apathy symptoms in older individuals.. **2022**, 17, e0266553 1

474 Fronto-temporal functional disconnection precedes hippocampal atrophy in clinically confirmed multi-domain amnesic Mild Cognitive Impairment. **2021**, 20, 1458-1473 ○

473	Hearing Loss and Cognition: What We Know and Where We Need to Go.. 2021 , 13, 769405	4
472	Alzheimer's disease: Newer biomarkers.. 2021 , 30, S315-S319	
471	The management of dementia worldwide: A review on policy practices, clinical guidelines, end-of-life care, and challenge along with aging population.. 2022 , 16,	0
470	Exercise and Alzheimer's disease. 2022 , 413-421	
469	PET Imaging of Amyloid and Tau in Alzheimer's Disease. 2022 , 307-323	0
468	Sex-Driven Differences in the Effectiveness of Individualized Clinical Management of Alzheimer's Disease Risk.	
467	Verbal fluency response times predict incident cognitive impairment.. 2022 , 14, e12277	0
466	The Role of Neuroimaging in Fall Prevention in Healthy Adults at Risk of Alzheimer's Disease. 2022 , 790-812	
465	Structural progression of Alzheimer's disease over decades: the MRI staging scheme.. 2022 , 4, fca109	2
464	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. 2022 , 10, 1045	1
463	Correlation Between Brain Structure Atrophy and Plasma Amyloid- β and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnesic Mild Cognitive Impairment Explored by Surface-Based Morphometry.. 2022 , 14, 816043	1
462	Everyday function profiles in prodromal stages of MCI: Prospective cohort study.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2 0
461	Regional Brain Fusion: Graph Convolutional Network for Alzheimer's Disease Prediction and Analysis.. 2022 , 16, 886365	1
460	Brain insulin resistance and the therapeutic value of insulin and insulin-sensitizing drugs in Alzheimer's disease neuropathology.. 2022 , 1	0
459	Gut Microbiota and Subjective Memory Complaints in Older Women.. 2022 ,	2
458	β Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.. 2022 , 14, 66	0
457	Automated Evaluation of Conventional Clock-Drawing Test Using Deep Neural Network: Potential as a Mass Screening Tool to Detect Individuals With Cognitive Decline.. 2022 , 13, 896403	0
456	Disrupted Value-Directed Strategic Processing in Individuals with Mild Cognitive Impairment: Behavioral and Neural Correlates. 2022 , 7, 56	

455	Understanding Brain Function in Vascular Cognitive Impairment and Dementia with EEG and MEG: a systematic review. 2022 , 103040	0
454	Antemortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy.. 2022 ,	0
453	Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer's Disease.. 2022 , 1	1
452	Impaired Affordance Perception as the Basis of Tool Use Deficiency in Alzheimer's Disease. 2022 , 10, 839	0
451	The cross-sectional and longitudinal relationship of diabetic retinopathy to cognitive impairment: a systematic review and meta-analysis.. 2022 ,	
450	Investigating the Association Between Polygenic Risk Scores for Alzheimer's Disease With Cognitive Performance and Intrinsic Functional Connectivity in Healthy Adults. 2022 , 14,	
449	Circulating micro-RNAs differentially expressed in Korean Alzheimer's patients with brain A β accumulation activate amyloidogenesis.. 2022 ,	0
448	A self-driven approach for multi-class discrimination in Alzheimer's disease based on wearable EEG.. 2022 , 220, 106841	1
447	A New Nomogram Model for Individualized Prediction of Cognitive Impairment in Patients with Acute Ischemic Stroke.. 2022 , 31, 106515	0
446	Applying Serious Games and Machine Learning for Cognitive Training and Screening: the COGNIPLAT Approach. 2021 ,	1
445	Cardiometabolic measures and cognition in early menopause - Analysis of baseline data from a randomized controlled trial. 2022 ,	
444	An Exploratory Study to Investigate the Utility of Clinical Screening for Neurodegenerative Disease in Age-Related Eye Disease Research.. 2022 ,	0
443	Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors. 2022 , 27, 3139	1
442	Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.. 2022 ,	1
441	New PET tracers for dementia evaluation: Coming to your clinic now. 21-29	
440	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility.. 2022 ,	4
439	A β oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo.. 2022 , 3, 100630	0
438	Concomitant Retinal Alterations in Neuronal Activity and TNF α Pathway Are Detectable during the Pre-Symptomatic Stage in a Mouse Model of Alzheimer's Disease. 2022 , 11, 1650	1

- 437 Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment.. **2022**, ○
- 436 Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre-Mild Cognitive Impairment.. **2022**, ○
- 435 Platelet Activating Factor Receptor Exaggerates Microglia-Mediated Microenvironment by IL10-STAT3 Signaling: A Novel Potential Biomarker and Target for Diagnosis and Treatment of Alzheimer's Disease.. **2022**, 14, 856628
- 434 NeuroProtect, a Candidate Formula From Traditional Chinese Medicine, Attenuates Amyloid- and Restores Synaptic Structures in APP/PS1 Transgenic Mice.. **2022**, 13, 850175
- 433 Alzheimer's Disease (AD): Risks, Treatments, Prevention, and Future Implementations. **2022**, 11, 11-21
- 432 Intervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer's Symptomatic Expression (INCREASE) Study: Results from a Randomized Controlled Study of Medication Therapy Management Targeting a Delay in Prodromal Dementia Symptom Progression.
- 431 The 5-Cog paradigm to improve detection of cognitive impairment and dementia: clinical trial protocol.
- 430 Low serum apelin levels are associated with mild cognitive impairment in Type 2 diabetic patients. **2022**, 22,
- 429 Brain-Derived Neurotrophic Factor: A Connecting Link Between Nutrition, Lifestyle, and Alzheimer's Disease. **2022**, 16, 2
- 428 Association between Cerebral Small Vessel and Alzheimer's Disease. **2022**, 83, 486
- 427 A Functional Assessment Tool to Distinguish Controls From Alzheimer's Disease in Lima, Peru. **2022**, 37, 153331752211043
- 426 Early memory deficits and extensive brain network disorganization in the App/MAPT double knock-in mouse model of familial Alzheimer's disease. **2022**, 2, 100042 ○
- 425 Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. 16, ○
- 424 Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. 14, ○
- 423 Spatial navigation in older adults with mild cognitive impairment and dementia: A systematic review and meta-analysis. **2022**, 111852 ○
- 422 Survey Results of Speech-Language Pathologists Working With Cognitive-Communication Disorders: Improving Practices for Mild Cognitive Impairment and Early-Stage Dementia From Alzheimer's Disease. 1-19 1
- 421 A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413 ○
- 420 Pre-dementia cognitive impairment. **2022**, 48-57 1

419	The Comparative Efficacy of Multiple Acupuncture for Alzheimer’s Disease: A Bayesian Network Meta-Analysis. 2022 , 2022, 1-26		0
418	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. 2022 , 63, 135-195		4
417	Integrated analysis of direct and proxy genome wide association studies highlights polygenicity of Alzheimer’s disease outside of the APOE region. 2022 , 18, e1010208		0
416	Cognitive Decline in Older People with Multiple Sclerosis – Narrative Review of the Literature. 2022 , 7, 61		
415	Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled , double-blind phase I/Ib studies in healthy subjects and patients.		1
414	Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer’s Disease. 2022 , 1-10		
413	Global estimates on the number of persons across the Alzheimer’s disease continuum. <i>Alzheimer’s and Dementia</i> ,	1.2	5
412	Dietary and Nutrient Patterns and Brain MRI Biomarkers in Dementia-Free Adults. 2022 , 14, 2345		2
411	Sensor-based System to Algorithmically Recognize Gait Disturbances Common to Vascular Dementia Onset. 2021 ,		
410	Predictive Accuracy of Digital Biomarker Technologies for Detection of Mild Cognitive Impairment and Pre-Frailty Amongst Older Adults: A Systematic Review and Meta-Analysis. 2022 , 1-13		
409	A Histochemical Analysis of Neurofibrillary Tangles in Olfactory Epithelium, a Study Based on an Autopsy Case of Juvenile Alzheimer’s Disease. 2022 ,		0
408	Histoire naturelle et diagnostic de la maladie d’Alzheimer. 2022 , 143-161		
407	AI Classifications Applied to Neuropsychological Trials in Normal Individuals that Predict Progression to Cognitive Decline. 2022 , 150-156		
406	Deficits in spontaneous and stimulus-dependent retrieval as an early sign of abnormal aging. 2022 , 12,		
405	Integrated Proteomics Identifies Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease.		0
404	Integrative co-methylation network analysis identifies novel DNA methylation signatures and their target genes in Alzheimer’s disease. 2022 ,		0
403	Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer’s Disease. 16,		1
402	Incremental diagnostic value of 18F-Fluorometamol PET in differential diagnoses of Alzheimer’s Disease-related neurodegenerative diseases from an unselected memory clinic cohort. 2022 , 12,		

- 401 Amygdalar and ERC Rostral Atrophy and Tau Pathology Reconstruction in Preclinical Alzheimer's Disease.
- 400 Risk of Dementia After Smoking Cessation in Patients With Newly Diagnosed Atrial Fibrillation. **2022**, 5, e2217132 ○
- 399 Digital biomarkers and sex impacts in Alzheimer's disease management | potential utility for innovative 3P medicine approach. **2022**, 13, 299-313 ○
- 398 Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum. 14, ○
- 397 Denoising Approach Affects Diagnostic Differences in Brain Connectivity across the Alzheimer's Disease Continuum.
- 396 Automated Classification of Mild Cognitive Impairment by Machine Learning With Hippocampus-Related White Matter Network. 14, ○
- 395 Functional Connectivity Dynamics Altered of the Resting Brain in Subjective Cognitive Decline. 14,
- 394 Anesthésie du patient avec délirium cognitif. **2022**,
- 393 High-Density Lipoprotein Changes in Alzheimer's Disease Are APOE Genotype-Specific. **2022**, 10, 1495
- 392 Molecular PET Imaging in Alzheimer's Disease. ○
- 391 Staging of Alzheimer's disease: past, present, and future perspectives. **2022**, 1
- 390 White matter lesions may be an early marker for age-related cognitive decline. **2022**, 103096 ○
- 389 The Relationship Between Cardiovascular Disease Risk Score and Postoperative Delirium: The PNDABLE Study. 14, ○
- 388 A multi-omics approach identifies a blood-based miRNA signature of cognitive decline in two large observational trials.
- 387 Combined therapy for Alzheimer's disease. **2022**, 14, 74-80
- 386 Alteration of Visuospatial System as an Early Marker of Cognitive Decline: A Double-Center Neuroimaging Study. 14,
- 385 Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. **2022**, 8,
- 384 A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnesic Mild Cognitive Impairment and Alzheimer's Disease: An Exploratory Study. **2022**, 11, 3655

- 383 Synapse pathology in Alzheimer's disease. **2022**, 2
- 382 Effect of simultaneous dual-task training on regional cerebral blood flow in older adults with amnesic mild cognitive impairment. **2022**, 19,
- 381 Effectivity of (Personalized) Cognitive Behavioral Therapy for Insomnia in Mental Health Populations and the Elderly: An Overview. **2022**, 12, 1070
- 380 Clinical Progression of Baseline Risk States for Mild Cognitive Impairment. **2022**, 1-8
- 379 ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. 1-13 0
- 378 Hippocampal grading provides higher Alzheimer's Disease prediction accuracy than hippocampal volume. 0
- 377 Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer's disease. **2022**, 17, e0270682 0
- 376 Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. 1
- 375 Multimorbidity and risk of incident dementia: role of disease clusters and genetic risk for dementia in a cohort of 206,960 participants.
- 374 Evaluating measurement properties of subjective cognitive decline self-reported outcome measures: a systematic review. **2022**, 11, 0
- 373 Subjective Cognitive Decline: Is a Resilient Personality Protective Against Progression to Objective Cognitive Impairment? Findings from Two Community-Based Cohort Studies. **2022**, 1-19
- 372 Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid- β and Cerebral Atrophy. **2022**, 1-18
- 371 FMRI complexity correlates with tau-PET in Late-Onset and Autosomal Dominant Alzheimer's Disease.
- 370 Neurovascular Coupling in Type 2 Diabetes With Cognitive Decline. A Narrative Review of Neuroimaging Findings and Their Pathophysiological Implications. 13, 1
- 369 Decreased levels of cytokines implicate altered immune response in plasma of moderate-stage Alzheimer's disease patients. **2022**, 136799 0
- 368 Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer's Disease in Nordic Populations. **2022**, 1-12
- 367 The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer's disease and estimate 5-year risks of cognitive decline and dementia. **2022**, 22, 0
- 366 EXPRESS: Accelerated forgetting in healthy older samples: implications for methodology, future ageing studies and early identification of risk of dementia.. 174702182211134

- 365 Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline. 1-20 0
- 364 Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. **2022**, 23, 7867 0
- 363 Voice Biomarkers as Indicators of Cognitive Changes in Middle and Later Adulthood. **2022**, 0
- 362 Organized Registration for the Assessment of Dementia by the Nationwide General Consortium Toward Effective Treatment (ORANGE) Registry: Current Status and Perspectives of Mild Cognitive Impairment. **2022**, 1-11 0
- 361 Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer's disease. **2022**, 82, 104175 1
- 360 Cognitive and neuroimaging correlates of financial exploitation vulnerability in older adults without dementia: Implications for early detection of Alzheimer's disease. **2022**, 140, 104773 0
- 359 Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid. **2022**, 172, 105813 0
- 358 Dementia. **2023**, 111-158 0
- 357 Alzheimer diseases. **2023**, 313-336 0
- 356 Insulin Resistance and Cognitive Impairment: Evidence From Neuroimaging. 0
- 355 Temporal Cortex Microarray Analysis Revealed Impaired Ribosomal Biogenesis and Hyperactivity of the Glutamatergic System: An Early Signature of Asymptomatic Alzheimer's Disease. 16, 1 0
- 354 Grey matter changes on brain MRI in subjective cognitive decline: a systematic review. **2022**, 14, 0
- 353 On-the-Pack Voluntary Well-Being Messaging for Milks Targeting Chinese Older Adults: A Content Analysis. **2022**, 11, 2212 0
- 352 Association Between Self-Reflection, Cognition, and Brain Health in Cognitively Unimpaired Older Adults. 10.1212/WNL.000000000200951 0
- 351 Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. 4
- 350 Association of Fatigue With Sleep Duration and Bedtime During the Third Trimester. 13, 0
- 349 Causal links among amyloid, tau, and neurodegeneration. 0
- 348 Cognitive Disorders: Outcomes After Intensive Care. **2022**, 395-402 0

- 347 From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. **2022**, 80, 24-35
- 346 Brain atrophy in middle age using magnetic resonance imaging scans from Japan's health screening programme. **2022**, 4, 1
- 345 The fractional amplitude of low-frequency fluctuations signals related to amyloid uptake in high-risk populations: A pilot fMRI study. 14,
- 344 Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology. **2022**, 1-12
- 343 Shared mechanisms across the major psychiatric and neurodegenerative diseases. **2022**, 13, 3
- 342 Subjective Cognitive Decline Associated with Discrimination in Medical Settings among Transgender and Nonbinary Older Adults. **2022**, 19, 9168 0
- 341 Development and validation of the age-associated dementia policy (AgeD-Pol) computer simulation model in the USA and Europe. **2022**, 12, e056546 0
- 340 Modulation of entorhinal cortex-hippocampus connectivity and recognition memory following electroacupuncture on 3Tg-AD model: Evidence from multimodal MRI and electrophysiological recordings. 16, 0
- 339 [18F]ROTrace detects oxidative stress in vivo and predicts progression of Alzheimer's disease pathology in APP/PS1 mice. **2022**, 12, 0
- 338 A systematic review of subjective cognitive characteristics predictive of longitudinal outcomes in older adults.
- 337 Research on clustering algorithm of cognitive rehabilitation based on multi-dimensional objects. **2022**,
- 336 Cortical neuroanatomical changes related to specific language impairments in primary progressive aphasia. 14,
- 335 Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. **2022**, 23, 8598 0
- 334 Increased risk of all-cause, Alzheimer's, and vascular dementia in adults with migraine in Korea: a population-based cohort study. **2022**, 23,
- 333 Brain ethanolamine phospholipids, neuropathology and cognition: A comparative post-mortem analysis of structurally specific plasmalogen and phosphatidyl species. 10,
- 332 Development and validation of immune-based biomarkers and deep learning models for Alzheimer's disease. 13, 0
- 331 Sirtuins promote brain homeostasis, preventing Alzheimer's disease through targeting neuroinflammation. 13, 0
- 330 Effectiveness of exercise and physical activity interventions to improve long-term patient-relevant cognitive and non-cognitive outcomes in people living with mild cognitive impairment: a protocol of a systematic review and meta-analysis. **2022**, 12, e063396

- 329 Tracking the Progression and Influence of Beta-Amyloid Plaques Using Percolation Centrality and Collective Influence Algorithm: A Study Using PET Images. 097275312211176
- 328 Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. 14,
- 327 Dysfunctional Glucose Metabolism in Alzheimer's Disease Onset and Potential Pharmacological Interventions. **2022**, 23, 9540 1
- 326 Textural features reflecting local activity of the hippocampus improve the diagnosis of Alzheimer's disease and amnesic mild cognitive impairment: A radiomics study based on functional magnetic resonance imaging. 16, 1
- 325 Exploring cognitive and brain oxygenation changes over a 1-year period in physically active individuals with mild cognitive impairment: a longitudinal fNIRS pilot study. **2022**, 22, 0
- 324 Associations of Sensory and Motor Function with Blood-Based Biomarkers of Neurodegeneration and Alzheimer's Disease in Midlife. **2022**,
- 323 Cerebrospinal fluid β synuclein as a synaptic biomarker for preclinical Alzheimer's disease. jnnp-2022-329124 0
- 322 Pharmaceutical Potential of Casein-Derived Tripeptide Met-Lys-Pro: Improvement in Cognitive Impairments and Suppression of Inflammation in APP/PS1 Mice. **2022**, 1-14
- 321 Associations Between Sub-Threshold Amyloid- β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE e4 Carrier Status in Cognitively Normal Older Adults. **2022**, 1-14
- 320 Elevated Levels of Naturally-Occurring Autoantibodies Against the Extracellular Domain of p75NTR Aggravate the Pathology of Alzheimer's Disease.
- 319 The genetic and environmental etiology of blood-based biomarkers related to risk of Alzheimer's Disease in a population-based sample of early old-age men.
- 318 Sleep duration, genetic susceptibility, and Alzheimer's disease: a longitudinal UK Biobank-based study. **2022**, 22, 0
- 317 Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer's Disease: The Role of Naturalistic Driving Studies. **2022**, 6, 521-528
- 316 The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. 2
- 315 ACCELERATED LONG-TERM FORGETTING IN NEURODEGENERATIVE DISORDERS: A SYSTEMATIC REVIEW OF THE LITERATURE. **2022**, 104815 0
- 314 Cognitive Improvement After Multi-Domain Lifestyle Interventions in an APOE e4 Homozygous Carrier with Mild Cognitive Impairment: A Case Report and Literature Review. **2022**, 1-12
- 313 Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer's disease. **2022**, 13, 0
- 312 Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. 0

311	Designing the next-generation clinical care pathway for Alzheimer’s disease. 2022 , 2, 692-703	3
310	International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease.	
309	Busyness, mental engagement, and stress: Relationships to neurocognitive aging and behavior. 14,	0
308	Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease. 2022 , 114486	0
307	Predicting progression to dementia with a comprehensive visual rating scale and machine learning algorithms. 13,	
306	Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimer’s disease. 14,	
305	Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer’s disease.	
304	Subjective Cognitive Decline is a Better Marker for Future Cognitive Decline in Females than in Males.	
303	Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer’s disease in Aotearoa, New Zealand. 1-22	
302	Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease: Integration of the glutamate/GABA-glutamine cycle. 2022 , 217, 102331	2
301	Individualized diagnosis of preclinical Alzheimer’s Disease using deep neural networks. 2022 , 210, 118511	0
300	Inflammation, metabolic dysregulation and environmental neurotoxins and risk of cognitive decline and impairment in midlife.	0
299	Exposure to a real traffic environment impairs brain cognition in aged mice. 2022 , 215, 114181	0
298	Effects of dose change on the success of clinical trials. 2022 , 30, 100988	1
297	How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. 2023 , 455-492	0
296	Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer’s Prevention. 2022 , 14,	0
295	Trajectory of clinical symptoms in relation to amyloid chronicity. 2022 , 14,	0
294	Amyloid PET ordering practices in a memory disorders clinic. 2022 , 8,	0

- 293 Asymmetric amyloid deposition in preclinical Alzheimer's disease: A PET study. **2022**, 2, 100048 ○
- 292 Sex and gender differences in dementia. **2022**, 179-233 ○
- 291 Olfactory Function Reflects Episodic Memory Performance and Atrophy in the Medial Temporal Lobe in Individuals at Risk for Alzheimer's Disease. ○
- 290 Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society. **2022**, 14, ○
- 289 Phenotype-informed polygenic risk scores are associated with worse outcome in individuals at risk of Alzheimer's disease. **2022**, 14, ○
- 288 Expression of Regional Amyloid Deposition in Centiloid Scale and Used for Quantitative Analysis in Alzheimer's Disease-A Multi-Site Study. ○
- 287 No difference in retinal fluorescence after oral curcumin intake in amyloid-proven AD cases compared to controls. **2022**, 14, ○
- 286 Effect of Coriander on H2O2-induced Oxidative Stress in PC12 Cells. ○
- 285 Machine learning and deep learning models for early-stage detection of Alzheimer's disease and its proliferation in human brain. **2023**, 49-60 ○
- 284 Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes. **2022**, 1-9 ○
- 283 Data-driven causal model discovery and personalized prediction in Alzheimer's disease. **2022**, 5, ○
- 282 Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. **2022**, 1-14 ○
- 281 Predicting conversion to Alzheimer's disease in individuals with Mild Cognitive Impairment using clinically transferable features. **2022**, 12, ○
- 280 Consistency analysis and conversion model establishment of mini-mental state examination and montreal cognitive assessment in Chinese patients with Alzheimer's disease. 13, ○
- 279 Machine learning models identify ferroptosis-related genes as potential diagnostic biomarkers for Alzheimer's disease. 14, ○
- 278 Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease. 1-13 ○
- 277 Evaluation of Plant Ceramide Species-Induced Exosome Release from Neuronal Cells and Exosome Loading Using Deuterium Chemistry. **2022**, 23, 10751 ○
- 276 Biomarkers for dementia in Latin American countries: Gaps and opportunities. 2

275	Episodic memory dysfunction and hypersynchrony in brain functional networks in cognitively intact subjects and MCI: a study of 379 individuals.	0
274	Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.	0
273	Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro. 2022 , 1-14	1
272	The relationship between mild cognitive impairment and postoperative delirium undergoing total knee arthroplasty: The PNDABLE study. 14,	0
271	Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer's disease. 14,	1
270	Modeling the Impact of Delay on the Aggregation of AD Proteins.	0
269	How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?.	0
268	Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic review and Meta-analysis. 2022 ,	0
267	Related amyloid burden and cortical atrophy in individuals with subtle cognitive decline.	0
266	Memory markers in the continuum of the Alzheimer's clinical syndrome. 2022 , 14,	0
265	Alterations of resting-state Gamma frequency characteristics in aging and Alzheimer's disease.	1
264	Association of Multimorbidity, Disease Clusters, and Modification by Genetic Factors With Risk of Dementia. 2022 , 5, e2232124	0
263	Plasma microRNAs as potential biomarkers in early Alzheimer disease expression. 2022 , 12,	0
262	Disrupted role of the connectivity between the locus coeruleus and the hippocampus in cognition of healthy, middle-aged individuals at risk of dementia: the PREVENT-Dementia study.	0
261	Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools. 2022 , 5, e38130	1
260	Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Biomarker Proteins Reveals Stage-Specific Changes in Alzheimer's Disease.	0
259	In pre-clinical AD small vessel disease is associated with altered hippocampal connectivity and atrophy. 2022 ,	0
258	Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer's disease.	3

- 257 Mini-Mental State Examination and Montreal Cognitive Assessment as Tools for Following Cognitive Changes in Alzheimer's Disease Neuroimaging Initiative Participants. **2022**, 1-8 ○
- 256 Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning. ○
- 255 Effects of Simvastatin on Plasma Amyloid- β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. **2022**, 1-14 ○
- 254 Hypertension differentially impacts cognition in men and women in early midlife. ○
- 253 Glymphatic MRI techniques in sleep and neurodegenerative diseases. **2022**, 28, 499-510 ○
- 252 Cognitive Functioning of Unaffected First-degree Relatives of Individuals With Late-onset Alzheimer's Disease: A Systematic Literature Review and Meta-analysis. ○
- 251 A β Protein Detector Based on AAO Confined Self-assembly System. ○
- 250 Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model. **2022**, 18, e1010481 ○
- 249 Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. **2022**, 1-13 ○
- 248 The relationship between depression and subjective cognitive decline in older adults of China: the mediating role of general self-efficacy. 1-11 ○
- 247 Brain state transition analysis using ultra-fast fMRI differentiates MCI from cognitively normal controls. 16, ○
- 246 Preliminary Validation Study of the French-Quebec Version of the Mild Behavioral Impairment Checklist. Publish Ahead of Print, ○
- 245 Estimating Likelihood of Dementia in the Absence of Diagnostic Data: A Latent Dementia Index in 10 Genetically Informed Studies. **2022**, 1-15 ○
- 244 Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer's disease. **2022**, 19, ○
- 243 Cognitive tasks propagate the neural entrainment in response to a visual 40 Hz stimulation in humans. 14, ○
- 242 Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals. 10.1212/WNL.0000000000201417 ○
- 241 Machine Learning Workflow to Explain Black-Box Models for Early Alzheimer's Disease Classification Evaluated for Multiple Datasets. **2022**, 3, ○
- 240 Comparison of plasma and CSF biomarkers in predicting cognitive decline. ○

239	Disclosing Individual Results in Dementia Research: A Proposed Study Participant’s Bill of Rights. 2022 , 1-8	1
238	Neuroimaging and clinical characteristics of cognitive migration in community-dwelling older adults. 2022 , 36, 103232	0
237	Correlation of Global and Regional Amyloid Burden by 18F-Florbetaben PET/CT With Cognitive Impairment Profile and Severity. 2022 , 47, 923-930	0
236	Cholinergic white matter pathways along the Alzheimer’s disease continuum.	0
235	Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer’s Disease Trials. 2022 , 1-10	0
234	Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans. 2022 , 12,	0
233	Ethical Frameworks for Disclosure of Alzheimer Disease Biomarkers to Research Participants: Conflicting Norms and a Nuanced Policy. 2022 , 44, 2-13	0
232	Hypothesis review: Alzheimer’s overture guidelines.	1
231	Developing a Danish version of the LASSI-L test –reliability and predictive value in patients with mild cognitive impairment, mild dementia due to AD and subjective cognitive decline. 1-13	0
230	Perivascular spaces as a potential biomarker of Alzheimer’s disease. 16,	0
229	Assessment of risk factors in dogs with presumptive advanced canine cognitive dysfunction. 9,	0
228	Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials.	0
227	Deep learning-based diagnosis of Alzheimer’s disease using brain magnetic resonance images: an empirical study. 2022 , 12,	1
226	Retinal Neurodegeneration Measured With Optical Coherence Tomography and Neuroimaging in Alzheimer Disease: A Systematic Review. 2022 , Publish Ahead of Print,	0
225	Sleep slow waves –negative-to-positive-phase transition: a marker of cognitive and apneic status in aging.	0
224	Directed functional brain connectivity is altered in sub-threshold amyloid- β accumulators.	0
223	SIRT1 activation and its circadian clock control: a promising approach against (frailty in) neurodegenerative disorders.	0
222	Blood Analytes as Biomarkers of Mechanisms Involved in Alzheimer’s Disease Progression. 2022 , 23, 13289	0

221	Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. 2022 , 12, 1747	0
220	Preclinical Alzheimer β dementia: a useful concept or another dead end?.	0
219	Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer β disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations. 14,	0
218	An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer β disease. 13,	0
217	Is Mitochondria DNA Variation a Biomarker for AD?. 2022 , 13, 1789	0
216	Morphological Temporal Analysis in Subjects with Alzheimer β Disease by Brain Graph Descriptors. 2023 , 363-370	0
215	Lifelong experiences as a proxy of cognitive reserve moderate the association between connectivity and cognition in Alzheimer's disease. 2022 ,	1
214	Brain PET and Cerebrovascular Disease. 2022 ,	0
213	Dual-probe fluorescence spectroscopy for sensitive quantitation of Alzheimer β amyloid pathology. 2022 , 10,	0
212	A Deep Longitudinal Model for Mild Cognitive Impairment to Alzheimer β Disease Conversion Prediction in Low-Income Countries. 2022 , 2022, 1-8	0
211	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis.	0
210	Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. 2022 , 74, 117047	1
209	Contributions of early-life cognitive reserve and late-life leisure activity to successful and pathological cognitive aging. 2022 , 22,	0
208	Electroencephalography for Early Detection of Alzheimer β Disease in Subjective Cognitive Decline. 2022 , 21, 126	0
207	Emotional characteristics of socially isolated older adults with MCI using tablet administered NIH toolbox: I-CONNECT study. 2022 , 14,	0
206	Study Design and Baseline Results in a Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia From Subjective Cognitive Decline (CoSCo) Study. 2022 , 21, 147	1
205	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer β Disease and Identifying Promising Drug Targets. 2022 , 12, 1676	3
204	Functional gradients reveal altered functional segregation in patients with amnesic mild cognitive impairment and Alzheimer's disease.	0

203	Cognitive Performance following Single- or Multi-Session Exercise Intervention in Middle Age: A Systematic Review. 1-37	0
202	Altered Functional Connectivity Pattern of Hippocampal Subfields in Individuals with Objectively-defined Subtle Cognitive Decline and its Association with Cognition and Cerebrospinal Fluid Biomarkers.	0
201	Detection of tau-PET positivity in clinically diagnosed mild cognitive impairment with multidimensional features..	0
200	Machine Learning-Based Classification of Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Dementia Using Neuroimage and Plasma Biomarkers.	1
199	PET molecular imaging for pathophysiological visualization in Alzheimer's disease.	1
198	Aromatic L-Amino Acid Decarboxylase is a novel fluid biomarker of Parkinson's disease.	0
197	Gaze tracking patterns on different types of traffic risk in early-stage Alzheimer's disease. 2022 , 91, 451-460	0
196	A review on Alzheimer's Disease Classification from Normal Controls and Mild Cognitive Impairment using structural MR Images. 2022 , 109745	1
195	Review of Quantitative Methods for the Detection of Alzheimer's Disease with Positron Emission Tomography. 2022 , 12, 11463	0
194	Adherence to a Mediterranean Diet is associated with physical and cognitive health: A cross-sectional analysis of community-dwelling older Australians. 10,	0
193	Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through immune landscape analysis. 2022 , 8,	0
192	Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease.	0
191	Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. 2022 , 86, 104336	2
190	Automatic Audio-based Screening System for Alzheimer's Disease Detection. 2022 ,	0
189	Graphene as the basis of biological sensors for the diagnosis of neurodegenerative dementia. 2022 , 41, 421-428	0
188	Increasing empathic concern relates to salience network hyperconnectivity in cognitively healthy older adults with elevated amyloid- β burden. 2023 , 37, 103282	0
187	Time-lagged relationships between a decade of air pollution exposure and first hospitalization with Alzheimer's disease and related dementias. 2023 , 171, 107694	0
186	Discovery of carbamate-based salicylic acid derivatives as novel cholinesterase inhibitor. 2023 , 1276, 134804	0

- 185 Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer's disease. **2022**, 14, ○
- 184 Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. **2022**, 14, ○
- 183 Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood. **2022**, 14, ○
- 182 The effect of biomechanical features on classification of dual-task gait. **2022**, 1-1 ○
- 181 Stakeholders' Perspectives on Preclinical Testing for Alzheimer's Disease. **2015**, 26, 297-306 3
- 180 Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease. **2022**, 22, 863-873 ○
- 179 A Machine Learning Model to Identify Best Blood Plasma Proteins for Early Detection of Alzheimer's Disease. **2022**, ○
- 178 Who's driving? The default mode network in healthy elderly individuals at risk of cognitive decline. 13, ○
- 177 Brain Insulin Resistance, Nitric Oxide and Alzheimer's Disease Pathology. **2022**, 238-259 ○
- 176 Big Five, self-reported depression, and anxiety are predictive for Alzheimer's disease. ○
- 175 Obesity marker trajectories and cognitive impairment in older adults: a 10-year follow-up in Taichung community health study for elders. **2022**, 22, ○
- 174 Brain Microstructural Changes in Patients with Amnesic mild Cognitive Impairment. ○
- 173 A Machine Learning Approach for Early Diagnosis of Cognitive Impairment Using Population-Based Data. **2022**, 1-13 ○
- 172 Gut microbiome alterations in preclinical Alzheimer's disease. **2022**, 17, e0278276 ○
- 171 Linking Cerebrovascular Dysfunction to Age-Related Hearing Loss and Alzheimer's Disease: Are Systemic Approaches for Diagnosis and Therapy Required?. **2022**, 12, 1717 ○
- 170 Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden. **2022**, 5, e2243232 ○
- 169 Connectivity between default mode and frontoparietal networks mediates the association between global amyloid- β and episodic memory. ○
- 168 Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease. **2022**, 14, ○

- 167 Unified Tensor Network for Multimodal Dementia Detection. **2023**, 409-416 ○
- 166 Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development. **2022**, 1-28 ○
- 165 A confidence ellipse analysis for stochastic dynamics model of Alzheimer's disease. ○
- 164 Plasma phosphorylated tau181 predicts cognitive and functional decline. ○
- 163 A 19-Year-Old Adolescent with Probable Alzheimer's Disease. **2022**, 1-8 2
- 162 Amyloid-PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis. ○
- 161 Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study. ○
- 160 Type 2 Diabetes Mellitus and Alzheimer's Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets. **2022**, 23, 15287 2
- 159 Sex, age, and regional differences in CHRM1 and CHRM3 genes expression levels in the human brain biopsies: potential targets for Alzheimer's disease-related sleep disturbances. **2022**, 21, ○
- 158 Molecular Basis of Role of Insulin Resistance in Pathophysiology of Alzheimer's Disease. 200-219 ○
- 157 GRK5 Deficiency in the Hippocampus Leads to Cognitive Impairment via Abnormal Microglial Alterations. ○
- 156 The use of an individual-based FDG-PET volume of interest approach in mild cognitive impairment: a multi-modality longitudinal follow-up study. ○
- 155 Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer's Disease. **2022**, 1-10 ○
- 154 BMI decline patterns and relation to dementia risk across four decades of follow-up in the Framingham Study. ○
- 153 Association Between Consumption of Ultraprocessed Foods and Cognitive Decline. ○
- 152 Differences in resting state functional connectivity underlie visuomotor performance declines in older adults with a genetic risk (APOE ϵ) for Alzheimer's disease. 14, ○
- 151 Update Amyloid-Bildgebung in der Diagnostik der Neurodegeneration. **2022**, 45, 256-265 ○
- 150 Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. ○

- 149 Exploring the intricacies and pitfalls of the ATN framework: An assessment across cohorts and thresholding methodologies. ○
- 148 Transferability of Alzheimer Disease Polygenic Risk Score Across Populations and Its Association With Alzheimer Disease-Related Phenotypes. **2022**, 5, e2247162 ○
- 147 Pyroptosis in Alzheimer’s disease: cell type-specific activation in microglia, astrocytes and neurons. ○
- 146 Heterogeneity of White Matter Hyperintensity and Cognitive Impairment in Patients with Acute Lacunar Stroke. **2022**, 12, 1674 ○
- 145 Association between walking energy utilisation and longitudinal cognitive performance in older adults. **2022**, 51, ○
- 144 Decreased circulating branched-chain amino acids are associated with development of Alzheimer’s disease in elderly individuals with mild cognitive impairment. 9, ○
- 143 Differences in Subjective and Objective Cognitive Decline Outcomes Are Associated with Modifiable Protective Factors: A 4-Year Longitudinal Study. **2022**, 11, 7441 ○
- 142 Vascular contributions to Alzheimer’s disease. **2022**, 1 ○
- 141 Combining Static and Dynamic Features to Improve Longitudinal Image Retrieval for Alzheimer’s Disease. **2022**, 107-120 ○
- 140 Electronic Plush Toy as a Non-pharmacological Tool in Therapies. **2023**, 111-122 ○
- 139 Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study. 12, 1
- 138 Deep brain stimulation of the entorhinal cortex modulates CA1 theta-gamma oscillations in mouse models of preclinical Alzheimer’s disease. **2023**, ○
- 137 Retinal Vascular Changes in Alzheimer’s Dementia and Mild Cognitive Impairment: A Pilot Study Using Ultra-Widefield Imaging. **2023**, 12, 13 ○
- 136 Experimental approaches for altering the expression of Abeta-degrading enzymes. 1
- 135 Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer’s disease. ○
- 134 GSNgene frameshift mutations in Alzheimer’s disease. jnnp-2022-330465 ○
- 133 Home-based transcranial direct current stimulation in mild neurocognitive disorder due to possible Alzheimer’s disease. A randomised, single-blind, controlled-placebo study. 13, ○
- 132 Case report: Ketogenic diet acutely improves cognitive function in patient with Down syndrome and Alzheimer’s disease. 13, ○

- 131 A transfer learning approach for multiclass classification of Alzheimer's disease using MRI images. 16,
- 130 Changes in self- and study partner-perceived cognitive functioning in relation to amyloid status and future clinical progression: Findings from the SCIENCE project.
- 129 Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer's Disease and Inhibitors of Amyloid Formation. **2023**, 13, 167
- 128 Efficacy of Souvenaid[®] Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer's Disease. **2023**, 1-11
- 127 Definitions of positive health: a systematic scoping review. 175797592211398
- 126 Fluid dynamics in aging-related dementias. **2023**, 177, 105986
- 125 Use of the Laboratory in the Diagnostic Workup of Older Adults. **2022**,
- 124 Subjective cognitive decline is a better marker for future cognitive decline in females than in males. **2022**, 14,
- 123 Disruption of mitochondrial respiration and the monoamine neurotransmitter system in Alzheimer's disease.
- 122 Development and validation of a deep learning algorithm based on fundus photographs for estimating the CAIDE dementia risk score. **2022**, 51,
- 121 Comparison of Usability and Prefrontal Cortex Activity of Cognitive-Motor Training Programs using Sensor-Based Interactive Systems. **2022**, 11, 571-578
- 120 Cortical Thickness and Brain Glucose Metabolism in Healthy Aging. 19,
- 119 Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers. **2023**, 6, e2252387
- 118 Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: The CoSCo prospective cohort study.
- 117 Robustness of CSF A β 2/40 and A β 2/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.
- 116 The Rat Brain Transcriptome: From Infancy to Aging and Sporadic Alzheimer's Disease-like Pathology. **2023**, 24, 1462
- 115 Association of Central Auditory Processing Dysfunction With Preclinical Alzheimer's Disease.
- 114 Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer's disease.

- 113 Cognitive and Emotional Aging Across the Life Span: Implications for Building the Cognitive Reserve and Resilience. **2023**, 287-309 ○
- 112 CELLULAR STRESS RESPONSE (HORMESIS) IN RESPONSE TO BIOACTIVE NUTRACEUTICALS WITH RELEVANCE TO ALZHEIMER DISEASE. ○
- 111 Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment. **2023**, 1-17 ○
- 110 Marital Status of Never Married with Rey Auditory Verbal Learning Test Cognition Performance Is Associated with Mild Cognitive Impairment. **2023**, 13, 1656 ○
- 109 Developing Early Markers of Cognitive Decline and Dementia Derived From Survey Response Behaviors: Protocol for Analyses of Preexisting Large-scale Longitudinal Data (Preprint). ○
- 108 Task-Evoked Pupillary Response as a Potential Biomarker of Dementia and Mild Cognitive Impairment: A Scoping Review. **2023**, 38, 153331752311600 ○
- 107 Cognitive and behavioral abnormalities in individuals with Alzheimer's disease, mild cognitive impairment, and subjective memory complaints. ○
- 106 Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment. **2023**, 21, ○
- 105 Cohort study of the effects of occupation and environmental tobacco smoke on the incidence of Alzheimer's disease among seniors. **2023**, 21, 1-8 ○
- 104 Sex differences in response to obesity and caloric restriction on cognition and hippocampal markers of autophagic-lysosomal pathway function. ○
- 103 Integrated Metabolomics and Transcriptomics Analysis Identifies Molecular Subtypes within the Early and Late Mild Cognitive Impairment Stages of Alzheimer's Disease. ○
- 102 Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care. **2023**, 92, 1051-1066 ○
- 101 Auditory Event-Related Potentials in Older Adults with Subjective Memory Complaints. **2023**, 92, 1093-1109 ○
- 100 Long-term effects of amyloid-beta deposits in human iPSC-derived astrocytes. **2023**, 125, 103839 ○
- 99 Plasma-based diagnostic and screening platform using a combination of biosensing signals in Alzheimer's disease. **2023**, 230, 115246 ○
- 98 Systematic assessment of plasma biomarkers in spinocerebellar ataxia. **2023**, 181, 106112 ○
- 97 Characterization of apathy-like behaviors in the 5xFAD mouse model of Alzheimer's disease. **2023**, 126, 113-122 ○
- 96 Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: A systematic review. **2023**, 87, 101911 ○

95	The unique neuropathological vulnerability of the human brain to aging. 2023 , 87, 101916	0
94	Diagnosis of Alzheimer’s disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. 2022 , 16, 25-39	0
93	. 306-308	0
92	My Genome, My Right. 183-199	0
91	Personalised Medicine and the Politics of Human Nuclear Genome Transfer. 17-36	0
90	Index. 302-305	0
89	Bibliography. 261-301	0
88	I Run, You Run, We Run. 226-244	0
87	Personalising Future Health Risk through Biological Insurance 52-76	0
86	The Best Me I Can Possibly Be 200-225	0
85	When There Is No Cure. 113-132	0
84	PSEN2 and ABCA7 variants causing early-onset preclinical pathological changes in Alzheimer’s disease: a case report and literature review.	0
83	Emotion recognition and baseline cortisol levels relationship in early Alzheimer disease. 2023 , 177, 108511	1
82	Longitudinal study of Alzheimer’s disease biomarkers, allostatic load, and cognition among memory clinic patients. 2023 , 28, 100592	0
81	A New Smart 2-Min Mobile Alerting Method for Mild Cognitive Impairment Due to Alzheimer’s Disease in the Community. 2023 , 13, 244	0
80	Genetic Risk for Alzheimer Disease and Plasma Tau Are Associated With Accelerated Parietal Cortex Thickness Change in Middle-Aged Adults. 2023 , 9, e200053	1
79	Linear and Nonlinear Effect of Years of Schooling, Sex, and Age on the CERAD-MX and Complementary Tasks in a Mexican Sample: A Cross-Sectional Study.	0
78	Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer’s Disease Continuum. 2023 , 92, 513-527	0

- 77 La expresi3n de emociones en la narrativa de los adultos mayores con deterioro cognitivo leve o moderado: An3lisis e intervenci3n metaling3stica. **2023**, 13, e83480 ○
- 76 The dynamics of plasma biomarkers across the Alzheimer3s continuum. **2023**, 15, ○
- 75 Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. **2023**, 375, 110387 ○
- 74 Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer3s disease. 14, ○
- 73 Using CNN Saliency Maps and EEG Modulation Spectra for Improved and More Interpretable Machine Learning-Based Alzheimer3s Disease Diagnosis. **2023**, 2023, 1-17 ○
- 72 Heterogeneity in Preclinical Alzheimer3s Disease Trial Cohort Identified by Image-based Data-Driven Disease Progression Modelling. ○
- 71 Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. **2023**, 187-218 ○
- 70 AlzheimerNet: An Effective Deep Learning Based Proposition for Alzheimer3s Disease Stages Classification From Functional Brain Changes in Magnetic Resonance Images. **2023**, 11, 16376-16395 ○
- 69 The Alzheimer3s Disease Mitochondrial Cascade Hypothesis: A Current Overview. **2023**, 92, 751-768 ○
- 68 Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging. **2023**, 13, ○
- 67 Associations Between Levels of Peripheral NCAPH2 Promoter Methylation and Different Stages of Alzheimer3s Disease: A Cross-Sectional Study. **2023**, 92, 899-909 ○
- 66 Effectiveness of lifestyle medicine on cognitive functions in mild cognitive impairments and dementia: A systematic review on randomized controlled trials. **2023**, 86, 101886 ○
- 65 Longitudinal changes in participant and informant reports of subjective cognitive complaints are associated with dementia risk. 15, ○
- 64 Developing Early Markers of Cognitive Decline and Dementia Derived From Survey Response Behaviors: Protocol for Analyses of Preexisting Large-scale Longitudinal Data. 12, e44627 ○
- 63 Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects. ○
- 62 Mental Fatigue Is Associated with Subjective Cognitive Decline among Older Adults. **2023**, 13, 376 ○
- 61 Effects of continuous positive airway pressure on comprehensive geriatric assessment and cognitive function in elderly patients with obstructive sleep apnea syndrome. **2023**, 18, 769-779 ○
- 60 A Tablet-based Quantitative Analysis: Diagnostic Value of Digital vs. Conventional Geriatric Complex Figure for Discriminating Patients with aMCI from Healthy Individuals. ○

59	Alcohol consumption from midlife and risk of disabling dementia in a large population-based cohort study in Japan. 2023 , 38,	0
58	Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. 2022 , 16, 25-39	0
57	The use of virtual reality in screening for preclinical Alzheimer’s disease: A scoping review protocol. 2023 , 18, e0282436	0
56	Endosome and Lysosome Membrane Properties Functionally Link to βSecretase in Live/Intact Cells. 2023 , 23, 2651	0
55	Detecting the effect of genetic diversity on brain composition in an Alzheimer’s disease mouse model.	0
54	The influence of stimulus eccentricity on prosaccade outcomes in patients with Alzheimer’s Disease dementia at an early stage and amnesic mild cognitive impairment. 2022 , 44, 713-729	2
53	Psychometric properties of the Alzheimer’s Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial. 2023 , 23,	0
52	Medicinal Cannabis for Alzheimer’s Disease. 2023 , 1-47	0
51	Clinical Validity of IntelliSpace Cognition Digital Assessment Platform in Mild Cognitive Impairment.	0
50	Toxic agents and health disparities in the socially marginalized. 2023 ,	0
49	Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects.	0
48	Reconfiguration of brain network dynamics underlying spatial deficits in subjective cognitive decline. 2023 ,	0
47	Diseases of the Central Nervous System. 2023 , 163-193	0
46	Atrophy, hypometabolism and implication regarding pathology in late-life major depression with suspected non-alzheimer pathophysiology (SNAP). 2023 ,	0
45	Low Ankle-Brachial Index Relates to Alzheimer-Signature Cerebral Glucose Metabolism in Cognitively Impaired Older Adults. 2023 , 1-9	0
44	Everyday Driving and Plasma Biomarkers in Alzheimer’s Disease: Leveraging Artificial Intelligence to Expand Our Diagnostic Toolkit. 2023 , 92, 1487-1497	0
43	Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline. 1-16	0
42	2023 Alzheimer’s disease facts and figures. 2023 , 19, 1598-1695	1

- 41 Early amygdala and ERC atrophy linked to 3D reconstruction of rostral neurofibrillary tau tangle pathology in Alzheimer's disease. **2023**, 38, 103374 ○
- 40 Effect of BRD4 Inhibitor on Cognitive Deficit and c-Fos /BDNF level in rats with Alzheimer's disease. ○
- 39 Enfermedad de Alzheimer. **2023**, 13, 4360-4371 ○
- 38 Alterations in theta-gamma coupling and sharp wave-ripple, signs of prodromal hippocampal network impairment in the TgF344-AD rat model. 15, ○
- 37 Telomere length and brain imaging phenotypes in UK Biobank. **2023**, 18, e0282363 ○
- 36 Detecting mild cognitive impairment remotely with the modified memory impairment screen by telephone. 1-13 ○
- 35 Prefrontal EEG slowing, synchronization, and ERP peak latency in association with prodementia stages of Alzheimer's disease. 15, ○
- 34 Dumbbell Aptamer Sensor Based on Dual Biomarkers for Early Detection of Alzheimer's Disease. **2023**, 15, 16394-16407 ○
- 33 Toward a new nosology of neurodegenerative diseases. ○
- 32 Natural language processing techniques for studying language in pathological ageing: A scoping review. ○
- 31 Diagnostic Performance of MRI Radiomics for Classification of Alzheimer's disease, Mild Cognitive Impairment, and Normal Subjects: A Systematic Review and Meta-analysis. ○
- 30 Disease trajectories in elders with suspected non-Alzheimer's pathophysiology and its comparison with Alzheimer's disease pathophysiology: a longitudinal study. ○
- 29 Directed Functional Brain Connectivity is Altered in Sub-threshold Amyloid- β Accumulation in Cognitively Normal Individuals. **2023**, 18, 263310552311616 ○
- 28 Nonlinear changes in delayed functional network topology in Alzheimer's disease: relationship with amyloid and tau pathology. ○
- 27 Cognitive Intervention Effects Vary as a Function of Plasma Neurofilament Light Chain Levels: A PICMOR Randomized Controlled Trial. ○
- 26 Fornix fractional anisotropy mediates the association between Mediterranean diet adherence and memory four years later in older adults without dementia. ○
- 25 Uncorrected errors and correct saccades in the antisaccade task distinguish between early-stage Alzheimer's disease dementia, amnesic mild cognitive impairment, and normal aging. 1-22 1
- 24 MCI Conversion Prediction Using 3D Zernike Moments and the Improved Dynamic Particle Swarm Optimization Algorithm. **2023**, 13, 4489 ○

- 23 Plasma β -microglobulin and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: the CABLE study. **2023**, 15, ○
- 22 Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease. **2023**, 100542 ○
- 21 Olfactory function reflects episodic memory performance and atrophy in the medial temporal lobe in individuals at risk for Alzheimer's disease. **2023**, ○
- 20 Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease. **2023**, ○
- 19 Cognitive dysfunction and increased phosphorylated tau are associated with reduced O-GlcNAc signaling in an aging mouse model of metabolic syndrome. ○
- 18 Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects. **2023**, 15, ○
- 17 Computer-based cognitive tests and cerebral pathology among Japanese older adults. **2023**, 23, ○
- 16 Vision for Ratiometric Nanoprobes: In Vivo Noninvasive Visualization and Readout of Physiological Hallmarks. ○
- 15 Study on the Mechanism and Influence of Cognitive Training on Alzheimer's Disease. **2023**, 13, 151-162 ○
- 14 Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders. **2023**, 14, ○
- 13 Psychometry in Dementia. ○
- 12 Stimulus material selection for the Dutch famous faces test for older adults. 10, ○
- 11 BANF1 Promotes Glutamate-induced Apoptosis of HT-22 Hippocampal Neurons. ○
- 10 Quantile partially linear additive model for data with dropouts and an application to modeling cognitive decline. ○
- 9 Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis. **2023**, 12, 1184 ○
- 8 Degradation of EEG microstates patterns in Subjective Cognitive Decline and Mild Cognitive Impairment: early biomarkers along the Alzheimer's Disease continuum?. **2023**, 103407 ○
- 7 Adaptive data-driven selection of sequences of biological and cognitive markers in pre-clinical diagnosis of dementia. **2023**, 13, ○
- 6 Genetic risk of late-onset Alzheimer's disease is associated with longitudinal loss of functional brain network segregation in middle-aged cognitively healthy individuals: The PREVENT-Dementia Study. ○

- 5 Informatics and computational methods in natural product drug discovery. **2023**, 147-166 ○
- 4 Associations of category fluency clustering performance with in vivo brain pathology in autosomal dominant Alzheimer's disease. 1-7 ○
- 3 Prevalence and risk factors for subjective cognitive decline and the correlation with objective cognition among community-dwelling older adults in China: Results from the Hubei memory and aging cohort study. ○
- 2 Antibodies Raised Against an A β Oligomer Mimic Recognize Pathological Features in Alzheimer's Disease and Associated Amyloid-Disease Brain Tissue. ○
- 1 Brain function effects of exercise interventions for cognitive decline: a systematic review and meta-analysis. 17, ○